Timothy F Cloughesy

Title(s)Professor of Clinical , Neurology
SchoolMedicine
vCardDownload vCard
    Other Positions
    Title(s)Professor of Clinical , Molecular and Medical Pharmacology


    Collapse Research 
    Collapse Research Activities and Funding
    Consortium Therapeutic Studies of Primary Central Nervous System Malignancies
    NIH U01CA105695May 14, 2004 - Dec 31, 2008
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. D-2-HG Inhibits IDH1mut Glioma Growth via FTO Inhibition and Resultant m6A Hypermethylation. Cancer Res Commun. 2024 Mar 06. Pianka ST, Li T, Prins TJ, Eldred BSC, Kevan BM, Liang H, Zapanta Rinonos S, Kornblum HI, Nathanson DA, Pellegrini M, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. PMID: 38445960.
      View in: PubMed   Mentions: Translation:HumansAnimals
    2. ACTION: A randomized phase 3 study of ONC201 (dordaviprone) in patients with newly diagnosed H3 K27M-mutant diffuse glioma. Neuro Oncol. 2024 Mar 06. Arrillaga-Romany I, Lassman A, McGovern SL, Mueller S, Nabors B, van den Bent M, Vogelbaum M, Allen JE, Melemed AS, Tarapore RS, Wen PY, Cloughesy T. PMID: 38445964.
      View in: PubMed   Mentions:    Fields:    
    3. Selective DRD2 Antagonist and ClpP Agonist ONC201 in a Recurrent Non-midline H3 K27M-mutant Glioma Cohort. Neuro Oncol. 2024 Feb 22. Odia Y, Hall MD, Cloughesy TF, Wen PY, Arrillaga-Romany I, Daghistani D, Mehta MP, Tarapore RS, Ramage SC, Allen JE. PMID: 38386699.
      View in: PubMed   Mentions:    Fields:    
    4. ONC201 (Dordaviprone) in Recurrent H3 K27M-Mutant Diffuse Midline Glioma. J Clin Oncol. 2024 Feb 09; JCO2301134. Arrillaga-Romany I, Gardner SL, Odia Y, Aguilera D, Allen JE, Batchelor T, Butowski N, Chen C, Cloughesy T, Cluster A, de Groot J, Dixit KS, Graber JJ, Haggiagi AM, Harrison RA, Kheradpour A, Kilburn LB, Kurz SC, Lu G, MacDonald TJ, Mehta M, Melemed AS, Nghiemphu PL, Ramage SC, Shonka N, Sumrall A, Tarapore RS, Taylor L, Umemura Y, Wen PY. PMID: 38335473.
      View in: PubMed   Mentions: 1     Fields:    
    5. Quantification of T2-FLAIR Mismatch in Nonenhancing Diffuse Gliomas Using Digital Subtraction. AJNR Am J Neuroradiol. 2024 Feb 07; 45(2):188-197. Cho NS, Sanvito F, Le VL, Oshima S, Teraishi A, Yao J, Telesca D, Raymond C, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Salamon N, Ellingson BM. PMID: 38238098.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    6. dCas9/CRISPR-based methylation of O-6-methylguanine-DNA methyltransferase enhances chemosensitivity to temozolomide in malignant glioma. J Neurooncol. 2024 Jan; 166(1):129-142. Zapanta Rinonos S, Li T, Pianka ST, Prins TJ, Eldred BSC, Kevan BM, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. PMID: 38224404; PMCID: PMC10824881.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    7. pH-Weighted amine chemical exchange saturation transfer echo planar imaging visualizes infiltrating glioblastoma cells. Neuro Oncol. 2024 01 05; 26(1):115-126. Patel KS, Yao J, Cho NS, Sanvito F, Tessema K, Alvarado A, Dudley L, Rodriguez F, Everson R, Cloughesy TF, Salamon N, Liau LM, Kornblum HI, Ellingson BM. PMID: 37591790; PMCID: PMC10768991.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    8. Author Correction: Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2024 Jan; 30(1):302. Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. PMID: 37400643; PMCID: PMC10803248.
      View in: PubMed   Mentions:    Fields:    
    9. Standardized brain tumor imaging protocols for clinical trials: current recommendations and tips for integration. Front Radiol. 2023; 3:1267615. Sanvito F, Kaufmann TJ, Cloughesy TF, Wen PY, Ellingson BM. PMID: 38152383; PMCID: PMC10751345.
      View in: PubMed   Mentions:
    10. Bevacizumab Alone and in Combination With Irinotecan in Recurrent Glioblastoma. J Clin Oncol. 2023 Nov 10; 41(32):4945-4952. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WKA, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. PMID: 37935104.
      View in: PubMed   Mentions: 1     Fields:    
    11. Clinical Efficacy of ONC201 in H3K27M-Mutant Diffuse Midline Gliomas Is Driven by Disruption of Integrated Metabolic and Epigenetic Pathways. Cancer Discov. 2023 11 01; 13(11):2370-2393. Venneti S, Kawakibi AR, Ji S, Waszak SM, Sweha SR, Mota M, Pun M, Deogharkar A, Chung C, Tarapore RS, Ramage S, Chi A, Wen PY, Arrillaga-Romany I, Batchelor TT, Butowski NA, Sumrall A, Shonka N, Harrison RA, de Groot J, Mehta M, Hall MD, Daghistani D, Cloughesy TF, Ellingson BM, Beccaria K, Varlet P, Kim MM, Umemura Y, Garton H, Franson A, Schwartz J, Jain R, Kachman M, Baum H, Burant CF, Mottl SL, Cartaxo RT, John V, Messinger D, Qin T, Peterson E, Sajjakulnukit P, Ravi K, Waugh A, Walling D, Ding Y, Xia Z, Schwendeman A, Hawes D, Yang F, Judkins AR, Wahl D, Lyssiotis CA, de la Nava D, Alonso MM, Eze A, Spitzer J, Schmidt SV, Duchatel RJ, Dun MD, Cain JE, Jiang L, Stopka SA, Baquer G, Regan MS, Filbin MG, Agar NYR, Zhao L, Kumar-Sinha C, Mody R, Chinnaiyan A, Kurokawa R, Pratt D, Yadav VN, Grill J, Kline C, Mueller S, Resnick A, Nazarian J, Allen JE, Odia Y, Gardner SL, Koschmann C. PMID: 37584601; PMCID: PMC10618742.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    12. Simultaneous quantification of perfusion, permeability, and leakage effects in brain gliomas using dynamic spin-and-gradient-echo echoplanar imaging MRI. Eur Radiol. 2023 Oct 26. Sanvito F, Raymond C, Cho NS, Yao J, Hagiwara A, Orpilla J, Liau LM, Everson RG, Nghiemphu PL, Lai A, Prins R, Salamon N, Cloughesy TF, Ellingson BM. PMID: 37882836.
      View in: PubMed   Mentions: 2     Fields:    
    13. Depth of Radiographic Response and Time to Tumor Regrowth Predicts Overall Survival Following Anti-VEGF Therapy in Recurrent Glioblastoma. Clin Cancer Res. 2023 10 13; 29(20):4186-4195. Ellingson BM, Hagiwara A, Morris CJ, Cho NS, Oshima S, Sanvito F, Oughourlian TC, Telesca D, Raymond C, Abrey LE, Garcia J, Aftab DT, Hessel C, Rachmilewitz Minei T, Harats D, Nathanson DA, Wen PY, Cloughesy TF. PMID: 37540556; PMCID: PMC10592195.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    14. Correcting the drug development paradigm for glioblastoma requires serial tissue sampling. Nat Med. 2023 Oct; 29(10):2402-2405. Singh K, Hotchkiss KM, Parney IF, De Groot J, Sahebjam S, Sanai N, Platten M, Galanis E, Lim M, Wen PY, Minniti G, Colman H, Cloughesy TF, Mehta MP, Geurts M, Arrillaga-Romany I, Desjardins A, Tanner K, Short S, Arons D, Duke E, Wick W, Bagley SJ, Ashley DM, Kumthekar P, Verhaak R, Chalmers AJ, Patel AP, Watts C, Fecci PE, Batchelor TT, Weller M, Vogelbaum MA, Preusser M, Berger MS, Khasraw M. PMID: 37488293.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    15. RANO 2.0: Update to the Response Assessment in Neuro-Oncology Criteria for High- and Low-Grade Gliomas in Adults. J Clin Oncol. 2023 Nov 20; 41(33):5187-5199. Wen PY, van den Bent M, Youssef G, Cloughesy TF, Ellingson BM, Weller M, Galanis E, Barboriak DP, de Groot J, Gilbert MR, Huang R, Lassman AB, Mehta M, Molinaro AM, Preusser M, Rahman R, Shankar LK, Stupp R, Villanueva-Meyer JE, Wick W, Macdonald DR, Reardon DA, Vogelbaum MA, Chang SM. PMID: 37774317; PMCID: PMC10860967.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    16. Dendritic Cell Vaccination in Conjunction with a TLR Agonist Polarizes Interferon Immune Responses in Malignant Glioma Patients. Res Sq. 2023 Sep 12. Everson RG, Hugo W, Sun L, Antonios J, Lee A, Ding L, Bu M, Khattab S, Chavez C, Billingslea-Yoon E, Salazar A, Ellingson BM, Cloughesy TF, Liau LM, Prins RM. PMID: 37790490; PMCID: PMC10543402.
      View in: PubMed   Mentions:
    17. Immune checkpoint blockade induces distinct alterations in the microenvironments of primary and metastatic brain tumors. J Clin Invest. 2023 09 01; 133(17). Sun L, Kienzler JC, Reynoso JG, Lee A, Shiuan E, Li S, Kim J, Ding L, Monteleone AJ, Owens GC, Phillips JJ, Everson RG, Nathanson D, Cloughesy TF, Li G, Liau LM, Hugo W, Kim W, Prins RM. PMID: 37655659; PMCID: PMC10471177.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    18. Spatial immune profiling of glioblastoma identifies an inflammatory, perivascular phenotype associated with longer survival. Acta Neuropathol. 2023 10; 146(4):647-649. Wirsching HG, Felsberg J, Prummer M, Moisoiu V, Lourman R, Hertler C, Antonios M, Cimino PJ, Roth P, Gorlia T, Prins RM, Cloughesy T, Wen PY, Holland EC, Reifenberger G, Weller M. PMID: 37573572; PMCID: PMC10499942.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Reply to Di Nunno et al. concerning objective response rates targets for recurrent glioblastoma clinical trials: Toward surrogate endpoints for phase II trials in patients with recurrent glioblastoma. Neuro Oncol. 2023 08 03; 25(8):1548-1549. Ellingson BM, Wen PY, Cloughesy TF. PMID: 37167013; PMCID: PMC10398798.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCTClinical Trials
    20. SREBP-1 upregulates lipophagy to maintain cholesterol homeostasis in brain tumor cells. Cell Rep. 2023 07 25; 42(7):112790. Geng F, Zhong Y, Su H, Lefai E, Magaki S, Cloughesy TF, Yong WH, Chakravarti A, Guo D. PMID: 37436895; PMCID: PMC10528745.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    21. Change in volumetric tumor growth rate after cytotoxic therapy is predictive of overall survival in recurrent glioblastoma. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad084. Oshima S, Hagiwara A, Raymond C, Wang C, Cho NS, Lu J, Eldred BSC, Nghiemphu PL, Lai A, Telesca D, Salamon N, Cloughesy TF, Ellingson BM. PMID: 37554221; PMCID: PMC10406419.
      View in: PubMed   Mentions:
    22. Diagnosis and management of complications from the treatment of primary central nervous system tumors in adults. Neuro Oncol. 2023 07 06; 25(7):1200-1224. Weller M, Le Rhun E, Van den Bent M, Chang SM, Cloughesy TF, Goldbrunner R, Hong YK, Jalali R, Jenkinson MD, Minniti G, Nagane M, Razis E, Roth P, Rudà R, Tabatabai G, Wen PY, Short SC, Preusser M. PMID: 36843451; PMCID: PMC10326495.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    23. The Future Glioblastoma Clinical Trials Landscape: Early Phase 0, Window of Opportunity, and Adaptive Phase I-III Studies. Curr Oncol Rep. 2023 09; 25(9):1047-1055. Cho NS, Wong WK, Nghiemphu PL, Cloughesy TF, Ellingson BM. PMID: 37402043; PMCID: PMC10474988.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    24. Accessible Data Collections for Improved Decision Making in Neuro-Oncology Clinical Trials. Clin Cancer Res. 2023 06 13; 29(12):2194-2198. Rahman R, Ventz S, Redd R, Cloughesy T, Alexander BM, Wen PY, Trippa L. PMID: 36939557; PMCID: PMC10681026.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    25. Multi-nuclear sodium, diffusion, and perfusion MRI in human gliomas. J Neurooncol. 2023 Jun; 163(2):417-427. Cho NS, Sanvito F, Thakuria S, Wang C, Hagiwara A, Nagaraj R, Oshima S, Lopez Kolkovsky AL, Lu J, Raymond C, Liau LM, Everson RG, Patel KS, Kim W, Yang I, Bergsneider M, Nghiemphu PL, Lai A, Nathanson DA, Cloughesy TF, Ellingson BM. PMID: 37294422; PMCID: PMC10322966.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    26. Vorasidenib in IDH1- or IDH2-Mutant Low-Grade Glioma. N Engl J Med. 2023 Aug 17; 389(7):589-601. Mellinghoff IK, van den Bent MJ, Blumenthal DT, Touat M, Peters KB, Clarke J, Mendez J, Yust-Katz S, Welsh L, Mason WP, Ducray F, Umemura Y, Nabors B, Holdhoff M, Hottinger AF, Arakawa Y, Sepulveda JM, Wick W, Soffietti R, Perry JR, Giglio P, de la Fuente M, Maher EA, Schoenfeld S, Zhao D, Pandya SS, Steelman L, Hassan I, Wen PY, Cloughesy TF, INDIGO Trial Investigators. PMID: 37272516.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    27. Objective response rate targets for recurrent glioblastoma clinical trials based on the historic association between objective response rate and median overall survival. Neuro Oncol. 2023 06 02; 25(6):1017-1028. Ellingson BM, Wen PY, Chang SM, van den Bent M, Vogelbaum MA, Li G, Li S, Kim J, Youssef G, Wick W, Lassman AB, Gilbert MR, de Groot JF, Weller M, Galanis E, Cloughesy TF. PMID: 36617262; PMCID: PMC10237425.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    28. CDKN2A deletion remodels lipid metabolism to prime glioblastoma for ferroptosis. Cancer Cell. 2023 06 12; 41(6):1048-1060.e9. Minami JK, Morrow D, Bayley NA, Fernandez EG, Salinas JJ, Tse C, Zhu H, Su B, Plawat R, Jones A, Sammarco A, Liau LM, Graeber TG, Williams KJ, Cloughesy TF, Dixon SJ, Bensinger SJ, Nathanson DA. PMID: 37236196; PMCID: PMC10330677.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    29. Oncolytic DNX-2401 virotherapy plus pembrolizumab in recurrent glioblastoma: a phase 1/2 trial. Nat Med. 2023 Jun; 29(6):1370-1378. Nassiri F, Patil V, Yefet LS, Singh O, Liu J, Dang RMA, Yamaguchi TN, Daras M, Cloughesy TF, Colman H, Kumthekar PU, Chen CC, Aiken R, Groves MD, Ong SS, Ramakrishna R, Vogelbaum MA, Khagi S, Kaley T, Melear JM, Peereboom DM, Rodriguez A, Yankelevich M, Nair SG, Puduvalli VK, Aldape K, Gao A, López-Janeiro Á, de Andrea CE, Alonso MM, Boutros P, Robbins J, Mason WP, Sonabend AM, Stupp R, Fueyo J, Gomez-Manzano C, Lang FF, Zadeh G. PMID: 37188783; PMCID: PMC10287560.
      View in: PubMed   Mentions: 34     Fields:    Translation:HumansCellsCTClinical Trials
    30. A single-institution retrospective analysis of pathologically determined malignant transformation in IDH mutant glioma patients. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad036. Liu V, Wetzel EA, Eldred BSC, Zapanta Rinonos S, Prins TJ, Khanlou N, Liau LM, Chong R, Nghiemphu PL, Cloughesy TF, Ellingson BM, Lai A. PMID: 37152809; PMCID: PMC10162112.
      View in: PubMed   Mentions:
    31. Evaluation of Standard Response Assessment in Neuro-Oncology, Modified Response Assessment in Neuro-Oncology, and Immunotherapy Response Assessment in Neuro-Oncology in Newly Diagnosed and Recurrent Glioblastoma. J Clin Oncol. 2023 06 10; 41(17):3160-3171. Youssef G, Rahman R, Bay C, Wang W, Lim-Fat MJ, Arnaout O, Bi WL, Cagney DN, Chang YS, Cloughesy TF, DeSalvo M, Ellingson BM, Flood TF, Gerstner ER, Gonzalez Castro LN, Guenette JP, Kim AE, Lee EQ, McFaline-Figueroa JR, Potter CA, Reardon DA, Huang RY, Wen PY. PMID: 37027809.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    32. Retrospective examination of pseudoprogression in IDH mutant gliomas. Neurooncol Adv. 2023 Jan-Dec; 5(1):vdad028. Wetzel EA, Farrell MJ, Eldred BSC, Liu V, Saha I, Zapanta Rinonos S, Prins T, Li T, Cao M, Hegde J, Kaprealian T, Khanlou N, Liau LM, Nghiemphu PL, Cloughesy TF, Chong RA, Ellingson BM, Lai A. PMID: 37128507; PMCID: PMC10148681.
      View in: PubMed   Mentions:
    33. Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trial. Nat Med. 2023 03; 29(3):615-622. Mellinghoff IK, Lu M, Wen PY, Taylor JW, Maher EA, Arrillaga-Romany I, Peters KB, Ellingson BM, Rosenblum MK, Chun S, Le K, Tassinari A, Choe S, Toubouti Y, Schoenfeld S, Pandya SS, Hassan I, Steelman L, Clarke JL, Cloughesy TF. PMID: 36823302; PMCID: PMC10313524.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    34. Multi-Parametric Radiomic Model to Predict 1p/19q Co-Deletion in Patients with IDH-1 Mutant Glioma: Added Value to the T2-FLAIR Mismatch Sign. Cancers (Basel). 2023 Feb 07; 15(4). Kihira S, Derakhshani A, Leung M, Mahmoudi K, Bauer A, Zhang H, Polson J, Arnold C, Tsankova NM, Hormigo A, Salehi B, Pham N, Ellingson BM, Cloughesy TF, Nael K. PMID: 36831380; PMCID: PMC9954034.
      View in: PubMed   Mentions: 2  
    35. Author Correction: Federated learning enables big data for rare cancer boundary detection. Nat Commun. 2023 Jan 26; 14(1):436. Pati S, Baid U, Edwards B, Sheller M, Wang SH, Reina GA, Foley P, Gruzdev A, Karkada D, Davatzikos C, Sako C, Ghodasara S, Bilello M, Mohan S, Vollmuth P, Brugnara G, Preetha CJ, Sahm F, Maier-Hein K, Zenk M, Bendszus M, Wick W, Calabrese E, Rudie J, Villanueva-Meyer J, Cha S, Ingalhalikar M, Jadhav M, Pandey U, Saini J, Garrett J, Larson M, Jeraj R, Currie S, Frood R, Fatania K, Huang RY, Chang K, Balaña C, Capellades J, Puig J, Trenkler J, Pichler J, Necker G, Haunschmidt A, Meckel S, Shukla G, Liem S, Alexander GS, Lombardo J, Palmer JD, Flanders AE, Dicker AP, Sair HI, Jones CK, Venkataraman A, Jiang M, So TY, Chen C, Heng PA, Dou Q, Kozubek M, Lux F, Michálek J, Matula P, Kerkovský M, Koprivová T, Dostál M, Vybíhal V, Vogelbaum MA, Mitchell JR, Farinhas J, Maldjian JA, Yogananda CGB, Pinho MC, Reddy D, Holcomb J, Wagner BC, Ellingson BM, Cloughesy TF, Raymond C, Oughourlian T, Hagiwara A, Wang C, To MS, Bhardwaj S, Chong C, Agzarian M, Falcão AX, Martins SB, Teixeira BCA, Sprenger F, Menotti D, Lucio DR, LaMontagne P, Marcus D, Wiestler B, Kofler F, Ezhov I, Metz M, Jain R, Lee M, Lui YW, McKinley R, Slotboom J, Radojewski P, Meier R, Wiest R, Murcia D, Fu E, Haas R, Thompson J, Ormond DR, Badve C, Sloan AE, Vadmal V, Waite K, Colen RR, Pei L, Ak M, Srinivasan A, Bapuraj JR, Rao A, Wang N, Yoshiaki O, Moritani T, Turk S, Lee J, Prabhudesai S, Morón F, Mandel J, Kamnitsas K, Glocker B, Dixon LVM, Williams M, Zampakis P, Panagiotopoulos V, Tsiganos P, Alexiou S, Haliassos I, Zacharaki EI, Moustakas K, Kalogeropoulou C, Kardamakis DM, Choi YS, Lee SK, Chang JH, Ahn SS, Luo B, Poisson L, Wen N, Tiwari P, Verma R, Bareja R, Yadav I, Chen J, Kumar N, Smits M, van der Voort SR, Alafandi A, Incekara F, Wijnenga MMJ, Kapsas G, Gahrmann R, Schouten JW, Dubbink HJ, Vincent AJPE, van den Bent MJ, French PJ, Klein S, Yuan Y, Sharma S, Tseng TC, Adabi S, Niclou SP, Keunen O, Hau AC, Vallières M, Fortin D, Lepage M, Landman B, Ramadass K, Xu K, Chotai S, Chambless LB, Mistry A, Thompson RC, Gusev Y, Bhuvaneshwar K, Sayah A, Bencheqroun C, Belouali A, Madhavan S, Booth TC, Chelliah A, Modat M, Shuaib H, Dragos C, Abayazeed A, Kolodziej K, Hill M, Abbassy A, Gamal S, Mekhaimar M, Qayati M, Reyes M, Park JE, Yun J, Kim HS, Mahajan A, Muzi M, Benson S, Beets-Tan RGH, Teuwen J, Herrera-Trujillo A, Trujillo M, Escobar W, Abello A, Bernal J, Gómez J, Choi J, Baek S, Kim Y, Ismael H, Allen B, Buatti JM, Kotrotsou A, Li H, Weiss T, Weller M, Bink A, Pouymayou B, Shaykh HF, Saltz J, Prasanna P, Shrestha S, Mani KM, Payne D, Kurc T, Pelaez E, Franco-Maldonado H, Loayza F, Quevedo S, Guevara P, Torche E, Mendoza C, Vera F, Ríos E, López E, Velastin SA, Ogbole G, Soneye M, Oyekunle D, Odafe-Oyibotha O, Osobu B, Shu'aibu M, Dorcas A, Dako F, Simpson AL, Hamghalam M, Peoples JJ, Hu R, Tran A, Cutler D, Moraes FY, Boss MA, Gimpel J, Veettil DK, Schmidt K, Bialecki B, Marella S, Price C, Cimino L, Apgar C, Shah P, Menze B, Barnholtz-Sloan JS, Martin J, Bakas S. PMID: 36702828; PMCID: PMC9879935.
      View in: PubMed   Mentions:    Fields:    
    36. Synthesizing MR Image Contrast Enhancement Using 3D High-Resolution ConvNets. IEEE Trans Biomed Eng. 2023 02; 70(2):401-412. Chen C, Raymond C, Speier W, Jin X, Cloughesy TF, Enzmann D, Ellingson BM, Arnold CW. PMID: 35853075; PMCID: PMC9928432.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    37. Corrigendum to: EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol. 2023 Jan 05; 25(1):213. Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, Binder ZA, O'Rourke DM, Nathanson DA, Furnari FB, Miller CR. PMID: 36416495; PMCID: PMC9825333.
      View in: PubMed   Mentions:    Fields:    
    38. Isocitrate dehydrogenase (IDH) mutant gliomas: A Society for Neuro-Oncology (SNO) consensus review on diagnosis, management, and future directions. Neuro Oncol. 2023 01 05; 25(1):4-25. Miller JJ, Gonzalez Castro LN, McBrayer S, Weller M, Cloughesy T, Portnow J, Andronesi O, Barnholtz-Sloan JS, Baumert BG, Berger MS, Bi WL, Bindra R, Cahill DP, Chang SM, Costello JF, Horbinski C, Huang RY, Jenkins RB, Ligon KL, Mellinghoff IK, Nabors LB, Platten M, Reardon DA, Shi DD, Schiff D, Wick W, Yan H, von Deimling A, van den Bent M, Kaelin WG, Wen PY. PMID: 36239925; PMCID: PMC9825337.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    39. Radiotherapy combined with nivolumab or temozolomide for newly diagnosed glioblastoma with unmethylated MGMT promoter: An international randomized phase III trial. Neuro Oncol. 2023 01 05; 25(1):123-134. Omuro A, Brandes AA, Carpentier AF, Idbaih A, Reardon DA, Cloughesy T, Sumrall A, Baehring J, van den Bent M, Bähr O, Lombardi G, Mulholland P, Tabatabai G, Lassen U, Sepulveda JM, Khasraw M, Vauleon E, Muragaki Y, Di Giacomo AM, Butowski N, Roth P, Qian X, Fu AZ, Liu Y, Potter V, Chalamandaris AG, Tatsuoka K, Lim M, Weller M. PMID: 35419607; PMCID: PMC9825306.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCTClinical Trials
    40. ABTC-0904: targeting glioma stem cells in GBM: a phase 0/II study of hedgehog pathway inhibitor GDC-0449. J Neurooncol. 2023 Jan; 161(1):33-43. Sloan AE, Nock CJ, Ye X, Buerki R, Chang S, Lesser G, Norden A, Cloughesy T, Olson J, Kerstetter-Fogle A, Rich J, Fisher J, Desideri S, Takebe N, Timmer W, Grossman S, Prados M. PMID: 36581779.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCells
    41. Federated learning enables big data for rare cancer boundary detection. Nat Commun. 2022 12 05; 13(1):7346. Pati S, Baid U, Edwards B, Sheller M, Wang SH, Reina GA, Foley P, Gruzdev A, Karkada D, Davatzikos C, Sako C, Ghodasara S, Bilello M, Mohan S, Vollmuth P, Brugnara G, Preetha CJ, Sahm F, Maier-Hein K, Zenk M, Bendszus M, Wick W, Calabrese E, Rudie J, Villanueva-Meyer J, Cha S, Ingalhalikar M, Jadhav M, Pandey U, Saini J, Garrett J, Larson M, Jeraj R, Currie S, Frood R, Fatania K, Huang RY, Chang K, Balaña C, Capellades J, Puig J, Trenkler J, Pichler J, Necker G, Haunschmidt A, Meckel S, Shukla G, Liem S, Alexander GS, Lombardo J, Palmer JD, Flanders AE, Dicker AP, Sair HI, Jones CK, Venkataraman A, Jiang M, So TY, Chen C, Heng PA, Dou Q, Kozubek M, Lux F, Michálek J, Matula P, Kerkovský M, Koprivová T, Dostál M, Vybíhal V, Vogelbaum MA, Mitchell JR, Farinhas J, Maldjian JA, Yogananda CGB, Pinho MC, Reddy D, Holcomb J, Wagner BC, Ellingson BM, Cloughesy TF, Raymond C, Oughourlian T, Hagiwara A, Wang C, To MS, Bhardwaj S, Chong C, Agzarian M, Falcão AX, Martins SB, Teixeira BCA, Sprenger F, Menotti D, Lucio DR, LaMontagne P, Marcus D, Wiestler B, Kofler F, Ezhov I, Metz M, Jain R, Lee M, Lui YW, McKinley R, Slotboom J, Radojewski P, Meier R, Wiest R, Murcia D, Fu E, Haas R, Thompson J, Ormond DR, Badve C, Sloan AE, Vadmal V, Waite K, Colen RR, Pei L, Ak M, Srinivasan A, Bapuraj JR, Rao A, Wang N, Yoshiaki O, Moritani T, Turk S, Lee J, Prabhudesai S, Morón F, Mandel J, Kamnitsas K, Glocker B, Dixon LVM, Williams M, Zampakis P, Panagiotopoulos V, Tsiganos P, Alexiou S, Haliassos I, Zacharaki EI, Moustakas K, Kalogeropoulou C, Kardamakis DM, Choi YS, Lee SK, Chang JH, Ahn SS, Luo B, Poisson L, Wen N, Tiwari P, Verma R, Bareja R, Yadav I, Chen J, Kumar N, Smits M, van der Voort SR, Alafandi A, Incekara F, Wijnenga MMJ, Kapsas G, Gahrmann R, Schouten JW, Dubbink HJ, Vincent AJPE, van den Bent MJ, French PJ, Klein S, Yuan Y, Sharma S, Tseng TC, Adabi S, Niclou SP, Keunen O, Hau AC, Vallières M, Fortin D, Lepage M, Landman B, Ramadass K, Xu K, Chotai S, Chambless LB, Mistry A, Thompson RC, Gusev Y, Bhuvaneshwar K, Sayah A, Bencheqroun C, Belouali A, Madhavan S, Booth TC, Chelliah A, Modat M, Shuaib H, Dragos C, Abayazeed A, Kolodziej K, Hill M, Abbassy A, Gamal S, Mekhaimar M, Qayati M, Reyes M, Park JE, Yun J, Kim HS, Mahajan A, Muzi M, Benson S, Beets-Tan RGH, Teuwen J, Herrera-Trujillo A, Trujillo M, Escobar W, Abello A, Bernal J, Gómez J, Choi J, Baek S, Kim Y, Ismael H, Allen B, Buatti JM, Kotrotsou A, Li H, Weiss T, Weller M, Bink A, Pouymayou B, Shaykh HF, Saltz J, Prasanna P, Shrestha S, Mani KM, Payne D, Kurc T, Pelaez E, Franco-Maldonado H, Loayza F, Quevedo S, Guevara P, Torche E, Mendoza C, Vera F, Ríos E, López E, Velastin SA, Ogbole G, Soneye M, Oyekunle D, Odafe-Oyibotha O, Osobu B, Shu'aibu M, Dorcas A, Dako F, Simpson AL, Hamghalam M, Peoples JJ, Hu R, Tran A, Cutler D, Moraes FY, Boss MA, Gimpel J, Veettil DK, Schmidt K, Bialecki B, Marella S, Price C, Cimino L, Apgar C, Shah P, Menze B, Barnholtz-Sloan JS, Martin J, Bakas S. PMID: 36470898; PMCID: PMC9722782.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    42. EGFR, the Lazarus target for precision oncology in glioblastoma. Neuro Oncol. 2022 12 01; 24(12):2035-2062. Lin B, Ziebro J, Smithberger E, Skinner KR, Zhao E, Cloughesy TF, Binder ZA, O'Rourke DM, Nathanson DA, Furnari FB, Miller CR. PMID: 36125064; PMCID: PMC9713527.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    43. Relapse patterns and radiation dose exposure in IDH wild-type glioblastoma at first radiographic recurrence following chemoradiation. J Neurooncol. 2022 Oct; 160(1):115-125. Shidoh S, Savjani RR, Cho NS, Ullman HE, Hagiwara A, Raymond C, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Kaprealian TB, Salamon N, Ellingson BM. PMID: 36053452; PMCID: PMC9622513.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    44. Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac124. Cho NS, Hagiwara A, Eldred BSC, Raymond C, Wang C, Sanvito F, Lai A, Nghiemphu P, Salamon N, Steelman L, Hassan I, Cloughesy TF, Ellingson BM. PMID: 36033919; PMCID: PMC9400453.
      View in: PubMed   Mentions: 3  
    45. Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumors. Neuro Oncol. 2022 08 01; 24(8):1219-1229. Ellingson BM, Gerstner ER, Lassman AB, Chung C, Colman H, Cole PE, Leung D, Allen JE, Ahluwalia MS, Boxerman J, Brown M, Goldin J, Nduom E, Hassan I, Gilbert MR, Mellinghoff IK, Weller M, Chang S, Arons D, Meehan C, Selig W, Tanner K, Alfred Yung WK, van den Bent M, Wen PY, Cloughesy TF. PMID: 35380705; PMCID: PMC9340639.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    46. Incidence, molecular characteristics, and imaging features of "clinically-defined pseudoprogression" in newly diagnosed glioblastoma treated with chemoradiation. J Neurooncol. 2022 Sep; 159(3):509-518. Hagiwara A, Schlossman J, Shabani S, Raymond C, Tatekawa H, Abrey LE, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Cloughesy TF, Ellingson BM. PMID: 35842871.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    47. Amine-weighted chemical exchange saturation transfer magnetic resonance imaging in brain tumors. NMR Biomed. 2023 06; 36(6):e4785. Cho NS, Hagiwara A, Yao J, Nathanson DA, Prins RM, Wang C, Raymond C, Desousa BR, Divakaruni A, Morrow DH, Nghiemphu PL, Lai A, Liau LM, Everson RG, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. PMID: 35704275.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    48. Circulating Immune Cell and Outcome Analysis from the Phase II Study of PD-L1 Blockade with Durvalumab for Newly Diagnosed and Recurrent Glioblastoma. Clin Cancer Res. 2022 06 13; 28(12):2567-2578. Nayak L, Standifer N, Dietrich J, Clarke JL, Dunn GP, Lim M, Cloughesy T, Gan HK, Flagg E, George E, Gaffey S, Hayden J, Holcroft C, Wen PY, Macri M, Park AJ, Ricciardi T, Ryan A, Schwarzenberger P, Venhaus R, Reyes ML, Durham NM, Creasy T, Huang RY, Kaley T, Reardon DA. PMID: 35395080; PMCID: PMC9940445.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    49. Diffusion MRI is an early biomarker of overall survival benefit in IDH wild-type recurrent glioblastoma treated with immune checkpoint inhibitors. Neuro Oncol. 2022 06 01; 24(6):1020-1028. Hagiwara A, Oughourlian TC, Cho NS, Schlossman J, Wang C, Yao J, Raymond C, Everson R, Patel K, Mareninov S, Rodriguez FJ, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Prins RM, Cloughesy TF, Ellingson BM. PMID: 34865129; PMCID: PMC9159421.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    50. Infigratinib in Patients with Recurrent Gliomas and FGFR Alterations: A Multicenter Phase II Study. Clin Cancer Res. 2022 06 01; 28(11):2270-2277. Lassman AB, Sepúlveda-Sánchez JM, Cloughesy TF, Gil-Gil MJ, Puduvalli VK, Raizer JJ, De Vos FYF, Wen PY, Butowski NA, Clement PMJ, Groves MD, Belda-Iniesta C, Giglio P, Soifer HS, Rowsey S, Xu C, Avogadri F, Wei G, Moran S, Roth P. PMID: 35344029; PMCID: PMC9167702.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    51. Characterization of Cognitive Function in Survivors of Diffuse Gliomas Using Morphometric Correlation Networks. Tomography. 2022 05 26; 8(3):1437-1452. Wang C, Cho NS, Dyk KV, Islam S, Raymond C, Choi J, Salamon N, Pope WB, Lai A, Cloughesy TF, Nghiemphu PL, Ellingson BM. PMID: 35736864; PMCID: PMC9229761.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    52. Diagnostic and Prognostic Value of pH- and Oxygen-Sensitive Magnetic Resonance Imaging in Glioma: A Retrospective Study. Cancers (Basel). 2022 May 20; 14(10). Yao J, Hagiwara A, Oughourlian TC, Wang C, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 35626127; PMCID: PMC9139712.
      View in: PubMed   Mentions: 1  
    53. Daily functioning in glioma survivors: associations with cognitive function, psychological factors and quality of life. CNS Oncol. 2022 06 01; 11(2):CNS84. Van Dyk K, Wall L, Heimberg BF, Choi J, Raymond C, Wang C, Lai A, Cloughesy TF, Ellingson BM, Nghiemphu P. PMID: 35583041; PMCID: PMC9134930.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    54. Volumetric measurements are preferred in the evaluation of mutant IDH inhibition in non-enhancing diffuse gliomas: Evidence from a phase I trial of ivosidenib. Neuro Oncol. 2022 05 04; 24(5):770-778. Ellingson BM, Kim GHJ, Brown M, Lee J, Salamon N, Steelman L, Hassan I, Pandya SS, Chun S, Linetsky M, Yoo B, Wen PY, Mellinghoff IK, Goldin J, Cloughesy TF. PMID: 34751786; PMCID: PMC9071341.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    55. Radiographic Response Assessment Strategies for Early-Phase Brain Trials in Complex Tumor Types and Drug Combinations: from Digital "Flipbooks" to Control Systems Theory. Neurotherapeutics. 2022 10; 19(6):1855-1868. Ellingson BM, Levin VA, Cloughesy TF. PMID: 35451676; PMCID: PMC9723080.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    56. Paradoxical Association Between Relative Cerebral Blood Volume Dynamics Following Chemoradiation and Increased Progression-Free Survival in Newly Diagnosed IDH Wild-Type MGMT Promoter Methylated Glioblastoma With Measurable Disease. Front Oncol. 2022; 12:849993. Goldman J, Hagiwara A, Yao J, Raymond C, Ong C, Bakhti R, Kwon E, Farhat M, Torres C, Erickson LG, Curl BJ, Lee M, Pope WB, Salamon N, Nghiemphu PL, Ji M, Eldred BS, Liau LM, Lai A, Cloughesy TF, Chung C, Ellingson BM. PMID: 35371980; PMCID: PMC8964348.
      View in: PubMed   Mentions: 1  
    57. Prognostic value of O6-methylguanine-DNA methyltransferase methylation in isocitrate dehydrogenase mutant gliomas. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac030. Lam K, Eldred BSC, Kevan B, Pianka S, Eldred BA, Zapanta Rinonos S, Yong WH, Liau LM, Nghiemphu PL, Cloughesy TF, Green RM, Lai A. PMID: 35386566; PMCID: PMC8982195.
      View in: PubMed   Mentions: 2  
    58. Publisher Correction: ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer. 2022 Mar; 3(3):373. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks JK, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat DJ, Zhang H, Cooper LAD, Zhang B, Sims P, Cloughesy TF, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto FM, Rabadan R, Sonabend AM. PMID: 35149861.
      View in: PubMed   Mentions:    Fields:    
    59. Nivolumab plus radiotherapy with or without temozolomide in newly diagnosed glioblastoma: Results from exploratory phase I cohorts of CheckMate 143. Neurooncol Adv. 2022 Jan-Dec; 4(1):vdac025. Omuro A, Reardon DA, Sampson JH, Baehring J, Sahebjam S, Cloughesy TF, Chalamandaris AG, Potter V, Butowski N, Lim M. PMID: 35402913; PMCID: PMC8989388.
      View in: PubMed   Mentions: 18  
    60. Balancing Risk and Efficiency in Drug Development for Rare and Challenging Tumors: A New Paradigm for Glioma. J Clin Oncol. 2022 10 20; 40(30):3510-3519. Mellinghoff IK, Cloughesy TF. PMID: 35201903; PMCID: PMC10166355.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    61. Designing Clinical Trials for Combination Immunotherapy: A Framework for Glioblastoma. Clin Cancer Res. 2022 02 15; 28(4):585-593. Singh K, Batich KA, Wen PY, Tan AC, Bagley SJ, Lim M, Platten M, Colman H, Ashley DM, Chang SM, Rahman R, Galanis E, Mansouri A, Puduvalli VK, Reardon DA, Sahebjam S, Sampson JH, Simes J, Berry DA, Zadeh G, Cloughesy TF, Mehta MP, Piantadosi S, Weller M, Heimberger AB, Khasraw M. PMID: 34561270; PMCID: PMC9306329.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    62. Glioblastoma Clinical Trials: Current Landscape and Opportunities for Improvement. Clin Cancer Res. 2022 02 15; 28(4):594-602. Bagley SJ, Kothari S, Rahman R, Lee EQ, Dunn GP, Galanis E, Chang SM, Nabors LB, Ahluwalia MS, Stupp R, Mehta MP, Reardon DA, Grossman SA, Sulman EP, Sampson JH, Khagi S, Weller M, Cloughesy TF, Wen PY, Khasraw M. PMID: 34561269; PMCID: PMC9044253.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    63. Visualization of tumor heterogeneity and prediction of isocitrate dehydrogenase mutation status for human gliomas using multiparametric physiologic and metabolic MRI. Sci Rep. 2022 01 20; 12(1):1078. Hagiwara A, Tatekawa H, Yao J, Raymond C, Everson R, Patel K, Mareninov S, Yong WH, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 35058510; PMCID: PMC8776874.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    64. ERK1/2 phosphorylation predicts survival following anti-PD-1 immunotherapy in recurrent glioblastoma. Nat Cancer. 2021 12; 2(12):1372-1386. Arrieta VA, Chen AX, Kane JR, Kang SJ, Kassab C, Dmello C, Zhao J, Burdett KB, Upadhyayula PS, Lee-Chang C, Shilati J, Jaishankar D, Chen L, Gould A, Zhang D, Yuan J, Zhao W, Ling X, Burks JK, Laffleur B, Amidei C, Bruce JN, Lukas RV, Yamaguchi JT, Cieremans D, Rothschild G, Basu U, McCord M, Brat DJ, Zhang H, Cooper LAD, Zhang B, Sims P, Cloughesy TF, Prins R, Canoll P, Stupp R, Heimberger AB, Horbinski C, Iwamoto FM, Rabadan R, Sonabend AM. PMID: 35121903; PMCID: PMC8818262.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCells
    65. Neoadjuvant PD-1 blockade induces T cell and cDC1 activation but fails to overcome the immunosuppressive tumor associated macrophages in recurrent glioblastoma. Nat Commun. 2021 11 26; 12(1):6938. Lee AH, Sun L, Mochizuki AY, Reynoso JG, Orpilla J, Chow F, Kienzler JC, Everson RG, Nathanson DA, Bensinger SJ, Liau LM, Cloughesy T, Hugo W, Prins RM. PMID: 34836966; PMCID: PMC8626557.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCells
    66. "Aerobic glycolytic imaging" of human gliomas using combined pH-, oxygen-, and perfusion-weighted magnetic resonance imaging. Neuroimage Clin. 2021; 32:102882. Hagiwara A, Yao J, Raymond C, Cho NS, Everson R, Patel K, Morrow DH, Desousa BR, Mareninov S, Chun S, Nathanson DA, Yong WH, Andrei G, Divakaruni AS, Salamon N, Pope WB, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 34911188; PMCID: PMC8609049.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    67. Targeting glioblastoma signaling and metabolism with a re-purposed brain-penetrant drug. Cell Rep. 2021 11 02; 37(5):109957. Bi J, Khan A, Tang J, Armando AM, Wu S, Zhang W, Gimple RC, Reed A, Jing H, Koga T, Wong IT, Gu Y, Miki S, Yang H, Prager B, Curtis EJ, Wainwright DA, Furnari FB, Rich JN, Cloughesy TF, Kornblum HI, Quehenberger O, Rzhetsky A, Cravatt BF, Mischel PS. PMID: 34731610; PMCID: PMC8856626.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansAnimalsCells
    68. Leveraging external data in the design and analysis of clinical trials in neuro-oncology. Lancet Oncol. 2021 10; 22(10):e456-e465. Rahman R, Ventz S, McDunn J, Louv B, Reyes-Rivera I, Polley MC, Merchant F, Abrey LE, Allen JE, Aguilar LK, Aguilar-Cordova E, Arons D, Tanner K, Bagley S, Khasraw M, Cloughesy T, Wen PY, Alexander BM, Trippa L. PMID: 34592195; PMCID: PMC8893120.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    69. Therapeutic Response Assessment of High-Grade Gliomas During Early-Phase Drug Development in the Era of Molecular and Immunotherapies. Cancer J. 2021 Sep-Oct 01; 27(5):395-403. Ellingson BM, Wen PY, Cloughesy TF. PMID: 34570454; PMCID: PMC8480435.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    70. Characterization of cognitive function in survivors of diffuse gliomas using resting-state functional MRI (rs-fMRI). Brain Imaging Behav. 2022 Feb; 16(1):239-251. Wang C, Van Dyk K, Cho N, Raymond C, Choi J, Salamon N, Pope WB, Lai A, Cloughesy TF, Nghiemphu PL, Ellingson BM. PMID: 34350525; PMCID: PMC8825610.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    71. Dopamine Receptor Antagonists, Radiation, and Cholesterol Biosynthesis in Mouse Models of Glioblastoma. J Natl Cancer Inst. 2021 08 02; 113(8):1094-1104. Bhat K, Saki M, Cheng F, He L, Zhang L, Ioannidis A, Nathanson D, Tsang J, Bensinger SJ, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. PMID: 33556960; PMCID: PMC8328983.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    72. Resolution of tissue signatures of therapy response in patients with recurrent GBM treated with neoadjuvant anti-PD1. Nat Commun. 2021 06 29; 12(1):4031. Lu Y, Ng AHC, Chow FE, Everson RG, Helmink BA, Tetzlaff MT, Thakur R, Wargo JA, Cloughesy TF, Prins RM, Heath JR. PMID: 34188042; PMCID: PMC8241935.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCells
    73. Erratum to: FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab059. Sharaf R, Pavlick DC, Frampton GM, Cooper M, Jenkins J, Danziger N, Haberberger J, Alexander BM, Cloughesy T, Yong WH, Liau LM, Nghiemphu PL, Ji M, Lai A, Ramkissoon SH, Albacker LA. PMID: 34169283; PMCID: PMC8218850.
      View in: PubMed   Mentions:
    74. Validation of diffusion MRI as a biomarker for efficacy using randomized phase III trial of bevacizumab with or without VB-111 in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab082. Ellingson BM, Patel K, Wang C, Raymond C, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Schlossman J, Rizvi S, Cohen YC, Lowenton-Spier N, Minei TR, Shmueli SF, Wen PY, Cloughesy TF. PMID: 34377989; PMCID: PMC8350152.
      View in: PubMed   Mentions: 2  
    75. Worse prognosis for IDH wild-type diffuse gliomas with larger residual biological tumor burden. Ann Nucl Med. 2021 Sep; 35(9):1022-1029. Tatekawa H, Uetani H, Hagiwara A, Bahri S, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. PMID: 34121166.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    76. Effects of the DRD2/3 antagonist ONC201 and radiation in glioblastoma. Radiother Oncol. 2021 08; 161:140-147. He L, Bhat K, Ioannidis A, Zhang L, Nguyen NT, Allen JE, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. PMID: 34097975; PMCID: PMC8480533.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimalsCells
    77. Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I Trial. Clin Cancer Res. 2021 08 15; 27(16):4491-4499. Mellinghoff IK, Penas-Prado M, Peters KB, Burris HA, Maher EA, Janku F, Cote GM, de la Fuente MI, Clarke JL, Ellingson BM, Chun S, Young RJ, Liu H, Choe S, Lu M, Le K, Hassan I, Steelman L, Pandya SS, Cloughesy TF, Wen PY. PMID: 34078652; PMCID: PMC8364866.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    78. Early results from the CODEL trial for anaplastic oligodendrogliomas: is temozolomide futile? Neuro Oncol. 2021 03 25; 23(3):347-349. Lassman AB, Cloughesy TF. PMID: 33560350; PMCID: PMC7992892.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    79. Unique challenges for glioblastoma immunotherapy-discussions across neuro-oncology and non-neuro-oncology experts in cancer immunology. Meeting Report from the 2019 SNO Immuno-Oncology Think Tank. Neuro Oncol. 2021 03 25; 23(3):356-375. Chuntova P, Chow F, Watchmaker PB, Galvez M, Heimberger AB, Newell EW, Diaz A, DePinho RA, Li MO, Wherry EJ, Mitchell D, Terabe M, Wainwright DA, Berzofsky JA, Herold-Mende C, Heath JR, Lim M, Margolin KA, Chiocca EA, Kasahara N, Ellingson BM, Brown CE, Chen Y, Fecci PE, Reardon DA, Dunn GP, Liau LM, Costello JF, Wick W, Cloughesy T, Timmer WC, Wen PY, Prins RM, Platten M, Okada H. PMID: 33367885; PMCID: PMC7992879.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    80. Preferential tumor localization in relation to 18F-FDOPA uptake for lower-grade gliomas. J Neurooncol. 2021 May; 152(3):573-582. Tatekawa H, Uetani H, Hagiwara A, Yao J, Yao J, Oughourlian TC, Ueda I, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Bahri S, Pope WB, Salamon N, Ellingson BM. PMID: 33704629; PMCID: PMC8221401.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    81. Differentiating IDH status in human gliomas using machine learning and multiparametric MR/PET. Cancer Imaging. 2021 Mar 10; 21(1):27. Tatekawa H, Hagiwara A, Uetani H, Bahri S, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. PMID: 33691798; PMCID: PMC7944911.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    82. Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trials. Neuro Oncol. 2021 02 25; 23(2):189-198. Ellingson BM, Brown MS, Boxerman JL, Gerstner ER, Kaufmann TJ, Cole PE, Bacha JA, Leung D, Barone A, Colman H, van den Bent MJ, Wen PY, Alfred Yung WK, Cloughesy TF, Goldin JG. PMID: 33130879; PMCID: PMC7906061.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    83. FoundationOne CDx testing accurately determines whole arm 1p19q codeletion status in gliomas. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab017. Sharaf R, Pavlick DC, Frampton GM, Cooper M, Jenkins J, Danziger N, Haberberger J, Alexander BM, Cloughesy T, Yong WH, Liau LM, Nghiemphu PL, Ji M, Lai A, Ramkissoon SH, Albacker LA. PMID: 33778493; PMCID: PMC7986056.
      View in: PubMed   Mentions: 5  
    84. Development of a gene expression-based prognostic signature for IDH wild-type glioblastoma. Neuro Oncol. 2020 12 18; 22(12):1742-1756. Johnson RM, Phillips HS, Bais C, Brennan CW, Cloughesy TF, Daemen A, Herrlinger U, Jenkins RB, Lai A, Mancao C, Weller M, Wick W, Bourgon R, Garcia J. PMID: 32897363; PMCID: PMC7746941.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    85. Volumetric analysis of IDH-mutant lower-grade glioma: a natural history study of tumor growth rates before and after treatment. Neuro Oncol. 2020 12 18; 22(12):1822-1830. Huang RY, Young RJ, Ellingson BM, Veeraraghavan H, Wang W, Tixier F, Um H, Nawaz R, Luks T, Kim J, Gerstner ER, Schiff D, Peters KB, Mellinghoff IK, Chang SM, Cloughesy TF, Wen PY. PMID: 32328652; PMCID: PMC7746936.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    86. Maximum Uptake and Hypermetabolic Volume of 18F-FDOPA PET Estimate Molecular Status and Overall Survival in Low-Grade Gliomas: A PET and MRI Study. Clin Nucl Med. 2020 Dec; 45(12):e505-e511. Tatekawa H, Yao J, Oughourlian TC, Hagiwara A, Wang C, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Salamon N, Ellingson BM. PMID: 33031233; PMCID: PMC7950323.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    87. Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial. JAMA Oncol. 2020 12 01; 6(12):1939-1946. Cloughesy TF, Petrecca K, Walbert T, Butowski N, Salacz M, Perry J, Damek D, Bota D, Bettegowda C, Zhu JJ, Iwamoto F, Placantonakis D, Kim L, Elder B, Kaptain G, Cachia D, Moshel Y, Brem S, Piccioni D, Landolfi J, Chen CC, Gruber H, Rao AR, Hogan D, Accomando W, Ostertag D, Montellano TT, Kheoh T, Kabbinavar F, Vogelbaum MA. PMID: 33119048; PMCID: PMC7596685.
      View in: PubMed   Mentions: 61     Fields:    Translation:Humans
    88. MRI Radiomic Features to Predict IDH1 Mutation Status in Gliomas: A Machine Learning Approach using Gradient Tree Boosting. Int J Mol Sci. 2020 Oct 27; 21(21). Sakai Y, Yang C, Kihira S, Tsankova N, Khan F, Hormigo A, Lai A, Cloughesy T, Nael K. PMID: 33121211; PMCID: PMC7662499.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    89. Relative oxygen extraction fraction (rOEF) MR imaging reveals higher hypoxia in human epidermal growth factor receptor (EGFR) amplified compared with non-amplified gliomas. Neuroradiology. 2021 Jun; 63(6):857-868. Oughourlian TC, Yao J, Yao J, Hagiwara A, Nathanson DA, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 33106922; PMCID: PMC8071834.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    90. Diffusion Magnetic Resonance Imaging Phenotypes Predict Overall Survival Benefit From Bevacizumab or Surgery in Recurrent Glioblastoma With Large Tumor Burden. Neurosurgery. 2020 10 15; 87(5):931-938. Patel KS, Everson RG, Yao J, Yao J, Raymond C, Goldman J, Schlossman J, Tsung J, Tan C, Pope WB, Ji MS, Nguyen NT, Lai A, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 32365185; PMCID: PMC7566341.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    91. Emerging immunotherapies for malignant glioma: from immunogenomics to cell therapy. Neuro Oncol. 2020 10 14; 22(10):1425-1438. Dunn GP, Cloughesy TF, Maus MV, Prins RM, Reardon DA, Sonabend AM. PMID: 32615600; PMCID: PMC7686464.
      View in: PubMed   Mentions: 26     Fields:    Translation:Humans
    92. Consensus recommendations for a dynamic susceptibility contrast MRI protocol for use in high-grade gliomas. Neuro Oncol. 2020 09 29; 22(9):1262-1275. Boxerman JL, Quarles CC, Hu LS, Erickson BJ, Gerstner ER, Smits M, Kaufmann TJ, Barboriak DP, Huang RH, Wick W, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Chung C, van den Bent MJ, Chang S, Al Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Rosen BR, Ellingson BM, Schmainda KM, Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. PMID: 32516388; PMCID: PMC7523451.
      View in: PubMed   Mentions: 71     Fields:    Translation:Humans
    93. Phase I/II study of sorafenib in combination with erlotinib for recurrent glioblastoma as part of a 3-arm sequential accrual clinical trial: NABTC 05-02. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa124. Chen H, Kuhn J, Lamborn KR, Abrey LE, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WKA, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Wen PY, Gilbert MR. PMID: 33235994; PMCID: PMC7668489.
      View in: PubMed   Mentions: 5  
    94. Lipid Droplets Maintain Energy Homeostasis and Glioblastoma Growth via Autophagic Release of Stored Fatty Acids. iScience. 2020 Oct 23; 23(10):101569. Wu X, Geng F, Cheng X, Guo Q, Zhong Y, Cloughesy TF, Yong WH, Chakravarti A, Guo D. PMID: 33083736; PMCID: PMC7549116.
      View in: PubMed   Mentions: 43  
    95. Multiparametric MR-PET measurements in hypermetabolic regions reflect differences in molecular status and tumor grade in treatment-naïve diffuse gliomas. J Neurooncol. 2020 Sep; 149(2):337-346. Tatekawa H, Hagiwara A, Uetani H, Yao J, Yao J, Oughourlian TC, Bahri S, Wang C, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. PMID: 32929644; PMCID: PMC7682113.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    96. Decorin expression is associated with predictive diffusion MR phenotypes of anti-VEGF efficacy in glioblastoma. Sci Rep. 2020 09 09; 10(1):14819. Patel KS, Yao J, Yao J, Raymond C, Yong W, Everson R, Liau LM, Nathanson D, Kornblum H, Wang C, Oughourlian T, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. PMID: 32908231; PMCID: PMC7481206.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimals
    97. Increased epithelial membrane protein 2 expression in glioblastoma after treatment with bevacizumab. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa112. Patel KS, Kejriwal S, Thammachantha S, Duong C, Murillo A, Gordon LK, Cloughesy TF, Liau L, Yong W, Yang I, Wadehra M. PMID: 33063013; PMCID: PMC7542982.
      View in: PubMed   Mentions: 3  
    98. Glioblastoma in adults: a Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) consensus review on current management and future directions. Neuro Oncol. 2020 08 17; 22(8):1073-1113. Wen PY, Weller M, Lee EQ, Alexander BM, Barnholtz-Sloan JS, Barthel FP, Batchelor TT, Bindra RS, Chang SM, Chiocca EA, Cloughesy TF, DeGroot JF, Galanis E, Gilbert MR, Hegi ME, Horbinski C, Huang RY, Lassman AB, Le Rhun E, Lim M, Mehta MP, Mellinghoff IK, Minniti G, Nathanson D, Platten M, Preusser M, Roth P, Sanson M, Schiff D, Short SC, Taphoorn MJB, Tonn JC, Tsang J, Verhaak RGW, von Deimling A, Wick W, Zadeh G, Reardon DA, Aldape KD, van den Bent MJ. PMID: 32328653; PMCID: PMC7594557.
      View in: PubMed   Mentions: 384     Fields:    Translation:Humans
    99. Human IDH mutant 1p/19q co-deleted gliomas have low tumor acidity as evidenced by molecular MRI and PET: a retrospective study. Sci Rep. 2020 07 17; 10(1):11922. Yao J, Yao J, Hagiwara A, Raymond C, Shabani S, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 32681084; PMCID: PMC7367867.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    100. Voxelwise and Patientwise Correlation of 18F-FDOPA PET, Relative Cerebral Blood Volume, and Apparent Diffusion Coefficient in Treatment-Naïve Diffuse Gliomas with Different Molecular Subtypes. J Nucl Med. 2021 03; 62(3):319-325. Tatekawa H, Hagiwara A, Yao J, Yao J, Oughourlian TC, Ueda I, Uetani H, Raymond C, Lai A, Cloughesy TF, Nghiemphu PL, Liau LM, Pope WB, Salamon N, Ellingson BM. PMID: 32646876; PMCID: PMC8049346.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCells
    101. Ivosidenib in Isocitrate Dehydrogenase 1-Mutated Advanced Glioma. J Clin Oncol. 2020 10 10; 38(29):3398-3406. Mellinghoff IK, Ellingson BM, Touat M, Maher E, De La Fuente MI, Holdhoff M, Cote GM, Burris H, Janku F, Young RJ, Huang R, Jiang L, Choe S, Fan B, Yen K, Lu M, Bowden C, Steelman L, Pandya SS, Cloughesy TF, Wen PY. PMID: 32530764; PMCID: PMC7527160.
      View in: PubMed   Mentions: 103     Fields:    Translation:HumansCTClinical Trials
    102. A phase 1 study of PF-06840003, an oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor in patients with recurrent malignant glioma. Invest New Drugs. 2020 12; 38(6):1784-1795. Reardon DA, Desjardins A, Rixe O, Cloughesy T, Alekar S, Williams JH, Li R, Taylor CT, Lassman AB. PMID: 32436060.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    103. Safety and efficacy of VB-111, an anticancer gene therapy, in patients with recurrent glioblastoma: results of a phase I/II study. Neuro Oncol. 2020 05 15; 22(5):694-704. Brenner AJ, Peters KB, Vredenburgh J, Bokstein F, Blumenthal DT, Yust-Katz S, Peretz I, Oberman B, Freedman LS, Ellingson BM, Cloughesy TF, Sher N, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Yakov N, Mendel I, Breitbart E, Wen PY. PMID: 31844886; PMCID: PMC7229257.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    104. A randomized controlled phase III study of VB-111 combined with bevacizumab vs bevacizumab monotherapy in patients with recurrent glioblastoma (GLOBE). Neuro Oncol. 2020 05 15; 22(5):705-717. Cloughesy TF, Brenner A, de Groot JF, Butowski NA, Zach L, Campian JL, Ellingson BM, Freedman LS, Cohen YC, Lowenton-Spier N, Rachmilewitz Minei T, Fain Shmueli S, GLOBE Study Investigators, Wen PY. PMID: 31844890; PMCID: PMC7229248.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCTClinical Trials
    105. The dopamine receptor antagonist trifluoperazine prevents phenotype conversion and improves survival in mouse models of glioblastoma. Proc Natl Acad Sci U S A. 2020 05 19; 117(20):11085-11096. Bhat K, Saki M, Vlashi E, Cheng F, Duhachek-Muggy S, Alli C, Yu G, Medina P, He L, Damoiseaux R, Pellegrini M, Zemke NR, Nghiemphu PL, Cloughesy TF, Liau LM, Kornblum HI, Pajonk F. PMID: 32358191; PMCID: PMC7245100.
      View in: PubMed   Mentions: 17     Fields:    Translation:Animals
    106. Development of a Potent Brain-Penetrant EGFR Tyrosine Kinase Inhibitor against Malignant Brain Tumors. ACS Med Chem Lett. 2020 Oct 08; 11(10):1799-1809. Tsang JE, Urner LM, Kim G, Chow K, Baufeld L, Faull K, Cloughesy TF, Clark PM, Jung ME, Nathanson DA. PMID: 33062157; PMCID: PMC7549123.
      View in: PubMed   Mentions: 12  
    107. Multiparametric MR-PET Imaging Predicts Pharmacokinetics and Clinical Response to GDC-0084 in Patients with Recurrent High-Grade Glioma. Clin Cancer Res. 2020 07 01; 26(13):3135-3144. Ellingson BM, Yao J, Yao J, Raymond C, Nathanson DA, Chakhoyan A, Simpson J, Garner JS, Olivero AG, Mueller LU, Rodon J, Gerstner E, Cloughesy TF, Wen PY. PMID: 32269051; PMCID: PMC8204664.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    108. Diffusion MRI changes in the anterior subventricular zone following chemoradiation in glioblastoma with posterior ventricular involvement. J Neurooncol. 2020 May; 147(3):643-652. Cho N, Wang C, Raymond C, Kaprealian T, Ji M, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 32239430; PMCID: PMC7769136.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    109. Targeted next-generation sequencing of 565 neuro-oncology patients at UCLA: A single-institution experience. Neurooncol Adv. 2020 Jan-Dec; 2(1):vdaa009. Ji MS, Eldred BSC, Liu R, Pianka ST, Molaie D, Kevan B, Pan S, Lai TJ, Nguyen NT, Chow FE, Yong WH, Cox CD, Reeh DN, Li T, Liau LM, Nghiemphu PL, Cloughesy TF, Li G, Lai A. PMID: 32118206; PMCID: PMC7034640.
      View in: PubMed   Mentions: 8  
    110. Rate of change in maximum 18F-FDOPA PET uptake and non-enhancing tumor volume predict malignant transformation and overall survival in low-grade gliomas. J Neurooncol. 2020 Mar; 147(1):135-145. Oughourlian TC, Yao J, Yao J, Schlossman J, Raymond C, Ji M, Tatekawa H, Salamon N, Pope WB, Czernin J, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 31981013; PMCID: PMC7080591.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    111. First-in-Human Phase I Study to Evaluate the Brain-Penetrant PI3K/mTOR Inhibitor GDC-0084 in Patients with Progressive or Recurrent High-Grade Glioma. Clin Cancer Res. 2020 04 15; 26(8):1820-1828. Wen PY, Cloughesy TF, Olivero AG, Morrissey KM, Wilson TR, Lu X, Mueller LU, Coimbra AF, Ellingson BM, Gerstner E, Lee EQ, Rodon J. PMID: 31937616.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCTClinical Trials
    112. The medical necessity of advanced molecular testing in the diagnosis and treatment of brain tumor patients. Neuro Oncol. 2019 12 17; 21(12):1498-1508. Horbinski C, Ligon KL, Brastianos P, Huse JT, Venere M, Chang S, Buckner J, Cloughesy T, Jenkins RB, Giannini C, Stupp R, Nabors LB, Wen PY, Aldape KJ, Lukas RV, Galanis E, Eberhart CG, Brat DJ, Sarkaria JN. PMID: 31276167; PMCID: PMC6917404.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    113. First-In-Human Phase I Study Of A Dual mTOR Kinase And DNA-PK Inhibitor (CC-115) In Advanced Malignancy. Cancer Manag Res. 2019; 11:10463-10476. Munster P, Mita M, Mahipal A, Nemunaitis J, Massard C, Mikkelsen T, Cruz C, Paz-Ares L, Hidalgo M, Rathkopf D, Blumenschein G, Smith DC, Eichhorst B, Cloughesy T, Filvaroff EH, Li S, Raymon H, de Haan H, Hege K, Bendell JC. PMID: 31853198; PMCID: PMC6916675.
      View in: PubMed   Mentions: 44  
    114. mTORC2 links growth factor signaling with epigenetic regulation of iron metabolism in glioblastoma. J Biol Chem. 2019 12 20; 294(51):19740-19751. Masui K, Harachi M, Ikegami S, Yang H, Onizuka H, Yong WH, Cloughesy TF, Muragaki Y, Kawamata T, Arai N, Komori T, Cavenee WK, Mischel PS, Shibata N. PMID: 31712311; PMCID: PMC6926466.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCells
    115. To randomize, or not to randomize, that is the question: using data from prior clinical trials to guide future designs. Neuro Oncol. 2019 10 09; 21(10):1239-1249. Vanderbeek AM, Ventz S, Rahman R, Fell G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. PMID: 31155679; PMCID: PMC6784282.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    116. Metabolic characterization of human IDH mutant and wild type gliomas using simultaneous pH- and oxygen-sensitive molecular MRI. Neuro Oncol. 2019 09 06; 21(9):1184-1196. Yao J, Yao J, Chakhoyan A, Nathanson DA, Yong WH, Salamon N, Raymond C, Mareninov S, Lai A, Nghiemphu PL, Prins RM, Pope WB, Everson RG, Liau LM, Cloughesy TF, Ellingson BM. PMID: 31066901; PMCID: PMC7594567.
      View in: PubMed   Mentions: 23     Fields:    Translation:HumansCells
    117. Letter: When Less is More: Dexamethasone Dosing for Brain Tumors. Neurosurgery. 2019 09 01; 85(3):E607-E608. Lim-Fat MJ, Bi WL, Lo J, Lee EQ, Ahluwalia MS, Batchelor TT, Chang SM, Chiocca EA, Chukwueke U, Cloughesy TF, Colman H, Deangelis LM, Galanis E, Gilbert MR, De Groot JF, Lassman AB, Liau LM, Mason W, McFaline-Figueroa JR, Mehta MP, Mellinghoff IK, Nabors LB, Nayak L, Reardon DA, Wen PY. PMID: 31215634; PMCID: PMC6904720.
      View in: PubMed   Mentions: 7     Fields:    
    118. Oncogene Amplification in Growth Factor Signaling Pathways Renders Cancers Dependent on Membrane Lipid Remodeling. Cell Metab. 2019 09 03; 30(3):525-538.e8. Bi J, Ichu TA, Zanca C, Yang H, Zhang W, Gu Y, Chowdhry S, Reed A, Ikegami S, Turner KM, Zhang W, Villa GR, Wu S, Quehenberger O, Yong WH, Kornblum HI, Rich JN, Cloughesy TF, Cavenee WK, Furnari FB, Cravatt BF, Mischel PS. PMID: 31303424; PMCID: PMC6742496.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansAnimalsCells
    119. Mechanisms of Resistance to EGFR Inhibition Reveal Metabolic Vulnerabilities in Human GBM. Mol Cancer Ther. 2019 09; 18(9):1565-1576. McKinney A, Lindberg OR, Engler JR, Chen KY, Kumar A, Gong H, Lu KV, Simonds EF, Cloughesy TF, Liau LM, Prados M, Bollen AW, Berger MS, Shieh JTC, James CD, Nicolaides TP, Yong WH, Lai A, Hegi ME, Weiss WA, Phillips JJ. PMID: 31270152; PMCID: PMC6726545.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    120. Design and Evaluation of an External Control Arm Using Prior Clinical Trials and Real-World Data. Clin Cancer Res. 2019 08 15; 25(16):4993-5001. Ventz S, Lai A, Cloughesy TF, Wen PY, Trippa L, Alexander BM. PMID: 31175098; PMCID: PMC6697596.
      View in: PubMed   Mentions: 29     Fields:    Translation:Humans
    121. Patterns of long-term survivorship following bevacizumab treatment for recurrent glioma: a case series. CNS Oncol. 2019 06 01; 8(2):CNS35. Liu LY, Ji MS, Nguyen NT, Chow FE, Molaie DM, Pianka ST, Green RM, Liau LM, Ellingson BM, Nghiemphu PL, Cloughesy TF, Lai A. PMID: 31293169; PMCID: PMC6713025.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    122. Somatostatin Receptor Ligand Therapy-A Potential Therapy for Neurocytoma. J Clin Endocrinol Metab. 2019 06 01; 104(6):2395-2402. Zhang D, Kim SSR, Kelly DF, Asa SL, Movassaghi M, Mareninov S, Yong WH, Cloughesy TF, Rodriguez FJ, McKeever P, Qian J, Li JY, Mao Q, Newell KL, Green RM, Welsh CT, Xiong Z, Heaney AP. PMID: 30722009.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    123. Safety, tolerability, and pharmacokinetics of anti-EGFRvIII antibody-drug conjugate AMG 595 in patients with recurrent malignant glioma expressing EGFRvIII. Cancer Chemother Pharmacol. 2019 08; 84(2):327-336. Rosenthal M, Curry R, Reardon DA, Rasmussen E, Upreti VV, Damore MA, Henary HA, Hill JS, Cloughesy T. PMID: 31154523.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    124. SPINT2 is hypermethylated in both IDH1 mutated and wild-type glioblastomas, and exerts tumor suppression via reduction of c-Met activation. J Neurooncol. 2019 May; 142(3):423-434. Liu F, Cox CD, Chowdhury R, Dovek L, Nguyen H, Li T, Li S, Ozer B, Chou A, Nguyen N, Wei B, Antonios J, Soto H, Kornblum H, Liau L, Prins R, Nghiemphu PL, Yong W, Cloughesy T, Lai A. PMID: 30838489; PMCID: PMC6516751.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    125. pH-weighted amine chemical exchange saturation transfer echoplanar imaging (CEST-EPI) as a potential early biomarker for bevacizumab failure in recurrent glioblastoma. J Neurooncol. 2019 May; 142(3):587-595. Yao J, Yao J, Tan CHP, Schlossman J, Chakhoyan A, Raymond C, Pope WB, Salamon N, Lai A, Ji M, Nghiemphu PL, Liau LM, Cloughesy TF, Ellingson BM. PMID: 30806888; PMCID: PMC6482078.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    126. Validation of vessel size imaging (VSI) in high-grade human gliomas using magnetic resonance imaging, image-guided biopsies, and quantitative immunohistochemistry. Sci Rep. 2019 02 26; 9(1):2846. Chakhoyan A, Yao J, Yao J, Leu K, Pope WB, Salamon N, Yong W, Lai A, Nghiemphu PL, Everson RG, Prins RM, Liau LM, Nathanson DA, Cloughesy TF, Ellingson BM. PMID: 30808879; PMCID: PMC6391482.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    127. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. PMID: 30742122; PMCID: PMC6408961.
      View in: PubMed   Mentions: 593     Fields:    Translation:HumansCells
    128. Buparlisib in Patients With Recurrent Glioblastoma Harboring Phosphatidylinositol 3-Kinase Pathway Activation: An Open-Label, Multicenter, Multi-Arm, Phase II Trial. J Clin Oncol. 2019 03 20; 37(9):741-750. Wen PY, Touat M, Alexander BM, Mellinghoff IK, Ramkissoon S, McCluskey CS, Pelton K, Haidar S, Basu SS, Gaffey SC, Brown LE, Martinez-Ledesma JE, Wu S, Kim J, Wei W, Park MA, Huse JT, Kuhn JG, Rinne ML, Colman H, Agar NYR, Omuro AM, DeAngelis LM, Gilbert MR, de Groot JF, Cloughesy TF, Chi AS, Roberts TM, Zhao JJ, Lee EQ, Nayak L, Heath JR, Horky LL, Batchelor TT, Beroukhim R, Chang SM, Ligon AH, Dunn IF, Koul D, Young GS, Prados MD, Reardon DA, Yung WKA, Ligon KL. PMID: 30715997; PMCID: PMC6553812.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansCellsCTClinical Trials
    129. Expression of PD-1 by T Cells in Malignant Glioma Patients Reflects Exhaustion and Activation. Clin Cancer Res. 2019 03 15; 25(6):1913-1922. Davidson TB, Lee A, Hsu M, Sedighim S, Orpilla J, Treger J, Mastall M, Roesch S, Rapp C, Galvez M, Mochizuki A, Antonios J, Garcia A, Kotecha N, Bayless N, Nathanson D, Wang A, Everson R, Yong WH, Cloughesy TF, Liau LM, Herold-Mende C, Prins RM. PMID: 30498094; PMCID: PMC6420851.
      View in: PubMed   Mentions: 38     Fields:    Translation:HumansCells
    130. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo. Neuro Oncol. 2018 10 09; 20(11):1525-1535. Ellingson BM, Abrey LE, Garcia J, Chinot O, Wick W, Saran F, Nishikawa R, Henriksson R, Mason WP, Harris RJ, Leu K, Woodworth DC, Mehta A, Raymond C, Chakhoyan A, Pope WB, Cloughesy TF. PMID: 29897562; PMCID: PMC6178278.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    131. Longitudinal Patterns in Clinical and Imaging Measurements Predict Residual Survival in Glioblastoma Patients. Sci Rep. 2018 09 26; 8(1):14429. Smedley NF, Ellingson BM, Cloughesy TF, Hsu W. PMID: 30258190; PMCID: PMC6158293.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    132. Bevacizumab at first recurrence after standard radio-chemotherapy is associated with improved overall survival in glioblastoma patients with large tumor burden. Neurooncol Pract. 2019 Mar; 6(2):103-111. Nguyen HT, Nguyen N, Liu LY, Dovek L, Lenchner D, Harris R, Ozer B, Ravelo A, Sommer N, Sim MS, Elashoff R, Green R, Nghiemphu PL, Cloughesy TF, Ellingson B, Lai A. PMID: 31386050; PMCID: PMC6656330.
      View in: PubMed   Mentions: 3  
    133. Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC. Neuro Oncol. 2018 09 03; 20(10):1383-1392. Cloughesy TF, Landolfi J, Vogelbaum MA, Ostertag D, Elder JB, Bloomfield S, Carter B, Chen CC, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu P, Piccioni D, Accomando W, Diago OR, Hogan DJ, Gammon D, Kasahara N, Kheoh T, Jolly DJ, Gruber HE, Das A, Walbert T. PMID: 29762717; PMCID: PMC6120351.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCellsCTClinical Trials
    134. Volumetric response quantified using T1 subtraction predicts long-term survival benefit from cabozantinib monotherapy in recurrent glioblastoma. Neuro Oncol. 2018 09 03; 20(10):1411-1418. Ellingson BM, Aftab DT, Schwab GM, Hessel C, Harris RJ, Woodworth DC, Leu K, Chakhoyan A, Raymond C, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Wen PY, Cloughesy TF. PMID: 29660005; PMCID: PMC6120362.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    135. Improving B0 Correction for pH-Weighted Amine Proton Chemical Exchange Saturation Transfer (CEST) Imaging by Use of k-Means Clustering and Lorentzian Estimation. Tomography. 2018 Sep; 4(3):123-137. Yao J, Yao J, Ruan D, Raymond C, Liau LM, Salamon N, Pope WB, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 30320212; PMCID: PMC6173788.
      View in: PubMed   Mentions: 15     Fields:    
    136. Correlation of commercially available quantitative MGMT (O-6-methylguanine-DNA methyltransferase) promoter methylation scores and GBM patient survival. Neurooncol Pract. 2019 May; 6(3):194-202. Dovek L, Nguyen NT, Ozer BH, Li N, Elashoff RM, Green RM, Liau L, Nghiemphu PL, Cloughesy TF, Lai A. PMID: 31386024; PMCID: PMC6656311.
      View in: PubMed   Mentions: 4  
    137. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. PMID: 29660006; PMCID: PMC6071654.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    138. Associations of anticoagulant use with outcome in newly diagnosed glioblastoma. Eur J Cancer. 2018 09; 101:95-104. Le Rhun E, Genbrugge E, Stupp R, Chinot OL, Nabors LB, Cloughesy T, Reardon DA, Wick W, Gorlia T, Weller M. PMID: 30036741.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    139. Is it time to reconsider the role of irinotecan for the treatment of high-grade gliomas? Neuro Oncol. 2018 07 05; 20(8):1144. Lee EQ, McFaline-Figueroa JR, Cloughesy TF, Wen PY. PMID: 29955870; PMCID: PMC6280142.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    140. The clinical trials landscape for glioblastoma: is it adequate to develop new treatments? Neuro Oncol. 2018 07 05; 20(8):1034-1043. Vanderbeek AM, Rahman R, Fell G, Ventz S, Chen T, Redd R, Parmigiani G, Cloughesy TF, Wen PY, Trippa L, Alexander BM. PMID: 29518210; PMCID: PMC6280141.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    141. Correction to: First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 06 29; 16(1):179. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29958537; PMCID: PMC6026340.
      View in: PubMed   Mentions: 10     Fields:    
    142. Mono-exponential, diffusion kurtosis and stretched exponential diffusion MR imaging response to chemoradiation in newly diagnosed glioblastoma. J Neurooncol. 2018 Sep; 139(3):651-659. Chakhoyan A, Woodworth DC, Harris RJ, Lai A, Nghiemphu PL, Liau LM, Pope WB, Cloughesy TF, Ellingson BM. PMID: 29855771; PMCID: PMC6126989.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    143. First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma. J Transl Med. 2018 05 29; 16(1):142. Liau LM, Ashkan K, Tran DD, Campian JL, Trusheim JE, Cobbs CS, Heth JA, Salacz M, Taylor S, D'Andre SD, Iwamoto FM, Dropcho EJ, Moshel YA, Walter KA, Pillainayagam CP, Aiken R, Chaudhary R, Goldlust SA, Bota DA, Duic P, Grewal J, Elinzano H, Toms SA, Lillehei KO, Mikkelsen T, Walbert T, Abram SR, Brenner AJ, Brem S, Ewend MG, Khagi S, Portnow J, Kim LJ, Loudon WG, Thompson RC, Avigan DE, Fink KL, Geoffroy FJ, Lindhorst S, Lutzky J, Sloan AE, Schackert G, Krex D, Meisel HJ, Wu J, Davis RP, Duma C, Etame AB, Mathieu D, Kesari S, Piccioni D, Westphal M, Baskin DS, New PZ, Lacroix M, May SA, Pluard TJ, Tse V, Green RM, Villano JL, Pearlman M, Petrecca K, Schulder M, Taylor LP, Maida AE, Prins RM, Cloughesy TF, Mulholland P, Bosch ML. PMID: 29843811; PMCID: PMC5975654.
      View in: PubMed   Mentions: 256     Fields:    Translation:HumansCellsCTClinical Trials
    144. Platform trials arrive on time for glioblastoma. Neuro Oncol. 2018 05 18; 20(6):723-725. Alexander BM, Cloughesy TF. PMID: 29617844; PMCID: PMC5961158.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    145. 18F-FDOPA PET and MRI characteristics correlate with degree of malignancy and predict survival in treatment-naïve gliomas: a cross-sectional study. J Neurooncol. 2018 Sep; 139(2):399-409. Patel CB, Fazzari E, Chakhoyan A, Yao J, Yao J, Raymond C, Nguyen H, Manoukian J, Nguyen N, Pope W, Cloughesy TF, Nghiemphu PL, Czernin J, Lai A, Ellingson BM. PMID: 29679199; PMCID: PMC6092195.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    146. Nivolumab with or without ipilimumab in patients with recurrent glioblastoma: results from exploratory phase I cohorts of CheckMate 143. Neuro Oncol. 2018 04 09; 20(5):674-686. Omuro A, Vlahovic G, Lim M, Sahebjam S, Baehring J, Cloughesy T, Voloschin A, Ramkissoon SH, Ligon KL, Latek R, Zwirtes R, Strauss L, Paliwal P, Harbison CT, Reardon DA, Sampson JH. PMID: 29106665; PMCID: PMC5892140.
      View in: PubMed   Mentions: 233     Fields:    Translation:HumansCTClinical Trials
    147. Simultaneous pH-sensitive and oxygen-sensitive MRI of human gliomas at 3 T using multi-echo amine proton chemical exchange saturation transfer spin-and-gradient echo echo-planar imaging (CEST-SAGE-EPI). Magn Reson Med. 2018 11; 80(5):1962-1978. Harris RJ, Yao J, Yao J, Chakhoyan A, Raymond C, Leu K, Liau LM, Nghiemphu PL, Lai A, Salamon N, Pope WB, Cloughesy TF, Ellingson BM. PMID: 29626359; PMCID: PMC6107417.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    148. Evidence and context of use for contrast enhancement as a surrogate of disease burden and treatment response in malignant glioma. Neuro Oncol. 2018 03 27; 20(4):457-471. Ellingson BM, Wen PY, Cloughesy TF. PMID: 29040703; PMCID: PMC5909663.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    149. Radiologic progression of glioblastoma under therapy-an exploratory analysis of AVAglio. Neuro Oncol. 2018 03 27; 20(4):557-566. Nowosielski M, Ellingson BM, Chinot OL, Garcia J, Revil C, Radbruch A, Nishikawa R, Mason WP, Henriksson R, Saran F, Kickingereder P, Platten M, Sandmann T, Abrey LE, Cloughesy TF, Bendszus M, Wick W. PMID: 29016943; PMCID: PMC5909665.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCellsCTClinical Trials
    150. D-2-Hydroxyglutarate Is Necessary and Sufficient for Isocitrate Dehydrogenase 1 Mutant-Induced MIR148A Promoter Methylation. Mol Cancer Res. 2018 06; 16(6):947-960. Li T, Cox CD, Ozer BH, Nguyen NT, Nguyen HN, Lai TJ, Li S, Liu F, Kornblum HI, Liau LM, Nghiemphu PL, Cloughesy TF, Lai A. PMID: 29545476; PMCID: PMC5984679.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    151. A gene expression signature predicts recurrence-free survival in meningioma. Oncotarget. 2018 Mar 23; 9(22):16087-16098. Olar A, Goodman LD, Wani KM, Boehling NS, Sharma DS, Mody RR, Gumin J, Claus EB, Lang FF, Cloughesy TF, Lai A, Aldape KD, DeMonte F, Sulman EP. PMID: 29662628; PMCID: PMC5882319.
      View in: PubMed   Mentions: 18     Fields:    
    152. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients naive to antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):249-258. Wen PY, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Holland J, Ping J, Weitzman R, Cloughesy TF. PMID: 29016998; PMCID: PMC5777496.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    153. Phase II study of cabozantinib in patients with progressive glioblastoma: subset analysis of patients with prior antiangiogenic therapy. Neuro Oncol. 2018 01 22; 20(2):259-267. Cloughesy TF, Drappatz J, de Groot J, Prados MD, Reardon DA, Schiff D, Chamberlain M, Mikkelsen T, Desjardins A, Ping J, Holland J, Weitzman R, Wen PY. PMID: 29036345; PMCID: PMC5777491.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    154. Phase 2 Study of Bortezomib Combined With Temozolomide and Regional Radiation Therapy for Upfront Treatment of Patients With Newly Diagnosed Glioblastoma Multiforme: Safety and Efficacy Assessment. Int J Radiat Oncol Biol Phys. 2018 04 01; 100(5):1195-1203. Kong XT, Nguyen NT, Choi YJ, Zhang G, Nguyen HN, Filka E, Green S, Yong WH, Liau LM, Green RM, Kaprealian T, Pope WB, Nghiemphu PL, Cloughesy T, Lassman A, Lai A. PMID: 29722661; PMCID: PMC6277207.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCTClinical Trials
    155. Phase 2 and biomarker study of trebananib, an angiopoietin-blocking peptibody, with and without bevacizumab for patients with recurrent glioblastoma. Cancer. 2018 04 01; 124(7):1438-1448. Reardon DA, Lassman AB, Schiff D, Yunus SA, Gerstner ER, Cloughesy TF, Lee EQ, Gaffey SC, Barrs J, Bruno J, Muzikansky A, Duda DG, Jain RK, Wen PY. PMID: 29266174.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    156. Prospective Feasibility Trial for Genomics-Informed Treatment in Recurrent and Progressive Glioblastoma. Clin Cancer Res. 2018 01 15; 24(2):295-305. Byron SA, Tran NL, Halperin RF, Phillips JJ, Kuhn JG, de Groot JF, Colman H, Ligon KL, Wen PY, Cloughesy TF, Mellinghoff IK, Butowski NA, Taylor JW, Clarke JL, Chang SM, Berger MS, Molinaro AM, Maggiora GM, Peng S, Nasser S, Liang WS, Trent JM, Berens ME, Carpten JD, Craig DW, Prados MD. PMID: 29074604; PMCID: PMC7516926.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    157. Cytoplasmic p53 couples oncogene-driven glucose metabolism to apoptosis and is a therapeutic target in glioblastoma. Nat Med. 2017 Nov; 23(11):1342-1351. Mai WX, Gosa L, Daniels VW, Ta L, Tsang JE, Higgins B, Gilmore WB, Bayley NA, Harati MD, Lee JT, Yong WH, Kornblum HI, Bensinger SJ, Mischel PS, Rao PN, Clark PM, Cloughesy TF, Letai A, Nathanson DA. PMID: 29035366; PMCID: PMC5683421.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansAnimalsCells
    158. Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02. J Neurooncol. 2018 Jan; 136(1):79-86. Nghiemphu PL, Ebiana VA, Wen P, Gilbert M, Abrey LE, Lieberman F, DeAngelis LM, Robins HI, Yung WKA, Chang S, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados M, Kuhn J, Cloughesy TF. PMID: 28988377; PMCID: PMC5756101.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    159. Tissue microarray analysis for epithelial membrane protein-2 as a novel biomarker for gliomas. Brain Tumor Pathol. 2018 Jan; 35(1):1-9. Chung LK, Pelargos PE, Chan AM, Demos JV, Lagman C, Sheppard JP, Nguyen T, Chang YL, Hojat SA, Prins RM, Liau LM, Nghiemphu L, Lai A, Cloughesy TF, Yong WH, Gordon LK, Wadehra M, Yang I. PMID: 28887715; PMCID: PMC6118858.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    160. Detection of immune responses after immunotherapy in glioblastoma using PET and MRI. Proc Natl Acad Sci U S A. 2017 09 19; 114(38):10220-10225. Antonios JP, Soto H, Everson RG, Moughon DL, Wang AC, Orpilla J, Radu C, Ellingson BM, Lee JT, Cloughesy T, Phelps ME, Czernin J, Liau LM, Prins RM. PMID: 28874539; PMCID: PMC5617282.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimalsCells
    161. Adaptive Global Innovative Learning Environment for Glioblastoma: GBM AGILE. Clin Cancer Res. 2018 02 15; 24(4):737-743. Alexander BM, Ba S, Berger MS, Berry DA, Cavenee WK, Chang SM, Cloughesy TF, Jiang T, Khasraw M, Li W, Mittman R, Poste GH, Wen PY, Yung WKA, Barker AD, GBM AGILE Network. PMID: 28814435.
      View in: PubMed   Mentions: 85     Fields:    Translation:Humans
    162. Report of safety of pulse dosing of lapatinib with temozolomide and radiation therapy for newly-diagnosed glioblastoma in a pilot phase II study. J Neurooncol. 2017 Sep; 134(2):357-362. Yu A, Faiq N, Green S, Lai A, Green R, Hu J, Cloughesy TF, Mellinghoff I, Nghiemphu PL. PMID: 28669012; PMCID: PMC6135089.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    163. Diffusion MRI Phenotypes Predict Overall Survival Benefit from Anti-VEGF Monotherapy in Recurrent Glioblastoma: Converging Evidence from Phase II Trials. Clin Cancer Res. 2017 Oct 01; 23(19):5745-5756. Ellingson BM, Gerstner ER, Smits M, Huang RY, Colen R, Abrey LE, Aftab DT, Schwab GM, Hessel C, Harris RJ, Chakhoyan A, Gahrmann R, Pope WB, Leu K, Raymond C, Woodworth DC, de Groot J, Wen PY, Batchelor TT, van den Bent MJ, Cloughesy TF. PMID: 28655794; PMCID: PMC5626594.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansCTClinical Trials
    164. Early experience with formalin-fixed paraffin-embedded (FFPE) based commercial clinical genomic profiling of gliomas-robust and informative with caveats. Exp Mol Pathol. 2017 08; 103(1):87-93. Movassaghi M, Shabihkhani M, Hojat SA, Williams RR, Chung LK, Im K, Lucey GM, Wei B, Mareninov S, Wang MW, Ng DW, Tashjian RS, Magaki S, Perez-Rosendahl M, Yang I, Khanlou N, Vinters HV, Liau LM, Nghiemphu PL, Lai A, Cloughesy TF, Yong WH. PMID: 28663030.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    165. Adult Glioblastoma. J Clin Oncol. 2017 Jul 20; 35(21):2402-2409. Alexander BM, Cloughesy TF. PMID: 28640706.
      View in: PubMed   Mentions: 340     Fields:    Translation:Humans
    166. mTORC2 Regulates Amino Acid Metabolism in Cancer by Phosphorylation of the Cystine-Glutamate Antiporter xCT. Mol Cell. 2017 Jul 06; 67(1):128-138.e7. Gu Y, Albuquerque CP, Braas D, Zhang W, Villa GR, Bi J, Ikegami S, Masui K, Gini B, Yang H, Gahman TC, Shiau AK, Cloughesy TF, Christofk HR, Zhou H, Guan KL, Mischel PS. PMID: 28648777; PMCID: PMC5521991.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansCells
    167. Immunosuppressive tumor-infiltrating myeloid cells mediate adaptive immune resistance via a PD-1/PD-L1 mechanism in glioblastoma. Neuro Oncol. 2017 06 01; 19(6):796-807. Antonios JP, Soto H, Everson RG, Moughon D, Orpilla JR, Shin NP, Sedighim S, Treger J, Odesa S, Tucker A, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PMID: 28115578; PMCID: PMC5464463.
      View in: PubMed   Mentions: 104     Fields:    Translation:HumansAnimalsCells
    168. Perfusion and diffusion MRI signatures in histologic and genetic subtypes of WHO grade II-III diffuse gliomas. J Neurooncol. 2017 Aug; 134(1):177-188. Leu K, Ott GA, Lai A, Nghiemphu PL, Pope WB, Yong WH, Liau LM, Cloughesy TF, Ellingson BM. PMID: 28547590; PMCID: PMC7927357.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCells
    169. The Neurologic Assessment in Neuro-Oncology (NANO) scale: a tool to assess neurologic function for integration into the Response Assessment in Neuro-Oncology (RANO) criteria. Neuro Oncol. 2017 05 01; 19(5):625-635. Nayak L, DeAngelis LM, Brandes AA, Peereboom DM, Galanis E, Lin NU, Soffietti R, Macdonald DR, Chamberlain M, Perry J, Jaeckle K, Mehta M, Stupp R, Muzikansky A, Pentsova E, Cloughesy T, Iwamoto FM, Tonn JC, Vogelbaum MA, Wen PY, van den Bent MJ, Reardon DA. PMID: 28453751; PMCID: PMC5464449.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    170. NovoTTF: where to go from here? Neuro Oncol. 2017 05 01; 19(5):605-608. Cloughesy TF, Lassman AB. PMID: 28453750; PMCID: PMC5464445.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    171. Harnessing Preclinical Molecular Imaging to Inform Advances in Personalized Cancer Medicine. J Nucl Med. 2017 May; 58(5):689-696. Clark PM, Ebiana VA, Gosa L, Cloughesy TF, Nathanson DA. PMID: 28385796.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansAnimals
    172. Modified Criteria for Radiographic Response Assessment in Glioblastoma Clinical Trials. Neurotherapeutics. 2017 04; 14(2):307-320. Ellingson BM, Wen PY, Cloughesy TF. PMID: 28108885; PMCID: PMC5398984.
      View in: PubMed   Mentions: 188     Fields:    Translation:Humans
    173. Human TERT promoter mutation enables survival advantage from MGMT promoter methylation in IDH1 wild-type primary glioblastoma treated by standard chemoradiotherapy. Neuro Oncol. 2017 03 01; 19(3):394-404. Nguyen HN, Lie A, Li T, Chowdhury R, Liu F, Ozer B, Wei B, Green RM, Ellingson BM, Wang HJ, Elashoff R, Liau LM, Yong WH, Nghiemphu PL, Cloughesy T, Lai A. PMID: 27571882; PMCID: PMC5464302.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    174. Incidence, survival, pathology, and genetics of adult Latino Americans with glioblastoma. J Neurooncol. 2017 04; 132(2):351-358. Shabihkhani M, Telesca D, Movassaghi M, Naeini YB, Naeini KM, Hojat SA, Gupta D, Lucey GM, Ontiveros M, Wang MW, Hanna LS, Sanchez DE, Mareninov S, Khanlou N, Vinters HV, Bergsneider M, Nghiemphu PL, Lai A, Liau LM, Cloughesy TF, Yong WH. PMID: 28161760.
      View in: PubMed   Mentions: 18     Fields:    Translation:Humans
    175. Phase I trial of aflibercept (VEGF trap) with radiation therapy and concomitant and adjuvant temozolomide in patients with high-grade gliomas. J Neurooncol. 2017 03; 132(1):181-188. Nayak L, de Groot J, Wefel JS, Cloughesy TF, Lieberman F, Chang SM, Omuro A, Drappatz J, Batchelor TT, DeAngelis LM, Gilbert MR, Aldape KD, Yung AW, Fisher J, Ye X, Chen A, Grossman S, Prados M, Wen PY. PMID: 28116649; PMCID: PMC5588922.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCTClinical Trials
    176. Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Onartuzumab Plus Bevacizumab Versus Placebo Plus Bevacizumab in Patients With Recurrent Glioblastoma: Efficacy, Safety, and Hepatocyte Growth Factor and O6-Methylguanine-DNA Methyltransferase Biomarker Analyses. J Clin Oncol. 2017 Jan 20; 35(3):343-351. Cloughesy T, Finocchiaro G, Belda-Iniesta C, Recht L, Brandes AA, Pineda E, Mikkelsen T, Chinot OL, Balana C, Macdonald DR, Westphal M, Hopkins K, Weller M, Bais C, Sandmann T, Bruey JM, Koeppen H, Liu B, Verret W, Phan SC, Shames DS. PMID: 27918718.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCellsCTClinical Trials
    177. Radiation Therapy for Glioblastoma: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation Oncology Guideline. J Clin Oncol. 2017 Jan 20; 35(3):361-369. Sulman EP, Ismaila N, Armstrong TS, Tsien C, Batchelor TT, Cloughesy T, Galanis E, Gilbert M, Gondi V, Lovely M, Mehta M, Mumber MP, Sloan A, Chang SM. PMID: 27893327.
      View in: PubMed   Mentions: 60     Fields:    Translation:Humans
    178. Phase I study of RO4929097 with bevacizumab in patients with recurrent malignant glioma. J Neurooncol. 2016 12; 130(3):571-579. Pan E, Supko JG, Kaley TJ, Butowski NA, Cloughesy T, Jung J, Desideri S, Grossman S, Ye X, Park DM. PMID: 27826680; PMCID: PMC5571739.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCTClinical Trials
    179. Biomarkers in NOA-04: another piece to the puzzle. Neuro Oncol. 2016 11; 18(11):1467-1469. Lassman AB, Cloughesy TF. PMID: 27738177; PMCID: PMC5063524.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    180. An LXR-Cholesterol Axis Creates a Metabolic Co-Dependency for Brain Cancers. Cancer Cell. 2016 Nov 14; 30(5):683-693. Villa GR, Hulce JJ, Zanca C, Bi J, Ikegami S, Cahill GL, Gu Y, Lum KM, Masui K, Yang H, Rong X, Hong C, Turner KM, Liu F, Hon GC, Jenkins D, Martini M, Armando AM, Quehenberger O, Cloughesy TF, Furnari FB, Cavenee WK, Tontonoz P, Gahman TC, Shiau AK, Cravatt BF, Mischel PS. PMID: 27746144; PMCID: PMC5479636.
      View in: PubMed   Mentions: 155     Fields:    Translation:HumansAnimalsCells
    181. Simulation, phantom validation, and clinical evaluation of fast pH-weighted molecular imaging using amine chemical exchange saturation transfer echo planar imaging (CEST-EPI) in glioma at 3 T. NMR Biomed. 2016 11; 29(11):1563-1576. Harris RJ, Cloughesy TF, Liau LM, Nghiemphu PL, Lai A, Pope WB, Ellingson BM. PMID: 27717216.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    182. Baseline pretreatment contrast enhancing tumor volume including central necrosis is a prognostic factor in recurrent glioblastoma: evidence from single and multicenter trials. Neuro Oncol. 2017 01; 19(1):89-98. Ellingson BM, Harris RJ, Woodworth DC, Leu K, Zaw O, Mason WP, Sahebjam S, Abrey LE, Aftab DT, Schwab GM, Hessel C, Lai A, Nghiemphu PL, Pope WB, Wen PY, Cloughesy TF. PMID: 27580889; PMCID: PMC5193027.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCTClinical Trials
    183. Evaluation of pseudoprogression rates and tumor progression patterns in a phase III trial of bevacizumab plus radiotherapy/temozolomide for newly diagnosed glioblastoma. Neuro Oncol. 2016 10; 18(10):1434-41. Wick W, Chinot OL, Bendszus M, Mason W, Henriksson R, Saran F, Nishikawa R, Revil C, Kerloeguen Y, Cloughesy T. PMID: 27515827; PMCID: PMC5035525.
      View in: PubMed   Mentions: 44     Fields:    Translation:HumansCTClinical Trials
    184. PD-1 blockade enhances the vaccination-induced immune response in glioma. JCI Insight. 2016 Jul 07; 1(10). Antonios JP, Soto H, Everson RG, Orpilla J, Moughon D, Shin N, Sedighim S, Yong WH, Li G, Cloughesy TF, Liau LM, Prins RM. PMID: 27453950; PMCID: PMC4951098.
      View in: PubMed   Mentions: 81     Fields:    
    185. Reply to F. Felix et al and M.F. Fay et al. J Clin Oncol. 2016 09 01; 34(25):3107-8. Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. PMID: 27298403.
      View in: PubMed   Mentions:    Fields:    
    186. Phase 1 trial of vocimagene amiretrorepvec and 5-fluorocytosine for recurrent high-grade glioma. Sci Transl Med. 2016 06 01; 8(341):341ra75. Cloughesy TF, Landolfi J, Hogan DJ, Bloomfield S, Carter B, Chen CC, Elder JB, Kalkanis SN, Kesari S, Lai A, Lee IY, Liau LM, Mikkelsen T, Nghiemphu PL, Piccioni D, Walbert T, Chu A, Das A, Diago OR, Gammon D, Gruber HE, Hanna M, Jolly DJ, Kasahara N, McCarthy D, Mitchell L, Ostertag D, Robbins JM, Rodriguez-Aguirre M, Vogelbaum MA. PMID: 27252174; PMCID: PMC6707068.
      View in: PubMed   Mentions: 99     Fields:    Translation:CellsCTClinical Trials
    187. Large-scale assessment of the gliomasphere model system. Neuro Oncol. 2016 10; 18(10):1367-78. Laks DR, Crisman TJ, Shih MY, Mottahedeh J, Gao F, Sperry J, Garrett MC, Yong WH, Cloughesy TF, Liau LM, Lai A, Coppola G, Kornblum HI. PMID: 27116978; PMCID: PMC5035518.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    188. Single-Cell Phosphoproteomics Resolves Adaptive Signaling Dynamics and Informs Targeted Combination Therapy in Glioblastoma. Cancer Cell. 2016 Apr 11; 29(4):563-573. Wei W, Shin YS, Xue M, Matsutani T, Masui K, Yang H, Ikegami S, Gu Y, Herrmann K, Johnson D, Ding X, Hwang K, Kim J, Zhou J, Su Y, Li X, Bonetti B, Chopra R, James CD, Cavenee WK, Cloughesy TF, Mischel PS, Heath JR, Gini B. PMID: 27070703; PMCID: PMC4831071.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCells
    189. Upfront bevacizumab may extend survival for glioblastoma patients who do not receive second-line therapy: an exploratory analysis of AVAglio. Neuro Oncol. 2016 09; 18(9):1313-8. Chinot OL, Nishikawa R, Mason W, Henriksson R, Saran F, Cloughesy T, Garcia J, Revil C, Abrey L, Wick W. PMID: 27006178; PMCID: PMC4999000.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    190. Contrast-enhancing tumor growth dynamics of preoperative, treatment-naive human glioblastoma. Cancer. 2016 06 01; 122(11):1718-27. Ellingson BM, Nguyen HN, Lai A, Nechifor RE, Zaw O, Pope WB, Yong WH, Nghiemphu PL, Liau LM, Cloughesy TF. PMID: 26998740.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    191. Bidirectional Contrast agent leakage correction of dynamic susceptibility contrast (DSC)-MRI improves cerebral blood volume estimation and survival prediction in recurrent glioblastoma treated with bevacizumab. J Magn Reson Imaging. 2016 11; 44(5):1229-1237. Leu K, Boxerman JL, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. PMID: 26971534.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    192. Clinical aggressiveness of malignant gliomas is linked to augmented metabolism of amino acids. J Neurooncol. 2016 05; 128(1):57-66. Panosyan EH, Lasky JL, Lin HJ, Lai A, Hai Y, Guo X, Quinn M, Nelson SF, Cloughesy TF, Nghiemphu PL. PMID: 26922345; PMCID: PMC5373108.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    193. Prioritization schema for immunotherapy clinical trials in glioblastoma. Oncoimmunology. 2016 Jun; 5(6):e1145332. Hodges TR, Ferguson SD, Caruso HG, Kohanbash G, Zhou S, Cloughesy TF, Berger MS, Poste GH, Khasraw M, Ba S, Jiang T, Mikkelson T, Yung WK, de Groot JF, Fine H, Cantley LC, Mellinghoff IK, Mitchell DA, Okada H, Heimberger AB. PMID: 27471611; PMCID: PMC4938323.
      View in: PubMed   Mentions: 11     Fields:    
    194. Reply to T.J. Kruser et al. J Clin Oncol. 2016 Apr 10; 34(11):1282-3. Chinot OL, Taphoorn MJ, Bais C, Bourgon R, Phillips HS, Abrey LE, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Cloughesy T. PMID: 26884575.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    195. Emerging Approaches for Targeting Metabolic Vulnerabilities in Malignant Glioma. Curr Neurol Neurosci Rep. 2016 Feb; 16(2):17. Clark PM, Mai WX, Cloughesy TF, Nathanson DA. PMID: 26759318.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    196. Bevacizumab, temozolomide, and radiotherapy for newly diagnosed glioblastoma: comprehensive safety results during and after first-line therapy. Neuro Oncol. 2016 07; 18(7):991-1001. Saran F, Chinot OL, Henriksson R, Mason W, Wick W, Cloughesy T, Dhar S, Pozzi E, Garcia J, Nishikawa R. PMID: 26809751; PMCID: PMC4896538.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCTClinical Trials
    197. Does Valproic Acid or Levetiracetam Improve Survival in Glioblastoma? A Pooled Analysis of Prospective Clinical Trials in Newly Diagnosed Glioblastoma. J Clin Oncol. 2016 Mar 01; 34(7):731-9. Happold C, Gorlia T, Chinot O, Gilbert MR, Nabors LB, Wick W, Pugh SL, Hegi M, Cloughesy T, Roth P, Reardon DA, Perry JR, Mehta MP, Stupp R, Weller M. PMID: 26786929; PMCID: PMC5070573.
      View in: PubMed   Mentions: 83     Fields:    Translation:Humans
    198. Phase 1 dose escalation trial of the safety and pharmacokinetics of cabozantinib concurrent with temozolomide and radiotherapy or temozolomide after radiotherapy in newly diagnosed patients with high-grade gliomas. Cancer. 2016 Feb 15; 122(4):582-7. Schiff D, Desjardins A, Cloughesy T, Mikkelsen T, Glantz M, Chamberlain MC, Reardon DA, Wen PY. PMID: 26588662.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    199. Bone morphogenetic protein 7 sensitizes O6-methylguanine methyltransferase expressing-glioblastoma stem cells to clinically relevant dose of temozolomide. Mol Cancer. 2015 Nov 06; 14:189. Tso JL, Yang S, Menjivar JC, Yamada K, Zhang Y, Hong I, Bui Y, Stream A, McBride WH, Liau LM, Nelson SF, Cloughesy TF, Yong WH, Lai A, Tso CL. PMID: 26546412; PMCID: PMC4636799.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCells
    200. Ribosomal Proteins RPS11 and RPS20, Two Stress-Response Markers of Glioblastoma Stem Cells, Are Novel Predictors of Poor Prognosis in Glioblastoma Patients. PLoS One. 2015; 10(10):e0141334. Yong WH, Shabihkhani M, Telesca D, Yang S, Tso JL, Menjivar JC, Wei B, Lucey GM, Mareninov S, Chen Z, Liau LM, Lai A, Nelson SF, Cloughesy TF, Tso CL. PMID: 26506620; PMCID: PMC4624638.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    201. Association between lesion location and language function in adult glioma using voxel-based lesion-symptom mapping. Neuroimage Clin. 2015; 9:617-24. Banerjee P, Leu K, Harris RJ, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB, Bookheimer SY, Ellingson BM. PMID: 26740915; PMCID: PMC4644251.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    202. The Impact of T2/FLAIR Evaluation per RANO Criteria on Response Assessment of Recurrent Glioblastoma Patients Treated with Bevacizumab. Clin Cancer Res. 2016 Feb 01; 22(3):575-81. Huang RY, Rahman R, Ballman KV, Felten SJ, Anderson SK, Ellingson BM, Nayak L, Lee EQ, Abrey LE, Galanis E, Reardon DA, Pope WB, Cloughesy TF, Wen PY. PMID: 26490307.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    203. Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study. Neuro Oncol. 2016 Apr; 18(4):557-64. Butowski N, Colman H, De Groot JF, Omuro AM, Nayak L, Wen PY, Cloughesy TF, Marimuthu A, Haidar S, Perry A, Huse J, Phillips J, West BL, Nolop KB, Hsu HH, Ligon KL, Molinaro AM, Prados M. PMID: 26449250; PMCID: PMC4799682.
      View in: PubMed   Mentions: 282     Fields:    Translation:HumansCTClinical Trials
    204. EGFR Mutation Promotes Glioblastoma through Epigenome and Transcription Factor Network Remodeling. Mol Cell. 2015 Oct 15; 60(2):307-18. Liu F, Hon GC, Villa GR, Turner KM, Ikegami S, Yang H, Ye Z, Li B, Kuan S, Lee AY, Zanca C, Wei B, Lucey G, Jenkins D, Zhang W, Barr CL, Furnari FB, Cloughesy TF, Yong WH, Gahman TC, Shiau AK, Cavenee WK, Ren B, Mischel PS. PMID: 26455392; PMCID: PMC4609298.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansAnimalsCells
    205. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma. Tomography. 2015 Sep; 1(1):37-43. Chang W, Pope WB, Harris RJ, Hardy AJ, Leu K, Mody RR, Nghiemphu PL, Lai A, Cloughesy TF, Ellingson BM. PMID: 26740971; PMCID: PMC4698970.
      View in: PubMed   Mentions: 7     Fields:    
    206. Consensus recommendations for a standardized Brain Tumor Imaging Protocol in clinical trials. Neuro Oncol. 2015 Sep; 17(9):1188-98. Ellingson BM, Bendszus M, Boxerman J, Barboriak D, Erickson BJ, Smits M, Nelson SJ, Gerstner E, Alexander B, Goldmacher G, Wick W, Vogelbaum M, Weller M, Galanis E, Kalpathy-Cramer J, Shankar L, Jacobs P, Pope WB, Yang D, Chung C, Knopp MV, Cha S, van den Bent MJ, Chang S, Yung WK, Cloughesy TF, Wen PY, Gilbert MR, Jumpstarting Brain Tumor Drug Development Coalition Imaging Standardization Steering Committee. PMID: 26250565; PMCID: PMC4588759.
      View in: PubMed   Mentions: 291     Fields:    Translation:Humans
    207. 2-Hydroxyglutarate Inhibits ATP Synthase and mTOR Signaling. Cell Metab. 2015 Sep 01; 22(3):508-15. Fu X, Chin RM, Vergnes L, Hwang H, Deng G, Xing Y, Pai MY, Li S, Ta L, Fazlollahi F, Chen C, Prins RM, Teitell MA, Nathanson DA, Lai A, Faull KF, Jiang M, Clarke SG, Cloughesy TF, Graeber TG, Braas D, Christofk HR, Jung ME, Reue K, Huang J. PMID: 26190651; PMCID: PMC4663076.
      View in: PubMed   Mentions: 124     Fields:    Translation:HumansAnimalsCells
    208. Glucose-dependent acetylation of Rictor promotes targeted cancer therapy resistance. Proc Natl Acad Sci U S A. 2015 Jul 28; 112(30):9406-11. Masui K, Tanaka K, Ikegami S, Villa GR, Yang H, Yong WH, Cloughesy TF, Yamagata K, Arai N, Cavenee WK, Mischel PS. PMID: 26170313; PMCID: PMC4522814.
      View in: PubMed   Mentions: 69     Fields:    Translation:HumansAnimalsCells
    209. Patients With Proneural Glioblastoma May Derive Overall Survival Benefit From the Addition of Bevacizumab to First-Line Radiotherapy and Temozolomide: Retrospective Analysis of the AVAglio Trial. J Clin Oncol. 2015 Sep 01; 33(25):2735-44. Sandmann T, Bourgon R, Garcia J, Li C, Cloughesy T, Chinot OL, Wick W, Nishikawa R, Mason W, Henriksson R, Saran F, Lai A, Moore N, Kharbanda S, Peale F, Hegde P, Abrey LE, Phillips HS, Bais C. PMID: 26124478; PMCID: PMC5015426.
      View in: PubMed   Mentions: 145     Fields:    Translation:Humans
    210. pH-weighted molecular imaging of gliomas using amine chemical exchange saturation transfer MRI. Neuro Oncol. 2015 Nov; 17(11):1514-24. Harris RJ, Cloughesy TF, Liau LM, Prins RM, Antonios JP, Li D, Yong WH, Pope WB, Lai A, Nghiemphu PL, Ellingson BM. PMID: 26113557; PMCID: PMC4648305.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansAnimals
    211. Radial expansion rates and tumor growth kinetics predict malignant transformation in contrast-enhancing low-grade diffuse astrocytoma. CNS Oncol. 2015; 4(4):247-56. Hathout L, Pope WB, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. PMID: 26095141; PMCID: PMC4538925.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    212. Relationship Between [18F]FDOPA PET Uptake, Apparent Diffusion Coefficient (ADC), and Proliferation Rate in Recurrent Malignant Gliomas. Mol Imaging Biol. 2015 Jun; 17(3):434-42. Karavaeva E, Harris RJ, Leu K, Shabihkhani M, Yong WH, Pope WB, Lai A, Nghiemphu PL, Liau LM, Chen W, Czernin J, Cloughesy TF, Ellingson BM. PMID: 25465392.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    213. Health-Related Quality of Life in a Randomized Phase III Study of Bevacizumab, Temozolomide, and Radiotherapy in Newly Diagnosed Glioblastoma. J Clin Oncol. 2015 Jul 01; 33(19):2166-75. Taphoorn MJ, Henriksson R, Bottomley A, Cloughesy T, Wick W, Mason WP, Saran F, Nishikawa R, Hilton M, Theodore-Oklota C, Ravelo A, Chinot OL. PMID: 26014298.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    214. Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma. Neuro Oncol. 2015 Sep; 17(9):1275-83. Wen PY, Omuro A, Ahluwalia MS, Fathallah-Shaykh HM, Mohile N, Lager JJ, Laird AD, Tang J, Jiang J, Egile C, Cloughesy TF. PMID: 26019185; PMCID: PMC4588757.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCTClinical Trials
    215. Toward precision medicine in glioblastoma: the promise and the challenges. Neuro Oncol. 2015 Aug; 17(8):1051-63. Prados MD, Byron SA, Tran NL, Phillips JJ, Molinaro AM, Ligon KL, Wen PY, Kuhn JG, Mellinghoff IK, de Groot JF, Colman H, Cloughesy TF, Chang SM, Ryken TC, Tembe WD, Kiefer JA, Berens ME, Craig DW, Carpten JD, Trent JM. PMID: 25934816; PMCID: PMC4490873.
      View in: PubMed   Mentions: 106     Fields:    Translation:Humans
    216. Patient-specific characterization of the invasiveness and proliferation of low-grade gliomas using serial MR imaging and a mathematical model of tumor growth. Oncol Rep. 2015 Jun; 33(6):2883-8. Hathout L, Ellingson BM, Cloughesy TF, Pope WB. PMID: 25962999.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    217. The MGMT promoter SNP rs16906252 is a risk factor for MGMT methylation in glioblastoma and is predictive of response to temozolomide. Neuro Oncol. 2015 Dec; 17(12):1589-98. Rapkins RW, Wang F, Nguyen HN, Cloughesy TF, Lai A, Ha W, Nowak AK, Hitchins MP, McDonald KL. PMID: 25910840; PMCID: PMC4633927.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCells
    218. Quantification of Nonenhancing Tumor Burden in Gliomas Using Effective T2 Maps Derived from Dual-Echo Turbo Spin-Echo MRI. Clin Cancer Res. 2015 Oct 01; 21(19):4373-83. Ellingson BM, Lai A, Nguyen HN, Nghiemphu PL, Pope WB, Cloughesy TF. PMID: 25901082; PMCID: PMC4592379.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    219. Heterogeneity of epidermal growth factor receptor signalling networks in glioblastoma. Nat Rev Cancer. 2015 May; 15(5):302-10. Furnari FB, Cloughesy TF, Cavenee WK, Mischel PS. PMID: 25855404; PMCID: PMC4875778.
      View in: PubMed   Mentions: 201     Fields:    Translation:HumansCells
    220. MRI perfusion measurements calculated using advanced deconvolution techniques predict survival in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2015 May; 122(3):497-505. Harris RJ, Cloughesy TF, Hardy AJ, Liau LM, Pope WB, Nghiemphu PL, Lai A, Ellingson BM. PMID: 25773062.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    221. Emerging function of mTORC2 as a core regulator in glioblastoma: metabolic reprogramming and drug resistance. Cancer Biol Med. 2014 Dec; 11(4):255-63. Wu SH, Bi JF, Cloughesy T, Cavenee WK, Mischel PS. PMID: 25610711; PMCID: PMC4296088.
      View in: PubMed   Mentions: 30     Fields:    
    222. Hypervascular tumor volume estimated by comparison to a large-scale cerebral blood volume radiographic atlas predicts survival in recurrent glioblastoma treated with bevacizumab. Cancer Imaging. 2014 Nov 14; 14:31. Leu K, Enzmann DR, Woodworth DC, Harris RJ, Tran AN, Lai A, Nghiemphu PL, Pope WB, Cloughesy TF, Ellingson BM. PMID: 25608485; PMCID: PMC4331836.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    223. A novel bicompartmental mathematical model of glioblastoma multiforme. Int J Oncol. 2015 Feb; 46(2):825-32. Hathout L, Ellingson BM, Cloughesy T, Pope WB. PMID: 25384756.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansAnimals
    224. Patient-specific metrics of invasiveness reveal significant prognostic benefit of resection in a predictable subset of gliomas. PLoS One. 2014; 9(10):e99057. Baldock AL, Ahn S, Rockne R, Johnston S, Neal M, Corwin D, Clark-Swanson K, Sterin G, Trister AD, Malone H, Ebiana V, Sonabend AM, Mrugala M, Rockhill JK, Silbergeld DL, Lai A, Cloughesy T, McKhann GM, Bruce JN, Rostomily RC, Canoll P, Swanson KR. PMID: 25350742; PMCID: PMC4211670.
      View in: PubMed   Mentions: 39     Fields:    Translation:Humans
    225. Report of the Jumpstarting Brain Tumor Drug Development Coalition and FDA clinical trials neuroimaging endpoint workshop (January 30, 2014, Bethesda MD). Neuro Oncol. 2014 Oct; 16 Suppl 7:vii36-47. Wen PY, Cloughesy TF, Ellingson BM, Reardon DA, Fine HA, Abrey L, Ballman K, Bendszuz M, Buckner J, Chang SM, Prados MD, Pope WB, Gregory Sorensen A, van den Bent M, Yung WK. PMID: 25313237; PMCID: PMC4195530.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    226. Pros and cons of current brain tumor imaging. Neuro Oncol. 2014 Oct; 16 Suppl 7:vii2-11. Ellingson BM, Wen PY, van den Bent MJ, Cloughesy TF. PMID: 25313235; PMCID: PMC4195528.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    227. Tumor-suppressive miR148a is silenced by CpG island hypermethylation in IDH1-mutant gliomas. Clin Cancer Res. 2014 Nov 15; 20(22):5808-22. Li S, Chowdhury R, Liu F, Chou AP, Li T, Mody RR, Lou JJ, Chen W, Reiss J, Soto H, Prins R, Liau LM, Mischel PS, Nghiemphu PL, Yong WH, Cloughesy TF, Lai A. PMID: 25224277; PMCID: PMC4233178.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansAnimalsCells
    228. Brain Malignancy Steering Committee clinical trials planning workshop: report from the Targeted Therapies Working Group. Neuro Oncol. 2015 Feb; 17(2):180-8. Alexander BM, Galanis E, Yung WK, Ballman KV, Boyett JM, Cloughesy TF, Degroot JF, Huse JT, Mann B, Mason W, Mellinghoff IK, Mikkelsen T, Mischel PS, O'Neill BP, Prados MD, Sarkaria JN, Tawab-Amiri A, Trippa L, Ye X, Ligon KL, Berry DA, Wen PY. PMID: 25165194; PMCID: PMC4288520.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    229. Recursive partitioning analysis of prognostic variables in newly diagnosed anaplastic oligodendroglial tumors. Neuro Oncol. 2014 Nov; 16(11):1541-6. Panageas KS, Reiner AS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. PMID: 24997140; PMCID: PMC4201067.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCells
    230. Bevacizumab for newly diagnosed glioblastoma. N Engl J Med. 2014 05 22; 370(21):2049. Chinot OL, Wick W, Cloughesy T. PMID: 24860870.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    231. Treatment response evaluation using 18F-FDOPA PET in patients with recurrent malignant glioma on bevacizumab therapy. Clin Cancer Res. 2014 Jul 01; 20(13):3550-9. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Grogan T, Elashoff D, Geist C, Silverman DH, Phelps ME, Chen W. PMID: 24687922; PMCID: PMC4079729.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    232. Deferred use of bevacizumab for recurrent glioblastoma is not associated with diminished efficacy. Neuro Oncol. 2014 Jun; 16(6):815-22. Piccioni DE, Selfridge J, Mody RR, Chowdhury R, Li S, Lalezari S, Wawrzynski J, Quan J, Zurayk M, Chou AP, Sanchez DE, Liau LM, Ellingson BM, Pope WB, Nghiemphu PL, Green RM, Wang HJ, Yong WH, Elashoff R, Cloughesy TF, Lai A. PMID: 24627236; PMCID: PMC4022228.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    233. ¹⁸F-FLT    and ¹⁸F-FDOPA PET kinetics in recurrent brain tumors. Eur J Nucl Med Mol Imaging. 2014 Jun; 41(6):1199-209. Wardak M, Schiepers C, Cloughesy TF, Dahlbom M, Phelps ME, Huang SC. PMID: 24604590; PMCID: PMC4008691.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    234. Bevacizumab plus radiotherapy-temozolomide for newly diagnosed glioblastoma. N Engl J Med. 2014 Feb 20; 370(8):709-22. Chinot OL, Wick W, Mason W, Henriksson R, Saran F, Nishikawa R, Carpentier AF, Hoang-Xuan K, Kavan P, Cernea D, Brandes AA, Hilton M, Abrey L, Cloughesy T. PMID: 24552318.
      View in: PubMed   Mentions: 1146     Fields:    Translation:HumansCTClinical Trials
    235. Asparagine depletion potentiates the cytotoxic effect of chemotherapy against brain tumors. Mol Cancer Res. 2014 May; 12(5):694-702. Panosyan EH, Wang Y, Xia P, Lee WN, Pak Y, Laks DR, Lin HJ, Moore TB, Cloughesy TF, Kornblum HI, Lasky JL. PMID: 24505127; PMCID: PMC4020976.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCells
    236. C-terminally truncated form of αB-crystallin is associated with IDH1 R132H mutation in anaplastic astrocytoma. J Neurooncol. 2014 Mar; 117(1):53-65. Avliyakulov NK, Rajavel KS, Le KM, Guo L, Mirsadraei L, Yong WH, Liau LM, Li S, Lai A, Nghiemphu PL, Cloughesy TF, Linetsky M, Haykinson MJ, Pope WB. PMID: 24473683.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    237. Phase I/II study of erlotinib and temsirolimus for patients with recurrent malignant gliomas: North American Brain Tumor Consortium trial 04-02. Neuro Oncol. 2014 Apr; 16(4):567-78. Wen PY, Chang SM, Lamborn KR, Kuhn JG, Norden AD, Cloughesy TF, Robins HI, Lieberman FS, Gilbert MR, Mehta MP, Drappatz J, Groves MD, Santagata S, Ligon AH, Yung WK, Wright JJ, Dancey J, Aldape KD, Prados MD, Ligon KL. PMID: 24470557; PMCID: PMC3956354.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansCTClinical Trials
    238. The procurement, storage, and quality assurance of frozen blood and tissue biospecimens in pathology, biorepository, and biobank settings. Clin Biochem. 2014 Mar; 47(4-5):258-66. Shabihkhani M, Lucey GM, Wei B, Mareninov S, Lou JJ, Vinters HV, Singer EJ, Cloughesy TF, Yong WH. PMID: 24424103; PMCID: PMC3982909.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCells
    239. Short-interval estimation of proliferation rate using serial diffusion MRI predicts progression-free survival in newly diagnosed glioblastoma treated with radiochemotherapy. J Neurooncol. 2014 Feb; 116(3):601-8. Zaw TM, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Ellingson BM. PMID: 24395348; PMCID: PMC3955987.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    240. Altered functional connectivity of the default mode network in diffuse gliomas measured with pseudo-resting state fMRI. J Neurooncol. 2014 Jan; 116(2):373-9. Harris RJ, Bookheimer SY, Cloughesy TF, Kim HJ, Pope WB, Lai A, Nghiemphu PL, Liau LM, Ellingson BM. PMID: 24234804; PMCID: PMC6763342.
      View in: PubMed   Mentions: 51     Fields:    Translation:Humans
    241. Nonlinear distortion correction of diffusion MR images improves quantitative DTI measurements in glioblastoma. J Neurooncol. 2014 Feb; 116(3):551-8. Woodworth DC, Pope WB, Liau LM, Kim HJ, Lai A, Nghiemphu PL, Cloughesy TF, Ellingson BM. PMID: 24318915; PMCID: PMC3918907.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    242. Targeted therapy resistance mediated by dynamic regulation of extrachromosomal mutant EGFR DNA. Science. 2014 Jan 03; 343(6166):72-6. Nathanson DA, Gini B, Mottahedeh J, Visnyei K, Koga T, Gomez G, Eskin A, Hwang K, Wang J, Masui K, Paucar A, Yang H, Ohashi M, Zhu S, Wykosky J, Reed R, Nelson SF, Cloughesy TF, James CD, Rao PN, Kornblum HI, Heath JR, Cavenee WK, Furnari FB, Mischel PS. PMID: 24310612; PMCID: PMC4049335.
      View in: PubMed   Mentions: 292     Fields:    Translation:HumansAnimalsCells
    243. Increased sensitivity to radiochemotherapy in IDH1 mutant glioblastoma as demonstrated by serial quantitative MR volumetry. Neuro Oncol. 2014 Mar; 16(3):414-20. Tran AN, Lai A, Li S, Pope WB, Teixeira S, Harris RJ, Woodworth DC, Nghiemphu PL, Cloughesy TF, Ellingson BM. PMID: 24305712; PMCID: PMC3922511.
      View in: PubMed   Mentions: 55     Fields:    Translation:Humans
    244. Comparison of visual and semiquantitative analysis of 18F-FDOPA-PET/CT for recurrence detection in glioblastoma patients. Neuro Oncol. 2014 Apr; 16(4):603-9. Herrmann K, Czernin J, Cloughesy T, Lai A, Pomykala KL, Benz MR, Buck AK, Phelps ME, Chen W. PMID: 24305722; PMCID: PMC3956344.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    245. Where are we now? And where are we going? A report from the Accelerate Brain Cancer Cure (ABC2) low-grade glioma research workshop. Neuro Oncol. 2014 Jan; 16(2):173-8. Huse JT, Wallace M, Aldape KD, Berger MS, Bettegowda C, Brat DJ, Cahill DP, Cloughesy T, Haas-Kogan DA, Marra M, Miller CR, Nelson SJ, Salama SR, Soffietti R, Wen PY, Yip S, Yen K, Costello JF, Chang S. PMID: 24305708; PMCID: PMC3895389.
      View in: PubMed   Mentions: 16     Fields:    Translation:Humans
    246. Recurrent glioblastoma treated with bevacizumab: contrast-enhanced T1-weighted subtraction maps improve tumor delineation and aid prediction of survival in a multicenter clinical trial. Radiology. 2014 Apr; 271(1):200-10. Ellingson BM, Kim HJ, Woodworth DC, Pope WB, Cloughesy JN, Harris RJ, Lai A, Nghiemphu PL, Cloughesy TF. PMID: 24475840; PMCID: PMC4263651.
      View in: PubMed   Mentions: 120     Fields:    Translation:HumansCTClinical Trials
    247. Protective properties of radio-chemoresistant glioblastoma stem cell clones are associated with metabolic adaptation to reduced glucose dependence. PLoS One. 2013; 8(11):e80397. Ye F, Zhang Y, Liu Y, Yamada K, Tso JL, Menjivar JC, Tian JY, Yong WH, Schaue D, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, McBride W, Tso CL. PMID: 24260384; PMCID: PMC3832364.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansCells
    248. mTOR complex 2 controls glycolytic metabolism in glioblastoma through FoxO acetylation and upregulation of c-Myc. Cell Metab. 2013 Nov 05; 18(5):726-39. Masui K, Tanaka K, Akhavan D, Babic I, Gini B, Matsutani T, Iwanami A, Liu F, Villa GR, Gu Y, Campos C, Zhu S, Yang H, Yong WH, Cloughesy TF, Mellinghoff IK, Cavenee WK, Shaw RJ, Mischel PS. PMID: 24140020; PMCID: PMC3840163.
      View in: PubMed   Mentions: 238     Fields:    Translation:HumansAnimalsCells
    249. The mTOR kinase inhibitors, CC214-1 and CC214-2, preferentially block the growth of EGFRvIII-activated glioblastomas. Clin Cancer Res. 2013 Oct 15; 19(20):5722-32. Gini B, Zanca C, Guo D, Matsutani T, Masui K, Ikegami S, Yang H, Nathanson D, Villa GR, Shackelford D, Zhu S, Tanaka K, Babic I, Akhavan D, Lin K, Assuncao A, Gu Y, Bonetti B, Mortensen DS, Xu S, Raymon HK, Cavenee WK, Furnari FB, James CD, Kroemer G, Heath JR, Hege K, Chopra R, Cloughesy TF, Mischel PS. PMID: 24030701; PMCID: PMC3815450.
      View in: PubMed   Mentions: 32     Fields:    Translation:HumansAnimalsCells
    250. Glioblastoma: from molecular pathology to targeted treatment. Annu Rev Pathol. 2014; 9:1-25. Cloughesy TF, Cavenee WK, Mischel PS. PMID: 23937436.
      View in: PubMed   Mentions: 278     Fields:    Translation:HumansAnimals
    251. EGFR mutation-induced alternative splicing of Max contributes to growth of glycolytic tumors in brain cancer. Cell Metab. 2013 Jun 04; 17(6):1000-1008. Babic I, Anderson ES, Tanaka K, Guo D, Masui K, Li B, Zhu S, Gu Y, Villa GR, Akhavan D, Nathanson D, Gini B, Mareninov S, Li R, Camacho CE, Kurdistani SK, Eskin A, Nelson SF, Yong WH, Cavenee WK, Cloughesy TF, Christofk HR, Black DL, Mischel PS. PMID: 23707073; PMCID: PMC3679227.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimalsCells
    252. Lyophilized brain tumor specimens can be used for histologic, nucleic acid, and protein analyses after 1 year of room temperature storage. J Neurooncol. 2013 Jul; 113(3):365-73. Mareninov S, De Jesus J, Sanchez DE, Kay AB, Wilson RW, Babic I, Chen W, Telesca D, Lou JJ, Mirsadraei L, Gardner TP, Khanlou N, Vinters HV, Shafa BB, Lai A, Liau LM, Mischel PS, Cloughesy TF, Yong WH. PMID: 23640138; PMCID: PMC3886564.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCells
    253. Response assessment criteria for glioblastoma: practical adaptation and implementation in clinical trials of antiangiogenic therapy. Curr Neurol Neurosci Rep. 2013 May; 13(5):347. Chinot OL, Macdonald DR, Abrey LE, Zahlmann G, Kerloëguen Y, Cloughesy TF. PMID: 23529375; PMCID: PMC3631110.
      View in: PubMed   Mentions: 63     Fields:    Translation:Humans
    254. Arsenic reverses glioblastoma resistance to mTOR-targeted therapies. Cell Cycle. 2013 May 15; 12(10):1473-4. Iwanami A, Cloughesy TF, Cavenee WK, Mischel PS. PMID: 23624839; PMCID: PMC3680520.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCells
    255. De-repression of PDGFRβ transcription promotes acquired resistance to EGFR tyrosine kinase inhibitors in glioblastoma patients. Cancer Discov. 2013 May; 3(5):534-47. Akhavan D, Pourzia AL, Nourian AA, Williams KJ, Nathanson D, Babic I, Villa GR, Tanaka K, Nael A, Yang H, Dang J, Vinters HV, Yong WH, Flagg M, Tamanoi F, Sasayama T, James CD, Kornblum HI, Cloughesy TF, Cavenee WK, Bensinger SJ, Mischel PS. PMID: 23533263; PMCID: PMC3651754.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    256. PDGFRA amplification is common in pediatric and adult high-grade astrocytomas and identifies a poor prognostic group in IDH1 mutant glioblastoma. Brain Pathol. 2013 Sep; 23(5):565-73. Phillips JJ, Aranda D, Ellison DW, Judkins AR, Croul SE, Brat DJ, Ligon KL, Horbinski C, Venneti S, Zadeh G, Santi M, Zhou S, Appin CL, Sioletic S, Sullivan LM, Martinez-Lage M, Robinson AE, Yong WH, Cloughesy T, Lai A, Phillips HS, Marshall R, Mueller S, Haas-Kogan DA, Molinaro AM, Perry A. PMID: 23438035; PMCID: PMC3715570.
      View in: PubMed   Mentions: 47     Fields:    Translation:Humans
    257. Reply to B. Freidlin et al. J Clin Oncol. 2013 Mar 01; 31(7):970-1. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. PMID: 23565532.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    258. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images. Neuro Oncol. 2013 May; 15(5):626-34. Naeini KM, Pope WB, Cloughesy TF, Harris RJ, Lai A, Eskin A, Chowdhury R, Phillips HS, Nghiemphu PL, Behbahanian Y, Ellingson BM. PMID: 23444259; PMCID: PMC3635524.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    259. PML mediates glioblastoma resistance to mammalian target of rapamycin (mTOR)-targeted therapies. Proc Natl Acad Sci U S A. 2013 Mar 12; 110(11):4339-44. Iwanami A, Gini B, Zanca C, Matsutani T, Assuncao A, Nael A, Dang J, Yang H, Zhu S, Kohyama J, Kitabayashi I, Cavenee WK, Cloughesy TF, Furnari FB, Nakamura M, Toyama Y, Okano H, Mischel PS. PMID: 23440206; PMCID: PMC3600508.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    260. Evaluation of high ipsilateral subventricular zone radiation therapy dose in glioblastoma: a pooled analysis. Int J Radiat Oncol Biol Phys. 2013 Jul 15; 86(4):609-15. Lee P, Eppinga W, Lagerwaard F, Cloughesy T, Slotman B, Nghiemphu PL, Wang PC, Kupelian P, Agazaryan N, Demarco J, Selch MT, Steinberg M, Kang JJ. PMID: 23462418.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    261. Response classification based on a minimal model of glioblastoma growth is prognostic for clinical outcomes and distinguishes progression from pseudoprogression. Cancer Res. 2013 May 15; 73(10):2976-86. Neal ML, Trister AD, Ahn S, Baldock A, Bridge CA, Guyman L, Lange J, Sodt R, Cloke T, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. PMID: 23400596; PMCID: PMC3740772.
      View in: PubMed   Mentions: 31     Fields:    Translation:Humans
    262. Comparison of glioma-associated antigen peptide-loaded versus autologous tumor lysate-loaded dendritic cell vaccination in malignant glioma patients. J Immunother. 2013 Feb; 36(2):152-7. Prins RM, Wang X, Soto H, Young E, Lisiero DN, Fong B, Everson R, Yong WH, Lai A, Li G, Cloughesy TF, Liau LM. PMID: 23377664; PMCID: PMC3568250.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    263. Pre- and post-contrast three-dimensional double inversion-recovery MRI in human glioblastoma. J Neurooncol. 2013 Apr; 112(2):257-66. Harris RJ, Cloughesy TF, Pope WB, Godinez S, Natsuaki Y, Nghiemphu PL, Meyer H, Paul D, Behbahanian Y, Lai A, Ellingson BM. PMID: 23344788; PMCID: PMC3616610.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    264. Cytokines associated with toxicity in the treatment of recurrent glioblastoma with aflibercept. Target Oncol. 2013 Jun; 8(2):117-25. Shonka N, Piao Y, Gilbert M, Yung A, Chang S, DeAngelis LM, Lassman AB, Liu J, Cloughesy T, Robins HI, Lloyd R, Chen A, Prados M, Wen PY, Heymach J, de Groot J. PMID: 23345034; PMCID: PMC4802008.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    265. Discriminating survival outcomes in patients with glioblastoma using a simulation-based, patient-specific response metric. PLoS One. 2013; 8(1):e51951. Neal ML, Trister AD, Cloke T, Sodt R, Ahn S, Baldock AL, Bridge CA, Lai A, Cloughesy TF, Mrugala MM, Rockhill JK, Rockne RC, Swanson KR. PMID: 23372647; PMCID: PMC3553125.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    266. Combined analysis of O6-methylguanine-DNA methyltransferase protein expression and promoter methylation provides optimized prognostication of glioblastoma outcome. Neuro Oncol. 2013 Mar; 15(3):370-81. Lalezari S, Chou AP, Tran A, Solis OE, Khanlou N, Chen W, Li S, Carrillo JA, Chowdhury R, Selfridge J, Sanchez DE, Wilson RW, Zurayk M, Lalezari J, Lou JJ, Ormiston L, Ancheta K, Hanna R, Miller P, Piccioni D, Ellingson BM, Buchanan C, Mischel PS, Nghiemphu PL, Green R, Wang HJ, Pope WB, Liau LM, Elashoff RM, Cloughesy TF, Yong WH, Lai A. PMID: 23328811; PMCID: PMC3578486.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    267. Imaging biomarkers for antiangiogenic therapy in malignant gliomas. CNS Oncol. 2013 Jan; 2(1):33-47. Leu K, Pope WB, Cloughesy TF, Lai A, Nghiemphu PL, Chen W, Liau LM, Ellingson BM. PMID: 24570837; PMCID: PMC3932329.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    268. Quantitative probabilistic functional diffusion mapping in newly diagnosed glioblastoma treated with radiochemotherapy. Neuro Oncol. 2013 Mar; 15(3):382-90. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. PMID: 23275575; PMCID: PMC3578489.
      View in: PubMed   Mentions: 20     Fields:    Translation:Humans
    269. Standards of care for treatment of recurrent glioblastoma--are we there yet? Neuro Oncol. 2013 Jan; 15(1):4-27. Weller M, Cloughesy T, Perry JR, Wick W. PMID: 23136223; PMCID: PMC3534423.
      View in: PubMed   Mentions: 346     Fields:    Translation:Humans
    270. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation. Neuro Oncol. 2013 Jan; 15(1):57-68. Li S, Chou AP, Chen W, Chen R, Deng Y, Phillips HS, Selfridge J, Zurayk M, Lou JJ, Everson RG, Wu KC, Faull KF, Cloughesy T, Liau LM, Lai A. PMID: 23115158; PMCID: PMC3534418.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansCells
    271. Phase I/II study of sorafenib in combination with temsirolimus for recurrent glioblastoma or gliosarcoma: North American Brain Tumor Consortium study 05-02. Neuro Oncol. 2012 Dec; 14(12):1511-8. Lee EQ, Kuhn J, Lamborn KR, Abrey L, DeAngelis LM, Lieberman F, Robins HI, Chang SM, Yung WK, Drappatz J, Mehta MP, Levin VA, Aldape K, Dancey JE, Wright JJ, Prados MD, Cloughesy TF, Gilbert MR, Wen PY. PMID: 23099651; PMCID: PMC3499017.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    272. PET Parametric Response Mapping for Clinical Monitoring and Treatment Response Evaluation in Brain Tumors. PET Clin. 2013 Apr; 8(2):201-17. Ellingson BM, Chen W, Harris RJ, Pope WB, Lai A, Nghiemphu PL, Czernin J, Phelps ME, Cloughesy TF. PMID: 27157948.
      View in: PubMed   Mentions: 1     Fields:    
    273. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation. Neuro Oncol. 2012 Dec; 14(12):1465-72. Lazovic J, Soto H, Piccioni D, Lou JR, Li S, Mirsadraei L, Yong W, Prins R, Liau LM, Ellingson BM, Cloughesy TF, Lai A, Pope WB. PMID: 23090985; PMCID: PMC3499014.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansAnimalsCells
    274. Identification of retinol binding protein 1 promoter hypermethylation in isocitrate dehydrogenase 1 and 2 mutant gliomas. J Natl Cancer Inst. 2012 Oct 03; 104(19):1458-69. Chou AP, Chowdhury R, Li S, Chen W, Kim AJ, Piccioni DE, Selfridge JM, Mody RR, Chang S, Lalezari S, Lin J, Sanchez DE, Wilson RW, Garrett MC, Harry B, Mottahedeh J, Nghiemphu PL, Kornblum HI, Mischel PS, Prins RM, Yong WH, Cloughesy T, Nelson SF, Liau LM, Lai A. PMID: 22945948; PMCID: PMC3529615.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    275. Phase I study of vorinostat in combination with temozolomide in patients with high-grade gliomas: North American Brain Tumor Consortium Study 04-03. Clin Cancer Res. 2012 Nov 01; 18(21):6032-9. Lee EQ, Puduvalli VK, Reid JM, Kuhn JG, Lamborn KR, Cloughesy TF, Chang SM, Drappatz J, Yung WK, Gilbert MR, Robins HI, Lieberman FS, Lassman AB, McGovern RM, Xu J, Desideri S, Ye X, Ames MM, Espinoza-Delgado I, Prados MD, Wen PY. PMID: 22923449; PMCID: PMC3947570.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansCTClinical Trials
    276. A dose escalation trial for the combination of erlotinib and sirolimus for recurrent malignant gliomas. J Neurooncol. 2012 Nov; 110(2):245-50. Nghiemphu PL, Lai A, Green RM, Reardon DA, Cloughesy T. PMID: 22918789; PMCID: PMC3472078.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    277. Glioblastoma therapy in the elderly: one age does not fit all. Lancet Oncol. 2012 Sep; 13(9):857-8. Nghiemphu PL, Cloughesy T. PMID: 22877850.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    278. Bevacizumab as first-line therapy for glioblastoma. Future Oncol. 2012 Aug; 8(8):929-38. Piccioni D, Lai A, Nghiemphu P, Cloughesy T. PMID: 22894667.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    279. 18F-FDOPA and 18F-FLT positron emission tomography parametric response maps predict response in recurrent malignant gliomas treated with bevacizumab. Neuro Oncol. 2012 Aug; 14(8):1079-89. Harris RJ, Cloughesy TF, Pope WB, Nghiemphu PL, Lai A, Zaw T, Czernin J, Phelps ME, Chen W, Ellingson BM. PMID: 22711609; PMCID: PMC3408264.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    280. Regional and voxel-wise comparisons of blood flow measurements between dynamic susceptibility contrast magnetic resonance imaging (DSC-MRI) and arterial spin labeling (ASL) in brain tumors. J Neuroimaging. 2014 Jan-Feb; 24(1):23-30. White CM, Pope WB, Zaw T, Qiao J, Naeini KM, Lai A, Nghiemphu PL, Wang JJ, Cloughesy TF, Ellingson BM. PMID: 22672084.
      View in: PubMed   Mentions: 27     Fields:    Translation:Humans
    281. Initial treatment patterns over time for anaplastic oligodendroglial tumors. Neuro Oncol. 2012 Jun; 14(6):761-7. Panageas KS, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán Urgoiti GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, Deangelis LM, Jhanwar SC, Rosenblum MK, Lassman AB. PMID: 22661585; PMCID: PMC3367843.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansCells
    282. Bayesian adaptive randomized trial design for patients with recurrent glioblastoma. J Clin Oncol. 2012 Sep 10; 30(26):3258-63. Trippa L, Lee EQ, Wen PY, Batchelor TT, Cloughesy T, Parmigiani G, Alexander BM. PMID: 22649140; PMCID: PMC3434985.
      View in: PubMed   Mentions: 44     Fields:    Translation:Humans
    283. Phase 2 trial design in neuro-oncology revisited: a report from the RANO group. Lancet Oncol. 2012 May; 13(5):e196-204. Galanis E, Wu W, Cloughesy T, Lamborn K, Mann B, Wen PY, Reardon DA, Wick W, Macdonald D, Armstrong TS, Weller M, Vogelbaum M, Colman H, Sargent DJ, van den Bent MJ, Gilbert M, Chang S. PMID: 22554547.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    284. Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov. 2012 May; 2(5):458-71. Vivanco I, Robins HI, Rohle D, Campos C, Grommes C, Nghiemphu PL, Kubek S, Oldrini B, Chheda MG, Yannuzzi N, Tao H, Zhu S, Iwanami A, Kuga D, Dang J, Pedraza A, Brennan CW, Heguy A, Liau LM, Lieberman F, Yung WK, Gilbert MR, Reardon DA, Drappatz J, Wen PY, Lamborn KR, Chang SM, Prados MD, Fine HA, Horvath S, Wu N, Lassman AB, DeAngelis LM, Yong WH, Kuhn JG, Mischel PS, Mehta MP, Cloughesy TF, Mellinghoff IK. PMID: 22588883; PMCID: PMC3354723.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansAnimalsCells
    285. Apparent diffusion coefficient histogram analysis stratifies progression-free and overall survival in patients with recurrent GBM treated with bevacizumab: a multi-center study. J Neurooncol. 2012 07; 108(3):491-8. Pope WB, Qiao XJ, Kim HJ, Lai A, Nghiemphu P, Xue X, Ellingson BM, Schiff D, Aregawi D, Cha S, Puduvalli VK, Wu J, Yung WK, Young GS, Vredenburgh J, Barboriak D, Abrey LE, Mikkelsen T, Jain R, Paleologos NA, Lada P, Prados M, Goldin J, Wen PY, Cloughesy T. PMID: 22426926; PMCID: PMC3997502.
      View in: PubMed   Mentions: 97     Fields:    Translation:Humans
    286. Phase I study of AEE788, a novel multitarget inhibitor of ErbB- and VEGF-receptor-family tyrosine kinases, in recurrent glioblastoma patients. Cancer Chemother Pharmacol. 2012 Jun; 69(6):1507-18. Reardon DA, Conrad CA, Cloughesy T, Prados MD, Friedman HS, Aldape KD, Mischel P, Xia J, DiLea C, Huang J, Mietlowski W, Dugan M, Chen W, Yung WK. PMID: 22392572; PMCID: PMC4351868.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCTClinical Trials
    287. Impact of 3,4-dihydroxy-6-18F-fluoro-L-phenylalanine PET/CT on managing patients with brain tumors: the referring physician's perspective. J Nucl Med. 2012 Mar; 53(3):393-8. Walter F, Cloughesy T, Walter MA, Lai A, Nghiemphu P, Wagle N, Fueger B, Satyamurthy N, Phelps ME, Czernin J. PMID: 22323780.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    288. Comparison between intensity normalization techniques for dynamic susceptibility contrast (DSC)-MRI estimates of cerebral blood volume (CBV) in human gliomas. J Magn Reson Imaging. 2012 Jun; 35(6):1472-7. Ellingson BM, Zaw T, Cloughesy TF, Naeini KM, Lalezari S, Mong S, Lai A, Nghiemphu PL, Pope WB. PMID: 22281731.
      View in: PubMed   Mentions: 38     Fields:    Translation:Humans
    289. Functional diffusion maps (fDMs) evaluated before and after radiochemotherapy predict progression-free and overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2012 Mar; 14(3):333-43. Ellingson BM, Cloughesy TF, Zaw T, Lai A, Nghiemphu PL, Harris R, Lalezari S, Wagle N, Naeini KM, Carrillo J, Liau LM, Pope WB. PMID: 22270220; PMCID: PMC3280805.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    290. Will kinase inhibitors make it as glioblastoma drugs? Curr Top Microbiol Immunol. 2012; 355:135-69. Mellinghoff IK, Schultz N, Mischel PS, Cloughesy TF. PMID: 22015553; PMCID: PMC3784987.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    291. 3'-deoxy-3'-18F-fluorothymidine PET and MRI for early survival predictions in patients with recurrent malignant glioma treated with bevacizumab. J Nucl Med. 2012 Jan; 53(1):29-36. Schwarzenberg J, Czernin J, Cloughesy TF, Ellingson BM, Pope WB, Geist C, Dahlbom M, Silverman DH, Satyamurthy N, Phelps ME, Chen W. PMID: 22159180; PMCID: PMC3424269.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    292. The impact of recent data on the optimization of standards of care in newly diagnosed glioblastoma. Semin Oncol. 2011 Dec; 38 Suppl 4:S11-20. Cloughesy T. PMID: 22078643.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    293. Evidence for sequenced molecular evolution of IDH1 mutant glioblastoma from a distinct cell of origin. J Clin Oncol. 2011 Dec 01; 29(34):4482-90. Lai A, Kharbanda S, Pope WB, Tran A, Solis OE, Peale F, Forrest WF, Pujara K, Carrillo JA, Pandita A, Ellingson BM, Bowers CW, Soriano RH, Schmidt NO, Mohan S, Yong WH, Seshagiri S, Modrusan Z, Jiang Z, Aldape KD, Mischel PS, Liau LM, Escovedo CJ, Chen W, Nghiemphu PL, James CD, Prados MD, Westphal M, Lamszus K, Cloughesy T, Phillips HS. PMID: 22025148; PMCID: PMC3236649.
      View in: PubMed   Mentions: 235     Fields:    Translation:HumansCells
    294. Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy. J Neurooncol. 2012 Mar; 107(1):197-205. Pope WB, Prins RM, Albert Thomas M, Nagarajan R, Yen KE, Bittinger MA, Salamon N, Chou AP, Yong WH, Soto H, Wilson N, Driggers E, Jang HG, Su SM, Schenkein DP, Lai A, Cloughesy TF, Kornblum HI, Wu H, Fantin VR, Liau LM. PMID: 22015945; PMCID: PMC3650613.
      View in: PubMed   Mentions: 149     Fields:    Translation:Humans
    295. Autocrine endothelin-3/endothelin receptor B signaling maintains cellular and molecular properties of glioblastoma stem cells. Mol Cancer Res. 2011 Dec; 9(12):1668-85. Liu Y, Ye F, Yamada K, Tso JL, Zhang Y, Nguyen DH, Dong Q, Soto H, Choe J, Dembo A, Wheeler H, Eskin A, Schmid I, Yong WH, Mischel PS, Cloughesy TF, Kornblum HI, Nelson SF, Liau LM, Tso CL. PMID: 22013079; PMCID: PMC3245317.
      View in: PubMed   Mentions: 24     Fields:    Translation:HumansAnimalsCells
    296. Pharmacokinetic drug interaction between AEE788 and RAD001 causing thrombocytopenia in patients with glioblastoma. Cancer Chemother Pharmacol. 2012 Jan; 69(1):281-7. Reardon DA, Cloughesy T, Rich J, Alfred Yung WK, Yung L, DiLea C, Huang J, Dugan M, Mietlowski W, Maes A, Conrad C. PMID: 21984222.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    297. Anatomic localization of O6-methylguanine DNA methyltransferase (MGMT) promoter methylated and unmethylated tumors: a radiographic study in 358 de novo human glioblastomas. Neuroimage. 2012 Jan 16; 59(2):908-16. Ellingson BM, Cloughesy TF, Pope WB, Zaw TM, Phillips H, Lalezari S, Nghiemphu PL, Ibrahim H, Naeini KM, Harris RJ, Lai A. PMID: 22001163.
      View in: PubMed   Mentions: 73     Fields:    Translation:HumansCells
    298. An LXR agonist promotes glioblastoma cell death through inhibition of an EGFR/AKT/SREBP-1/LDLR-dependent pathway. Cancer Discov. 2011 Oct; 1(5):442-56. Guo D, Reinitz F, Youssef M, Hong C, Nathanson D, Akhavan D, Kuga D, Amzajerdi AN, Soto H, Zhu S, Babic I, Tanaka K, Dang J, Iwanami A, Gini B, Dejesus J, Lisiero DD, Huang TT, Prins RM, Wen PY, Robins HI, Prados MD, Deangelis LM, Mellinghoff IK, Mehta MP, James CD, Chakravarti A, Cloughesy TF, Tontonoz P, Mischel PS. PMID: 22059152; PMCID: PMC3207317.
      View in: PubMed   Mentions: 222     Fields:    Translation:HumansAnimalsCells
    299. Oncogenic EGFR signaling activates an mTORC2-NF-κB pathway that promotes chemotherapy resistance. Cancer Discov. 2011 Nov; 1(6):524-38. Tanaka K, Babic I, Nathanson D, Akhavan D, Guo D, Gini B, Dang J, Zhu S, Yang H, De Jesus J, Amzajerdi AN, Zhang Y, Dibble CC, Dan H, Rinkenbaugh A, Yong WH, Vinters HV, Gera JF, Cavenee WK, Cloughesy TF, Manning BD, Baldwin AS, Mischel PS. PMID: 22145100; PMCID: PMC3229221.
      View in: PubMed   Mentions: 169     Fields:    Translation:HumansCells
    300. Discriminant analysis of ¹⁸F-fluorothymidine kinetic parameters to predict survival in patients with recurrent high-grade glioma. Clin Cancer Res. 2011 Oct 15; 17(20):6553-62. Wardak M, Schiepers C, Dahlbom M, Cloughesy T, Chen W, Satyamurthy N, Czernin J, Phelps ME, Huang SC. PMID: 21868765; PMCID: PMC3833447.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    301. Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Oct; 13(10):1151-61. Ellingson BM, Cloughesy TF, Lai A, Mischel PS, Nghiemphu PL, Lalezari S, Schmainda KM, Pope WB. PMID: 21856685; PMCID: PMC3177656.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    302. Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma? Neuro Oncol. 2011 Oct; 13(10):1118-24. Clarke JL, Ennis MM, Yung WK, Chang SM, Wen PY, Cloughesy TF, Deangelis LM, Robins HI, Lieberman FS, Fine HA, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Lamborn KR, Prados MD, North American Brain Tumor Consortium. PMID: 21813511; PMCID: PMC3177665.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    303. It is time to include patients with brain tumors in phase I trials in oncology. J Clin Oncol. 2011 Aug 20; 29(24):3211-3. Wen PY, Schiff D, Cloughesy TF, Reardon DA, Batchelor TT, Chabner BA, Flaherty K, de Groot JF, Gilbert MR, Galanis E, Chang SM, Schwartz GK, Peereboom D, Mehta MP, Yung WK, Grossman SA, Prados MD, DeAngelis LM. PMID: 21768451; PMCID: PMC4836609.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    304. Cilengitide in patients with recurrent glioblastoma: the results of NABTC 03-02, a phase II trial with measures of treatment delivery. J Neurooncol. 2012 Jan; 106(1):147-53. Gilbert MR, Kuhn J, Lamborn KR, Lieberman F, Wen PY, Mehta M, Cloughesy T, Lassman AB, Deangelis LM, Chang S, Prados M. PMID: 21739168; PMCID: PMC4351869.
      View in: PubMed   Mentions: 59     Fields:    Translation:HumansCTClinical Trials
    305. Quantification of edema reduction using differential quantitative T2 (DQT2) relaxometry mapping in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2012 Jan; 106(1):111-9. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Lalezari S, Zaw T, Motevalibashinaeini K, Mischel PS, Pope WB. PMID: 21706273.
      View in: PubMed   Mentions: 34     Fields:    Translation:Humans
    306. Nonlinear registration of diffusion-weighted images improves clinical sensitivity of functional diffusion maps in recurrent glioblastoma treated with bevacizumab. Magn Reson Med. 2012 Jan; 67(1):237-45. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. PMID: 21702063.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    307. Myeloid biomarkers associated with glioblastoma response to anti-VEGF therapy with aflibercept. Clin Cancer Res. 2011 Jul 15; 17(14):4872-81. de Groot JF, Piao Y, Tran H, Gilbert M, Wu HK, Liu J, Bekele BN, Cloughesy T, Mehta M, Robins HI, Lassman A, DeAngelis L, Camphausen K, Chen A, Yung WK, Prados M, Wen PY, Heymach JV. PMID: 21632852; PMCID: PMC3139700.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCellsCTClinical Trials
    308. International retrospective study of over 1000 adults with anaplastic oligodendroglial tumors. Neuro Oncol. 2011 Jun; 13(6):649-59. Lassman AB, Iwamoto FM, Cloughesy TF, Aldape KD, Rivera AL, Eichler AF, Louis DN, Paleologos NA, Fisher BJ, Ashby LS, Cairncross JG, Roldán GB, Wen PY, Ligon KL, Schiff D, Robins HI, Rocque BG, Chamberlain MC, Mason WP, Weaver SA, Green RM, Kamar FG, Abrey LE, DeAngelis LM, Jhanwar SC, Rosenblum MK, Panageas KS. PMID: 21636710; PMCID: PMC3107101.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCells
    309. Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2011 Jul 01; 29(19):2689-95. de Groot JF, Lamborn KR, Chang SM, Gilbert MR, Cloughesy TF, Aldape K, Yao J, Jackson EF, Lieberman F, Robins HI, Mehta MP, Lassman AB, Deangelis LM, Yung WK, Chen A, Prados MD, Wen PY. PMID: 21606416; PMCID: PMC3139373.
      View in: PubMed   Mentions: 92     Fields:    Translation:HumansCTClinical Trials
    310. Neurocognitive function in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jun; 13(6):660-8. Wefel JS, Cloughesy T, Zazzali JL, Zheng M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. PMID: 21558074; PMCID: PMC3107095.
      View in: PubMed   Mentions: 55     Fields:    Translation:HumansCTClinical Trials
    311. High order diffusion tensor imaging in human glioblastoma. Acad Radiol. 2011 Aug; 18(8):947-54. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Liau LM, Pope WB. PMID: 21536466.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    312. Cell invasion, motility, and proliferation level estimate (CIMPLE) maps derived from serial diffusion MR images in recurrent glioblastoma treated with bevacizumab. J Neurooncol. 2011 Oct; 105(1):91-101. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Pope WB. PMID: 21442275.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    313. Quantitative volumetric analysis of conventional MRI response in recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Apr; 13(4):401-9. Ellingson BM, Cloughesy TF, Lai A, Nghiemphu PL, Mischel PS, Pope WB. PMID: 21324937; PMCID: PMC3064698.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    314. Clinical trial end points for high-grade glioma: the evolving landscape. Neuro Oncol. 2011 Mar; 13(3):353-61. Reardon DA, Galanis E, DeGroot JF, Cloughesy TF, Wefel JS, Lamborn KR, Lassman AB, Gilbert MR, Sampson JH, Wick W, Chamberlain MC, Macdonald DR, Mehta MP, Vogelbaum MA, Chang SM, Van den Bent MJ, Wen PY. PMID: 21310734; PMCID: PMC3064608.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    315. A phase II study evaluating the efficacy and safety of AMG 102 (rilotumumab) in patients with recurrent glioblastoma. Neuro Oncol. 2011 Apr; 13(4):437-46. Wen PY, Schiff D, Cloughesy TF, Raizer JJ, Laterra J, Smitt M, Wolf M, Oliner KS, Anderson A, Zhu M, Loh E, Reardon DA. PMID: 21297127; PMCID: PMC3064694.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCTClinical Trials
    316. Considerations for uniform and accurate biospecimen labelling in a biorepository and research environment. J Clin Pathol. 2011 Jul; 64(7):634-6. Kay AB, Estrada DK, Mareninov S, Silver SS, Magyar CE, Dry SM, Cloughesy TF, Yong WH. PMID: 21217091.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    317. New strategies in the molecular targeting of glioblastoma: how do you hit a moving target? Clin Cancer Res. 2011 Jan 01; 17(1):6-11. Cloughesy TF, Mischel PS. PMID: 21208902; PMCID: PMC3075730.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    318. Corticosteroid use in patients with glioblastoma at first or second relapse treated with bevacizumab in the BRAIN study. Oncologist. 2010; 15(12):1329-34. Vredenburgh JJ, Cloughesy T, Samant M, Prados M, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Das A, Friedman HS. PMID: 21147867; PMCID: PMC3227925.
      View in: PubMed   Mentions: 53     Fields:    Translation:HumansCTClinical Trials
    319. Phase II study of bevacizumab plus temozolomide during and after radiation therapy for patients with newly diagnosed glioblastoma multiforme. J Clin Oncol. 2011 Jan 10; 29(2):142-8. Lai A, Tran A, Nghiemphu PL, Pope WB, Solis OE, Selch M, Filka E, Yong WH, Mischel PS, Liau LM, Phuphanich S, Black K, Peak S, Green RM, Spier CE, Kolevska T, Polikoff J, Fehrenbacher L, Elashoff R, Cloughesy T. PMID: 21135282; PMCID: PMC3058273.
      View in: PubMed   Mentions: 227     Fields:    Translation:HumansCTClinical Trials
    320. FDA accelerated approval benefits glioblastoma. Lancet Oncol. 2010 Dec; 11(12):1120. Cloughesy T. PMID: 21126686.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    321. Response as a predictor of survival in patients with recurrent glioblastoma treated with bevacizumab. Neuro Oncol. 2011 Jan; 13(1):143-51. Prados M, Cloughesy T, Samant M, Fang L, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Das A, Friedman HS. PMID: 21084434; PMCID: PMC3018914.
      View in: PubMed   Mentions: 36     Fields:    Translation:Humans
    322. A phase I trial of tipifarnib with radiation therapy, with and without temozolomide, for patients with newly diagnosed glioblastoma. Int J Radiat Oncol Biol Phys. 2011 Dec 01; 81(5):1422-7. Nghiemphu PL, Wen PY, Lamborn KR, Drappatz J, Robins HI, Fink K, Malkin MG, Lieberman FS, DeAngelis LM, Torres-Trejo A, Chang SM, Abrey L, Fine HA, Demopoulos A, Lassman AB, Kesari S, Mehta MP, Prados MD, Cloughesy TF, North American Brain Tumor Consortium. PMID: 20934264; PMCID: PMC3020272.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    323. Clinical outcome in pediatric glial and embryonal brain tumors correlates with in vitro multi-passageable neurosphere formation. Pediatr Blood Cancer. 2010 Oct; 55(4):644-51. Panosyan EH, Laks DR, Masterman-Smith M, Mottahedeh J, Yong WH, Cloughesy TF, Lazareff JA, Mischel PS, Moore TB, Kornblum HI. PMID: 20589659; PMCID: PMC4017922.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    324. Rosette-forming glioneuronal tumor: a pineal region case with IDH1 and IDH2 mutation analyses and literature review of 43 cases. J Neurooncol. 2011 May; 102(3):477-84. Solis OE, Mehta RI, Lai A, Mehta RI, Farchoukh LO, Green RM, Cheng JC, Natarajan S, Vinters HV, Cloughesy T, Yong WH. PMID: 20872044; PMCID: PMC3089723.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    325. Correlation of 6-18F-fluoro-L-dopa PET uptake with proliferation and tumor grade in newly diagnosed and recurrent gliomas. J Nucl Med. 2010 Oct; 51(10):1532-8. Fueger BJ, Czernin J, Cloughesy T, Silverman DH, Geist CL, Walter MA, Schiepers C, Nghiemphu P, Lai A, Phelps ME, Chen W. PMID: 20847166.
      View in: PubMed   Mentions: 59     Fields:    Translation:Humans
    326. Safety and efficacy of erlotinib in first-relapse glioblastoma: a phase II open-label study. Neuro Oncol. 2010 Oct; 12(10):1061-70. Yung WK, Vredenburgh JJ, Cloughesy TF, Nghiemphu P, Klencke B, Gilbert MR, Reardon DA, Prados MD. PMID: 20615922; PMCID: PMC3018931.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCTClinical Trials
    327. Update and developments in the treatment of glioblastoma multiforme - focus on bevacizumab. Pharmgenomics Pers Med. 2010; 3:79-85. Wagle N, Nghiemphu L, Lai A, Pope W, Mischel PS, Cloughesy T. PMID: 23226044; PMCID: PMC3513210.
      View in: PubMed   Mentions: 4  
    328. mTOR signaling in glioblastoma: lessons learned from bench to bedside. Neuro Oncol. 2010 Aug; 12(8):882-9. Akhavan D, Cloughesy TF, Mischel PS. PMID: 20472883; PMCID: PMC2940679.
      View in: PubMed   Mentions: 97     Fields:    Translation:HumansAnimalsCells
    329. Kinetics of 3'-deoxy-3'-18F-fluorothymidine during treatment monitoring of recurrent high-grade glioma. J Nucl Med. 2010 May; 51(5):720-7. Schiepers C, Dahlbom M, Chen W, Cloughesy T, Czernin J, Phelps ME, Huang SC. PMID: 20395318.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    330. The phosphatase and tensin homolog regulates epidermal growth factor receptor (EGFR) inhibitor response by targeting EGFR for degradation. Proc Natl Acad Sci U S A. 2010 Apr 06; 107(14):6459-64. Vivanco I, Rohle D, Versele M, Iwanami A, Kuga D, Oldrini B, Tanaka K, Dang J, Kubek S, Palaskas N, Hsueh T, Evans M, Mulholland D, Wolle D, Rajasekaran S, Rajasekaran A, Liau LM, Cloughesy TF, Dikic I, Brennan C, Wu H, Mischel PS, Perera T, Mellinghoff IK. PMID: 20308550; PMCID: PMC2851999.
      View in: PubMed   Mentions: 54     Fields:    Translation:HumansAnimalsCells
    331. Updated response assessment criteria for high-grade gliomas: response assessment in neuro-oncology working group. J Clin Oncol. 2010 Apr 10; 28(11):1963-72. Wen PY, Macdonald DR, Reardon DA, Cloughesy TF, Sorensen AG, Galanis E, Degroot J, Wick W, Gilbert MR, Lassman AB, Tsien C, Mikkelsen T, Wong ET, Chamberlain MC, Stupp R, Lamborn KR, Vogelbaum MA, van den Bent MJ, Chang SM. PMID: 20231676.
      View in: PubMed   Mentions: 1782     Fields:    Translation:Humans
    332. AMPK: A metabolic checkpoint that regulates the growth of EGFR activated glioblastomas. Cell Cycle. 2010 Jan 15; 9(2):211-2. Guo D, Cloughesy TF, Radu CG, Mischel PS. PMID: 20023392; PMCID: PMC3180897.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCells
    333. In Silico Enhanced Restriction Enzyme Based Methylation Analysis of the Human Glioblastoma Genome Using Agilent 244K CpG Island Microarrays. Front Neurosci. 2009; 3:57. Tran A, Escovedo C, Migdall-Wilson J, Chou AP, Chen W, Cloughesy T, Nelson S, Lai A. PMID: 20582289; PMCID: PMC2858617.
      View in: PubMed   Mentions: 2  
    334. EGFR signaling through an Akt-SREBP-1-dependent, rapamycin-resistant pathway sensitizes glioblastomas to antilipogenic therapy. Sci Signal. 2009 Dec 15; 2(101):ra82. Guo D, Prins RM, Dang J, Kuga D, Iwanami A, Soto H, Lin KY, Huang TT, Akhavan D, Hock MB, Zhu S, Kofman AA, Bensinger SJ, Yong WH, Vinters HV, Horvath S, Watson AD, Kuhn JG, Robins HI, Mehta MP, Wen PY, DeAngelis LM, Prados MD, Mellinghoff IK, Cloughesy TF, Mischel PS. PMID: 20009104; PMCID: PMC2978002.
      View in: PubMed   Mentions: 195     Fields:    Translation:HumansCells
    335. A phase II trial of erlotinib in patients with recurrent malignant gliomas and nonprogressive glioblastoma multiforme postradiation therapy. Neuro Oncol. 2010 Jan; 12(1):95-103. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KA, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium. PMID: 20150372; PMCID: PMC2940554.
      View in: PubMed   Mentions: 133     Fields:    Translation:HumansCTClinical Trials
    336. A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomas. Neuro Oncol. 2010 Jan; 12(1):87-94. Raizer JJ, Abrey LE, Lassman AB, Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Aldape KD, Wen PY, Fine HA, Mehta M, Deangelis LM, Lieberman F, Cloughesy TF, Robins HI, Dancey J, Prados MD, North American Brain Tumor Consortium. PMID: 20150371; PMCID: PMC2940559.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansCTClinical Trials
    337. Phase II study of imatinib mesylate for recurrent meningiomas (North American Brain Tumor Consortium study 01-08). Neuro Oncol. 2009 Dec; 11(6):853-60. Wen PY, Yung WK, Lamborn KR, Norden AD, Cloughesy TF, Abrey LE, Fine HA, Chang SM, Robins HI, Fink K, Deangelis LM, Mehta M, Di Tomaso E, Drappatz J, Kesari S, Ligon KL, Aldape K, Jain RK, Stiles CD, Egorin MJ, Prados MD. PMID: 19293394; PMCID: PMC2802405.
      View in: PubMed   Mentions: 67     Fields:    Translation:HumansCTClinical Trials
    338. Somatic mutations of the Parkinson's disease-associated gene PARK2 in glioblastoma and other human malignancies. Nat Genet. 2010 Jan; 42(1):77-82. Veeriah S, Taylor BS, Meng S, Fang F, Yilmaz E, Vivanco I, Janakiraman M, Schultz N, Hanrahan AJ, Pao W, Ladanyi M, Sander C, Heguy A, Holland EC, Paty PB, Mischel PS, Liau L, Cloughesy TF, Mellinghoff IK, Solit DB, Chan TA. PMID: 19946270; PMCID: PMC4002225.
      View in: PubMed   Mentions: 201     Fields:    Translation:HumansAnimalsCells
    339. Prognostic significance of growth kinetics in newly diagnosed glioblastomas revealed by combining serial imaging with a novel biomathematical model. Cancer Res. 2009 Dec 01; 69(23):9133-40. Wang CH, Rockhill JK, Mrugala M, Peacock DL, Lai A, Jusenius K, Wardlaw JM, Cloughesy T, Spence AM, Rockne R, Alvord EC, Swanson KR. PMID: 19934335; PMCID: PMC3467150.
      View in: PubMed   Mentions: 93     Fields:    Translation:Humans
    340. Genomic landscape of meningiomas. Brain Pathol. 2010 Jul; 20(4):751-62. Lee Y, Liu J, Patel S, Cloughesy T, Lai A, Farooqi H, Seligson D, Dong J, Liau L, Becker D, Mischel P, Shams S, Nelson S. PMID: 20015288; PMCID: PMC3167483.
      View in: PubMed   Mentions: 65     Fields:    Translation:Humans
    341. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma. J Clin Oncol. 2009 Oct 01; 27(28):4733-40. Friedman HS, Prados MD, Wen PY, Mikkelsen T, Schiff D, Abrey LE, Yung WK, Paleologos N, Nicholas MK, Jensen R, Vredenburgh J, Huang J, Zheng M, Cloughesy T. PMID: 19720927.
      View in: PubMed   Mentions: 1141     Fields:    Translation:HumansCTClinical Trials
    342. Fyn and SRC are effectors of oncogenic epidermal growth factor receptor signaling in glioblastoma patients. Cancer Res. 2009 Sep 01; 69(17):6889-98. Lu KV, Zhu S, Cvrljevic A, Huang TT, Sarkaria S, Ahkavan D, Dang J, Dinca EB, Plaisier SB, Oderberg I, Lee Y, Chen Z, Caldwell JS, Xie Y, Loo JA, Seligson D, Chakravari A, Lee FY, Weinmann R, Cloughesy TF, Nelson SF, Bergers G, Graeber T, Furnari FB, James CD, Cavenee WK, Johns TG, Mischel PS. PMID: 19690143; PMCID: PMC2770839.
      View in: PubMed   Mentions: 96     Fields:    Translation:HumansAnimalsCells
    343. Stem cell associated gene expression in glioblastoma multiforme: relationship to survival and the subventricular zone. J Neurooncol. 2010 Feb; 96(3):359-67. Kappadakunnel M, Eskin A, Dong J, Nelson SF, Mischel PS, Liau LM, Ngheimphu P, Lai A, Cloughesy TF, Goldin J, Pope WB. PMID: 19655089; PMCID: PMC2808508.
      View in: PubMed   Mentions: 58     Fields:    Translation:HumansCells
    344. Striking the balance between PTEN and PDK1: it all depends on the cell context. Genes Dev. 2009 Aug 01; 23(15):1699-704. Iwanami A, Cloughesy TF, Mischel PS. PMID: 19651981; PMCID: PMC2720262.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansAnimalsCells
    345. The AMPK agonist AICAR inhibits the growth of EGFRvIII-expressing glioblastomas by inhibiting lipogenesis. Proc Natl Acad Sci U S A. 2009 Aug 04; 106(31):12932-7. Guo D, Hildebrandt IJ, Prins RM, Soto H, Mazzotta MM, Dang J, Czernin J, Shyy JY, Watson AD, Phelps M, Radu CG, Cloughesy TF, Mischel PS. PMID: 19625624; PMCID: PMC2714280.
      View in: PubMed   Mentions: 136     Fields:    Translation:HumansAnimalsCells
    346. Proteasomal and genetic inactivation of the NF1 tumor suppressor in gliomagenesis. Cancer Cell. 2009 Jul 07; 16(1):44-54. McGillicuddy LT, Fromm JA, Hollstein PE, Kubek S, Beroukhim R, De Raedt T, Johnson BW, Williams SM, Nghiemphu P, Liau LM, Cloughesy TF, Mischel PS, Parret A, Seiler J, Moldenhauer G, Scheffzek K, Stemmer-Rachamimov AO, Sawyers CL, Brennan C, Messiaen L, Mellinghoff IK, Cichowski K. PMID: 19573811; PMCID: PMC2897249.
      View in: PubMed   Mentions: 86     Fields:    Translation:AnimalsCells
    347. Recurrent glioblastoma multiforme: ADC histogram analysis predicts response to bevacizumab treatment. Radiology. 2009 Jul; 252(1):182-9. Pope WB, Kim HJ, Huo J, Alger J, Brown MS, Gjertson D, Sai V, Young JR, Tekchandani L, Cloughesy T, Mischel PS, Lai A, Nghiemphu P, Rahmanuddin S, Goldin J. PMID: 19561256.
      View in: PubMed   Mentions: 186     Fields:    Translation:Humans
    348. Targeted therapy for malignant glioma patients: lessons learned and the road ahead. Neurotherapeutics. 2009 Jul; 6(3):500-12. Huang TT, Sarkaria SM, Cloughesy TF, Mischel PS. PMID: 19560740; PMCID: PMC3600166.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    349. Phase II trials of erlotinib or gefitinib in patients with recurrent meningioma. J Neurooncol. 2010 Jan; 96(2):211-7. Norden AD, Raizer JJ, Abrey LE, Lamborn KR, Lassman AB, Chang SM, Yung WK, Gilbert MR, Fine HA, Mehta M, Deangelis LM, Cloughesy TF, Robins HI, Aldape K, Dancey J, Prados MD, Lieberman F, Wen PY. PMID: 19562255; PMCID: PMC3786190.
      View in: PubMed   Mentions: 77     Fields:    Translation:HumansCTClinical Trials
    350. Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors. J Neurooncol. 2009 Aug; 94(1):1-19. Liu Q, Nguyen DH, Dong Q, Shitaku P, Chung K, Liu OY, Tso JL, Liu JY, Konkankit V, Cloughesy TF, Mischel PS, Lane TF, Liau LM, Nelson SF, Tso CL. PMID: 19468690; PMCID: PMC2705704.
      View in: PubMed   Mentions: 63     Fields:    Translation:HumansAnimalsCells
    351. Neurosphere formation is an independent predictor of clinical outcome in malignant glioma. Stem Cells. 2009 Apr; 27(4):980-7. Laks DR, Masterman-Smith M, Visnyei K, Angenieux B, Orozco NM, Foran I, Yong WH, Vinters HV, Liau LM, Lazareff JA, Mischel PS, Cloughesy TF, Horvath S, Kornblum HI. PMID: 19353526; PMCID: PMC3177534.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansAnimalsCells
    352. A tool for improving the longitudinal imaging characterization for neuro-oncology cases. AMIA Annu Symp Proc. 2008 Nov 06; 712-6. Taira RK, Taira R, Bui A, Bui AA, Hsu W, Bashyam V, Dube S, Watt E, Andrada L, El-Saden S, Cloughesy T, Kangarloo H. PMID: 18999139; PMCID: PMC2656085.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    353. Randomized phase II study of cilengitide, an integrin-targeting arginine-glycine-aspartic acid peptide, in recurrent glioblastoma multiforme. J Clin Oncol. 2008 Dec 01; 26(34):5610-7. Reardon DA, Fink KL, Mikkelsen T, Cloughesy TF, O'Neill A, Plotkin S, Glantz M, Ravin P, Raizer JJ, Rich KM, Schiff D, Shapiro WR, Burdette-Radoux S, Dropcho EJ, Wittemer SM, Nippgen J, Picard M, Nabors LB. PMID: 18981465.
      View in: PubMed   Mentions: 211     Fields:    Translation:HumansCTClinical Trials
    354. Gene expression analysis of glioblastomas identifies the major molecular basis for the prognostic benefit of younger age. BMC Med Genomics. 2008 Oct 21; 1:52. Lee Y, Scheck AC, Cloughesy TF, Lai A, Dong J, Farooqi HK, Liau LM, Horvath S, Mischel PS, Nelson SF. PMID: 18940004; PMCID: PMC2596165.
      View in: PubMed   Mentions: 127     Fields:    
    355. A North American brain tumor consortium phase II study of poly-ICLC for adult patients with recurrent anaplastic gliomas. J Neurooncol. 2009 Jan; 91(2):183-9. Butowski N, Lamborn KR, Lee BL, Prados MD, Cloughesy T, DeAngelis LM, Abrey L, Fink K, Lieberman F, Mehta M, Ian Robins H, Junck L, Salazar AM, Chang SM. PMID: 18850068; PMCID: PMC3104130.
      View in: PubMed   Mentions: 35     Fields:    Translation:HumansCTClinical Trials
    356. Relationship between gene expression and enhancement in glioblastoma multiforme: exploratory DNA microarray analysis. Radiology. 2008 Oct; 249(1):268-77. Pope WB, Chen JH, Dong J, Carlson MR, Perlina A, Cloughesy TF, Liau LM, Mischel PS, Nghiemphu P, Lai A, Nelson SF. PMID: 18796682; PMCID: PMC2798090.
      View in: PubMed   Mentions: 78     Fields:    Translation:Humans
    357. The L84F polymorphic variant of human O6-methylguanine-DNA methyltransferase alters stability in U87MG glioma cells but not temozolomide sensitivity. Neuro Oncol. 2009 Feb; 11(1):22-32. Remington M, Chtchetinin J, Ancheta K, Nghiemphu PL, Cloughesy T, Lai A. PMID: 18812520; PMCID: PMC2718956.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCells
    358. A phase II clinical trial of poly-ICLC with radiation for adult patients with newly diagnosed supratentorial glioblastoma: a North American Brain Tumor Consortium (NABTC01-05). J Neurooncol. 2009 Jan; 91(2):175-82. Butowski N, Chang SM, Junck L, DeAngelis LM, Abrey L, Fink K, Cloughesy T, Lamborn KR, Salazar AM, Prados MD. PMID: 18797818; PMCID: PMC4779120.
      View in: PubMed   Mentions: 60     Fields:    Translation:HumansCTClinical Trials
    359. Cytomegalovirus immunity after vaccination with autologous glioblastoma lysate. N Engl J Med. 2008 Jul 31; 359(5):539-41. Prins RM, Cloughesy TF, Liau LM. PMID: 18669440; PMCID: PMC2775501.
      View in: PubMed   Mentions: 82     Fields:    Translation:HumansCellsCTClinical Trials
    360. Neurooncology clinical trial design for targeted therapies: lessons learned from the North American Brain Tumor Consortium. Neuro Oncol. 2008 Aug; 10(4):631-42. Chang SM, Lamborn KR, Kuhn JG, Yung WK, Gilbert MR, Wen PY, Fine HA, Mehta MP, DeAngelis LM, Lieberman FS, Cloughesy TF, Robins HI, Abrey LE, Prados MD, North American Brain Tumor Consortium. PMID: 18559968; PMCID: PMC2666238.
      View in: PubMed   Mentions: 11     Fields:    Translation:Humans
    361. 18F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol. 2009 Aug; 71(2):242-8. Ledezma CJ, Chen W, Sai V, Freitas B, Cloughesy T, Czernin J, Pope W. PMID: 18511228.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    362. Safety of anticoagulation use and bevacizumab in patients with glioma. Neuro Oncol. 2008 Jun; 10(3):355-60. Nghiemphu PL, Green RM, Pope WB, Lai A, Cloughesy TF. PMID: 18436627; PMCID: PMC2563058.
      View in: PubMed   Mentions: 35     Fields:    Translation:Humans
    363. Time course of imaging changes of GBM during extended bevacizumab treatment. J Neurooncol. 2008 Jul; 88(3):339-47. Ananthnarayan S, Bahng J, Roring J, Nghiemphu P, Lai A, Cloughesy T, Pope WB. PMID: 18389177.
      View in: PubMed   Mentions: 56     Fields:    Translation:Humans
    364. Phase II pilot study of bevacizumab in combination with temozolomide and regional radiation therapy for up-front treatment of patients with newly diagnosed glioblastoma multiforme: interim analysis of safety and tolerability. Int J Radiat Oncol Biol Phys. 2008 Aug 01; 71(5):1372-80. Lai A, Filka E, McGibbon B, Nghiemphu PL, Graham C, Yong WH, Mischel P, Liau LM, Bergsneider M, Pope W, Selch M, Cloughesy T. PMID: 18355978.
      View in: PubMed   Mentions: 78     Fields:    Translation:HumansCTClinical Trials
    365. Progression-free survival: an important end point in evaluating therapy for recurrent high-grade gliomas. Neuro Oncol. 2008 Apr; 10(2):162-70. Lamborn KR, Yung WK, Chang SM, Wen PY, Cloughesy TF, DeAngelis LM, Robins HI, Lieberman FS, Fine HA, Fink KL, Junck L, Abrey L, Gilbert MR, Mehta M, Kuhn JG, Aldape KD, Hibberts J, Peterson PM, Prados MD, North American Brain Tumor Consortium. PMID: 18356283; PMCID: PMC2613818.
      View in: PubMed   Mentions: 228     Fields:    Translation:Humans
    366. Antitumor activity of rapamycin in a Phase I trial for patients with recurrent PTEN-deficient glioblastoma. PLoS Med. 2008 Jan 22; 5(1):e8. Cloughesy TF, Yoshimoto K, Nghiemphu P, Brown K, Dang J, Zhu S, Hsueh T, Chen Y, Wang W, Youngkin D, Liau L, Martin N, Becker D, Bergsneider M, Lai A, Green R, Oglesby T, Koleto M, Trent J, Horvath S, Mischel PS, Mellinghoff IK, Sawyers CL. PMID: 18215105; PMCID: PMC2211560.
      View in: PubMed   Mentions: 302     Fields:    Translation:HumansCellsCTClinical Trials
    367. Development of a real-time RT-PCR assay for detecting EGFRvIII in glioblastoma samples. Clin Cancer Res. 2008 Jan 15; 14(2):488-93. Yoshimoto K, Dang J, Zhu S, Nathanson D, Huang T, Dumont R, Seligson DB, Yong WH, Xiong Z, Rao N, Winther H, Chakravarti A, Bigner DD, Mellinghoff IK, Horvath S, Cavenee WK, Cloughesy TF, Mischel PS. PMID: 18223223.
      View in: PubMed   Mentions: 58     Fields:    Translation:Humans
    368. Maternal embryonic leucine zipper kinase is a key regulator of the proliferation of malignant brain tumors, including brain tumor stem cells. J Neurosci Res. 2008 Jan; 86(1):48-60. Nakano I, Masterman-Smith M, Saigusa K, Paucar AA, Horvath S, Shoemaker L, Watanabe M, Negro A, Bajpai R, Howes A, Lelievre V, Waschek JA, Lazareff JA, Freije WA, Liau LM, Gilbertson RJ, Cloughesy TF, Geschwind DH, Nelson SF, Mischel PS, Terskikh AV, Kornblum HI. PMID: 17722061.
      View in: PubMed   Mentions: 90     Fields:    Translation:HumansAnimalsCells
    369. Pharmacokinetic and tumor distribution characteristics of temsirolimus in patients with recurrent malignant glioma. Clin Cancer Res. 2007 Dec 15; 13(24):7401-6. Kuhn JG, Chang SM, Wen PY, Cloughesy TF, Greenberg H, Schiff D, Conrad C, Fink KL, Robins HI, Mehta M, DeAngelis L, Raizer J, Hess K, Lamborn KR, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute. PMID: 18094423; PMCID: PMC4918812.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    370. Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A. 2007 Dec 11; 104(50):20007-12. Beroukhim R, Getz G, Nghiemphu L, Barretina J, Hsueh T, Linhart D, Vivanco I, Lee JC, Huang JH, Alexander S, Du J, Kau T, Thomas RK, Shah K, Soto H, Perner S, Prensner J, Debiasi RM, Demichelis F, Hatton C, Rubin MA, Garraway LA, Nelson SF, Liau L, Mischel PS, Cloughesy TF, Meyerson M, Golub TA, Lander ES, Mellinghoff IK, Sellers WR. PMID: 18077431; PMCID: PMC2148413.
      View in: PubMed   Mentions: 583     Fields:    Translation:HumansCells
    371. Phase I study of temozolomide and irinotecan for recurrent malignant gliomas in patients receiving enzyme-inducing antiepileptic drugs: a north american brain tumor consortium study. Clin Cancer Res. 2007 Dec 01; 13(23):7133-8. Loghin ME, Prados MD, Wen P, Junck L, Lieberman F, Fine H, Fink KL, Metha M, Kuhn J, Lamborn K, Chang SM, Cloughesy T, DeAngelis LM, Robins IH, Aldape KD, Yung WK. PMID: 18056194; PMCID: PMC4802002.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    372. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study. J Clin Oncol. 2007 Oct 20; 25(30):4714-21. Chen W, Delaloye S, Silverman DH, Geist C, Czernin J, Sayre J, Satyamurthy N, Pope W, Lai A, Phelps ME, Cloughesy T. PMID: 17947718.
      View in: PubMed   Mentions: 151     Fields:    Translation:Humans
    373. 18F-FDOPA kinetics in brain tumors. J Nucl Med. 2007 Oct; 48(10):1651-61. Schiepers C, Chen W, Cloughesy T, Dahlbom M, Huang SC. PMID: 17873130.
      View in: PubMed   Mentions: 52     Fields:    Translation:Humans
    374. Phase-1 trial of gefitinib and temozolomide in patients with malignant glioma: a North American brain tumor consortium study. Cancer Chemother Pharmacol. 2008 May; 61(6):1059-67. Prados MD, Yung WK, Wen PY, Junck L, Cloughesy T, Fink K, Chang S, Robins HI, Dancey J, Kuhn J. PMID: 17694310; PMCID: PMC3873156.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    375. Relationship between survival and edema in malignant gliomas: role of vascular endothelial growth factor and neuronal pentraxin 2. Clin Cancer Res. 2007 May 01; 13(9):2592-8. Carlson MR, Pope WB, Horvath S, Braunstein JG, Nghiemphu P, Tso CL, Mellinghoff I, Lai A, Liau LM, Mischel PS, Dong J, Nelson SF, Cloughesy TF. PMID: 17473188.
      View in: PubMed   Mentions: 62     Fields:    Translation:Humans
    376. 18F-fluorothymidine kinetics of malignant brain tumors. Eur J Nucl Med Mol Imaging. 2007 Jul; 34(7):1003-11. Schiepers C, Chen W, Dahlbom M, Cloughesy T, Hoh CK, Huang SC. PMID: 17295039.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    377. High-throughput oncogene mutation profiling in human cancer. Nat Genet. 2007 Mar; 39(3):347-51. Thomas RK, Baker AC, Debiasi RM, Winckler W, Laframboise T, Lin WM, Wang M, Feng W, Zander T, MacConaill L, Macconnaill LE, Lee JC, Nicoletti R, Hatton C, Goyette M, Girard L, Majmudar K, Ziaugra L, Wong KK, Gabriel S, Beroukhim R, Peyton M, Barretina J, Dutt A, Emery C, Greulich H, Shah K, Sasaki H, Gazdar A, Minna J, Armstrong SA, Mellinghoff IK, Hodi FS, Dranoff G, Mischel PS, Cloughesy TF, Nelson SF, Liau LM, Mertz K, Rubin MA, Moch H, Loda M, Catalona W, Fletcher J, Signoretti S, Kaye F, Anderson KC, Demetri GD, Dummer R, Wagner S, Herlyn M, Sellers WR, Meyerson M, Garraway LA. PMID: 17293865.
      View in: PubMed   Mentions: 500     Fields:    Translation:Humans
    378. PTEN-mediated resistance to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2007 Jan 15; 13(2 Pt 1):378-81. Mellinghoff IK, Cloughesy TF, Mischel PS. PMID: 17255257.
      View in: PubMed   Mentions: 49     Fields:    Translation:HumansAnimalsCells
    379. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain. PLoS Med. 2006 Dec; 3(12):e485. Lee JC, Vivanco I, Beroukhim R, Huang JH, Feng WL, DeBiasi RM, Yoshimoto K, King JC, Nghiemphu P, Yuza Y, Xu Q, Greulich H, Thomas RK, Paez JG, Peck TC, Linhart DJ, Glatt KA, Getz G, Onofrio R, Ziaugra L, Levine RL, Gabriel S, Kawaguchi T, O'Neill K, Khan H, Liau LM, Nelson SF, Rao PN, Mischel P, Pieper RO, Cloughesy T, Leahy DJ, Sellers WR, Sawyers CL, Meyerson M, Mellinghoff IK. PMID: 17177598; PMCID: PMC1702556.
      View in: PubMed   Mentions: 166     Fields:    Translation:HumansAnimalsCells
    380. A North American brain tumor consortium (NABTC 99-04) phase II trial of temozolomide plus thalidomide for recurrent glioblastoma multiforme. J Neurooncol. 2007 Feb; 81(3):271-7. Groves MD, Puduvalli VK, Chang SM, Conrad CA, Gilbert MR, Tremont-Lukats IW, Liu TJ, Peterson P, Schiff D, Cloughesy TF, Wen PY, Greenberg H, Abrey LE, DeAngelis LM, Hess KR, Lamborn KR, Prados MD, Yung WK. PMID: 17031561.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    381. Primary glioblastomas express mesenchymal stem-like properties. Mol Cancer Res. 2006 Sep; 4(9):607-19. Tso CL, Shintaku P, Chen J, Liu Q, Liu J, Chen Z, Yoshimoto K, Mischel PS, Cloughesy TF, Liau LM, Nelson SF. PMID: 16966431.
      View in: PubMed   Mentions: 118     Fields:    Translation:HumansCells
    382. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res. 2006 Aug 15; 12(16):4899-907. Wen PY, Yung WK, Lamborn KR, Dahia PL, Wang Y, Peng B, Abrey LE, Raizer J, Cloughesy TF, Fink K, Gilbert M, Chang S, Junck L, Schiff D, Lieberman F, Fine HA, Mehta M, Robins HI, DeAngelis LM, Groves MD, Puduvalli VK, Levin V, Conrad C, Maher EA, Aldape K, Hayes M, Letvak L, Egorin MJ, Capdeville R, Kaplan R, Murgo AJ, Stiles C, Prados MD. PMID: 16914578.
      View in: PubMed   Mentions: 157     Fields:    Translation:HumansCTClinical Trials
    383. Mammalian target of rapamycin inhibition promotes response to epidermal growth factor receptor kinase inhibitors in PTEN-deficient and PTEN-intact glioblastoma cells. Cancer Res. 2006 Aug 15; 66(16):7864-9. Wang MY, Lu KV, Zhu S, Dia EQ, Vivanco I, Shackleford GM, Cavenee WK, Mellinghoff IK, Cloughesy TF, Sawyers CL, Mischel PS. PMID: 16912159.
      View in: PubMed   Mentions: 130     Fields:    Translation:HumansCells
    384. Phase II trial of tipifarnib in patients with recurrent malignant glioma either receiving or not receiving enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2006 Aug 01; 24(22):3651-6. Cloughesy TF, Wen PY, Robins HI, Chang SM, Groves MD, Fink KL, Junck L, Schiff D, Abrey L, Gilbert MR, Lieberman F, Kuhn J, DeAngelis LM, Mehta M, Raizer JJ, Yung WK, Aldape K, Wright J, Lamborn KR, Prados MD. PMID: 16877733.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansCTClinical Trials
    385. 18F-FDOPA PET imaging of brain tumors: comparison study with 18F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med. 2006 Jun; 47(6):904-11. Chen W, Silverman DH, Delaloye S, Czernin J, Kamdar N, Pope W, Satyamurthy N, Schiepers C, Cloughesy T. PMID: 16741298.
      View in: PubMed   Mentions: 163     Fields:    Translation:Humans
    386. Using molecular information to guide brain tumor therapy. Nat Clin Pract Neurol. 2006 May; 2(5):232-3. Mischel PS, Cloughesy T. PMID: 16932555.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    387. A phase 2 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2006 Apr; 8(2):189-93. Prados MD, Lamborn K, Yung WK, Jaeckle K, Robins HI, Mehta M, Fine HA, Wen PY, Cloughesy T, Chang S, Nicholas MK, Schiff D, Greenberg H, Junck L, Fink K, Hess K, Kuhn J, North American Brain Tumor Consortium. PMID: 16533878; PMCID: PMC1871932.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    388. Distinct transcription profiles of primary and secondary glioblastoma subgroups. Cancer Res. 2006 Jan 01; 66(1):159-67. Tso CL, Freije WA, Day A, Chen Z, Merriman B, Perlina A, Lee Y, Dia EQ, Yoshimoto K, Mischel PS, Liau LM, Cloughesy TF, Nelson SF. PMID: 16397228.
      View in: PubMed   Mentions: 76     Fields:    Translation:HumansCells
    389. Content based image retrieval for MR image studies of brain tumors. Conf Proc IEEE Eng Med Biol Soc. 2006; 2006:3337-40. Dube S, El-Saden S, Cloughesy TF, Sinha U. PMID: 17946561.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    390. Molecular determinants of the response of glioblastomas to EGFR kinase inhibitors. N Engl J Med. 2005 Nov 10; 353(19):2012-24. Mellinghoff IK, Wang MY, Vivanco I, Haas-Kogan DA, Zhu S, Dia EQ, Lu KV, Yoshimoto K, Huang JH, Chute DJ, Riggs BL, Horvath S, Liau LM, Cavenee WK, Rao PN, Beroukhim R, Peck TC, Lee JC, Sellers WR, Stokoe D, Prados M, Cloughesy TF, Sawyers CL, Mischel PS. PMID: 16282176.
      View in: PubMed   Mentions: 598     Fields:    Translation:HumansCells
    391. MR imaging correlates of survival in patients with high-grade gliomas. AJNR Am J Neuroradiol. 2005 Nov-Dec; 26(10):2466-74. Pope WB, Sayre J, Perlina A, Villablanca JP, Mischel PS, Cloughesy TF. PMID: 16286386; PMCID: PMC7976216.
      View in: PubMed   Mentions: 206     Fields:    Translation:Humans
    392. Phase I trial of tipifarnib in patients with recurrent malignant glioma taking enzyme-inducing antiepileptic drugs: a North American Brain Tumor Consortium Study. J Clin Oncol. 2005 Sep 20; 23(27):6647-56. Cloughesy TF, Kuhn J, Robins HI, Abrey L, Wen P, Fink K, Lieberman FS, Mehta M, Chang S, Yung A, DeAngelis L, Schiff D, Junck L, Groves M, Paquette S, Wright J, Lamborn K, Sebti SM, Prados M. PMID: 16170172.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    393. Dendritic cell vaccination in glioblastoma patients induces systemic and intracranial T-cell responses modulated by the local central nervous system tumor microenvironment. Clin Cancer Res. 2005 Aug 01; 11(15):5515-25. Liau LM, Prins RM, Kiertscher SM, Odesa SK, Kremen TJ, Giovannone AJ, Lin JW, Chute DJ, Mischel PS, Cloughesy TF, Roth MD. PMID: 16061868.
      View in: PubMed   Mentions: 243     Fields:    Translation:HumansCellsCTClinical Trials
    394. Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs. 2005 Aug; 23(4):357-61. Chang SM, Wen P, Cloughesy T, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, De Angelis L, Raizer J, Hess K, Aldape K, Lamborn KR, Kuhn J, Dancey J, Prados MD, North American Brain Tumor Consortium and the National Cancer Institute. PMID: 16012795.
      View in: PubMed   Mentions: 154     Fields:    Translation:HumansCTClinical Trials
    395. Imaging proliferation in brain tumors with 18F-FLT PET: comparison with 18F-FDG. J Nucl Med. 2005 Jun; 46(6):945-52. Chen W, Cloughesy T, Kamdar N, Satyamurthy N, Bergsneider M, Liau L, Mischel P, Czernin J, Phelps ME, Silverman DH. PMID: 15937304.
      View in: PubMed   Mentions: 161     Fields:    Translation:Humans
    396. Robustness of gene expression profiling in glioma specimen samplings and derived cell lines. Brain Res Mol Brain Res. 2005 May 20; 136(1-2):99-103. Mehrian Shai R, Reichardt JK, Ya-Hsuan H, Kremen TJ, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. PMID: 15893592.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    397. Differential induction of glioblastoma migration and growth by two forms of pleiotrophin. J Biol Chem. 2005 Jul 22; 280(29):26953-64. Lu KV, Jong KA, Kim GY, Singh J, Dia EQ, Yoshimoto K, Wang MY, Cloughesy TF, Nelson SF, Mischel PS. PMID: 15908427.
      View in: PubMed   Mentions: 52     Fields:    Translation:HumansCells
    398. EGF activates intracellular and intercellular calcium signaling by distinct pathways in tumor cells. Cancer Biol Ther. 2004 Dec; 3(12):1243-9. Bryant JA, Finn RS, Slamon DJ, Cloughesy TF, Charles AC. PMID: 15611621.
      View in: PubMed   Mentions: 33     Fields:    Translation:HumansCells
    399. Phase I/pharmacokinetic study of CCI-779 in patients with recurrent malignant glioma on enzyme-inducing antiepileptic drugs. Invest New Drugs. 2004 Nov; 22(4):427-35. Chang SM, Kuhn J, Wen P, Greenberg H, Schiff D, Conrad C, Fink K, Robins HI, Cloughesy T, De Angelis L, Razier J, Hess K, Dancey J, Prados MD, North American Brain Tumor Consortium And The National Cancer Institute. PMID: 15292713.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    400. Phase II study of fenretinide (NSC 374551) in adults with recurrent malignant gliomas: A North American Brain Tumor Consortium study. J Clin Oncol. 2004 Nov 01; 22(21):4282-9. Puduvalli VK, Yung WK, Hess KR, Kuhn JG, Groves MD, Levin VA, Zwiebel J, Chang SM, Cloughesy TF, Junck L, Wen P, Lieberman F, Conrad CA, Gilbert MR, Meyers CA, Liu V, Mehta MP, Nicholas MK, Prados M, North American Brain Tumor Consortium. PMID: 15514370; PMCID: PMC3820102.
      View in: PubMed   Mentions: 40     Fields:    Translation:HumansCTClinical Trials
    401. Brain tumor treatment: chemotherapy and other new developments. Semin Oncol Nurs. 2004 Nov; 20(4):260-72. Graham CA, Cloughesy TF. PMID: 15612602.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    402. DNA-microarray analysis of brain cancer: molecular classification for therapy. Nat Rev Neurosci. 2004 Oct; 5(10):782-92. Mischel PS, Cloughesy TF, Nelson SF. PMID: 15378038.
      View in: PubMed   Mentions: 66     Fields:    Translation:HumansAnimals
    403. Gene expression profiling of gliomas strongly predicts survival. Cancer Res. 2004 Sep 15; 64(18):6503-10. Freije WA, Castro-Vargas FE, Fang Z, Horvath S, Cloughesy T, Liau LM, Mischel PS, Nelson SF. PMID: 15374961.
      View in: PubMed   Mentions: 349     Fields:    Translation:Humans
    404. Prediction of neurocognitive outcome in adult brain tumor patients. J Neurooncol. 2004 Mar-Apr; 67(1-2):245-53. Kaleita TA, Wellisch DK, Cloughesy TF, Ford JM, Freeman D, Belin TR, Goldman J. PMID: 15072475.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    405. p53 disruption profoundly alters the response of human glioblastoma cells to DNA topoisomerase I inhibition. Oncogene. 2004 Feb 12; 23(6):1283-90. Wang Y, Zhu S, Cloughesy TF, Liau LM, Mischel PS. PMID: 14961077.
      View in: PubMed   Mentions: 30     Fields:    Translation:HumansCells
    406. A prospective blinded study of the predictive value of an extreme drug resistance assay in patients receiving CPT-11 for recurrent glioma. J Neurooncol. 2004 Feb; 66(3):365-75. Parker RJ, Fruehauf JP, Mehta R, Filka E, Cloughesy T. PMID: 15015670.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansCTClinical Trials
    407. Phase 1 trial of irinotecan (CPT-11) in patients with recurrent malignant glioma: a North American Brain Tumor Consortium study. Neuro Oncol. 2004 Jan; 6(1):44-54. Prados MD, Yung WK, Jaeckle KA, Robins HI, Mehta MP, Fine HA, Wen PY, Cloughesy TF, Chang SM, Nicholas MK, Schiff D, Greenberg HS, Junck L, Fink KL, Hess KR, Kuhn J, North American Brain Tumor Consortium study. PMID: 14769140; PMCID: PMC1871968.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansCTClinical Trials
    408. Upregulation of tissue inhibitor of metalloproteinases (TIMP)-2 promotes matrix metalloproteinase (MMP)-2 activation and cell invasion in a human glioblastoma cell line. Lab Invest. 2004 Jan; 84(1):8-20. Lu KV, Jong KA, Rajasekaran AK, Cloughesy TF, Mischel PS. PMID: 14631378.
      View in: PubMed   Mentions: 50     Fields:    Translation:HumansCells
    409. Oncodiagnosis panel: 2002. Metastatic NSCLC. Radiographics. 2003 Nov-Dec; 23(6):1591-611. Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF, Oncodiagosis panel, 2002 RSNA Scientific Assembly. PMID: 14628846.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    410. Oncodiagnosis panel: 2002. Patient's symptoms not related to the lesion seen in the MR images. Radiographics. 2003 Nov-Dec; 23(6):1591-611. Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF, Oncodiagosis panel, 2002 RSNA Scientific Assembly. PMID: 14635615.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    411. Oncodiagnosis panel: 2002. Optic nerve glioma or optic nerve meningioma. Radiographics. 2003 Nov-Dec; 23(6):1591-611. Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF, Oncodiagosis panel, 2002 RSNA Scientific Assembly. PMID: 14635617.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    412. Oncodiagnosis panel: 2002. Primary glial neoplasm or less likely an intracranial abscess. Radiographics. 2003 Nov-Dec; 23(6):1591-611. Brown PD, Wald JT, McDermott MW, Baumann GS, Cloughesy TF, Oncodiagosis panel, 2002 RSNA Scientific Assembly. PMID: 14635616.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    413. Gene expression profiling identifies molecular subtypes of gliomas. Oncogene. 2003 Jul 31; 22(31):4918-23. Shai R, Shi T, Kremen TJ, Horvath S, Liau LM, Cloughesy TF, Mischel PS, Nelson SF. PMID: 12894235.
      View in: PubMed   Mentions: 138     Fields:    Translation:Humans
    414. Phase II evaluation of temozolomide and 13-cis-retinoic acid for the treatment of recurrent and progressive malignant glioma: a North American Brain Tumor Consortium study. J Clin Oncol. 2003 Jun 15; 21(12):2305-11. Jaeckle KA, Hess KR, Yung WK, Greenberg H, Fine H, Schiff D, Pollack IF, Kuhn J, Fink K, Mehta M, Cloughesy T, Nicholas MK, Chang S, Prados M, North American Brain Tumor Consortium. PMID: 12805331.
      View in: PubMed   Mentions: 48     Fields:    Translation:HumansCTClinical Trials
    415. Analysis of the phosphatidylinositol 3'-kinase signaling pathway in glioblastoma patients in vivo. Cancer Res. 2003 Jun 01; 63(11):2742-6. Choe G, Horvath S, Cloughesy TF, Crosby K, Seligson D, Palotie A, Inge L, Smith BL, Sawyers CL, Mischel PS. PMID: 12782577.
      View in: PubMed   Mentions: 168     Fields:    Translation:HumansCells
    416. Two studies evaluating irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Cancer. 2003 May 01; 97(9 Suppl):2381-6. Cloughesy TF, Filka E, Kuhn J, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. PMID: 12712460.
      View in: PubMed   Mentions: 42     Fields:    Translation:Humans
    417. Molecular analysis of glioblastoma: pathway profiling and its implications for patient therapy. Cancer Biol Ther. 2003 May-Jun; 2(3):242-7. Mischel PS, Nelson SF, Cloughesy TF. PMID: 12878856.
      View in: PubMed   Mentions: 22     Fields:    Translation:HumansAnimalsCells
    418. Identification of molecular subtypes of glioblastoma by gene expression profiling. Oncogene. 2003 Apr 17; 22(15):2361-73. Mischel PS, Shai R, Shi T, Horvath S, Lu KV, Choe G, Seligson D, Kremen TJ, Palotie A, Liau LM, Cloughesy TF, Nelson SF. PMID: 12700671.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCells
    419. Targeted molecular therapy of GBM. Brain Pathol. 2003 Jan; 13(1):52-61. Mischel PS, Cloughesy TF. PMID: 12580545; PMCID: PMC8095874.
      View in: PubMed   Mentions: 84     Fields:    Translation:HumansAnimalsCells
    420. Active matrix metalloproteinase 9 expression is associated with primary glioblastoma subtype. Clin Cancer Res. 2002 Sep; 8(9):2894-901. Choe G, Park JK, Jouben-Steele L, Kremen TJ, Liau LM, Vinters HV, Cloughesy TF, Mischel PS. PMID: 12231534.
      View in: PubMed   Mentions: 70     Fields:    Translation:HumansCells
    421. Novel methodology for the archiving and interactive reading of clinical magnetic resonance spectroscopic imaging. Magn Reson Med. 2002 Sep; 48(3):411-8. Alger JR, Frew AJ, Cloughesy TF, Del Vecchio W, Villablanca JP, Curran JG. PMID: 12210904.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    422. Predicting major depression in brain tumor patients. Psychooncology. 2002 May-Jun; 11(3):230-8. Wellisch DK, Kaleita TA, Freeman D, Cloughesy T, Goldman J. PMID: 12112483.
      View in: PubMed   Mentions: 57     Fields:    Translation:Humans
    423. Irinotecan treatment for recurrent malignant glioma using an every-3-week regimen. Am J Clin Oncol. 2002 Apr; 25(2):204-8. Cloughesy TF, Filka E, Nelson G, Kabbinavar F, Friedman H, Miller LL, Elfring GL. PMID: 11943904.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCTClinical Trials
    424. A phase II trial of thymidine and carboplatin for recurrent malignant glioma: a North American Brain Tumor Consortium Study. Neuro Oncol. 2002 Apr; 4(2):109-14. Robins HI, Chang SM, Prados MD, Yung WK, Hess K, Schiff D, Greenberg H, Fink K, Nicolas K, Kuhn JG, Cloughesy T, Junck L, Mehta M. PMID: 11916502; PMCID: PMC1920656.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    With one click, see people who:

    Run Clinical Trials

    See more options in the Advanced Search tab

    Timothy's Networks
    Concepts (810)
    Derived automatically from this person's publications.
    Explore
    _
    Co-Authors (150)
    People in Profiles who have published with this person.
    Explore
    _
    Similar People (60)
    People who share similar concepts with this person.
    Explore
    _
    Same Department
    Search Department
    _

    UCLA Profiles is managed by the UCSF Clinical and Translational Science Institute (CTSI), part of the Clinical and Translational Science Award program funded by the National Center for Advancing Translational Sciences (Grant Number UL1 TR000004) at the National Institutes of Health (NIH).
    This site is running Profiles RNS version UCSF-v3.1.0-3-g1ef1264b on PROFILES-PWEB03. We use cookies to operate our website. We also use cookies to analyze our site’s performance and improve your experience on our site. For more information about how we use cookies, please see our Website Terms of Use.

    Copyright © The Regents of the University of California